EP2351483A1 - Prevention and treatment of blood coagulation-related diseases - Google Patents
Prevention and treatment of blood coagulation-related diseases Download PDFInfo
- Publication number
- EP2351483A1 EP2351483A1 EP10180790A EP10180790A EP2351483A1 EP 2351483 A1 EP2351483 A1 EP 2351483A1 EP 10180790 A EP10180790 A EP 10180790A EP 10180790 A EP10180790 A EP 10180790A EP 2351483 A1 EP2351483 A1 EP 2351483A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- chain
- human
- humanized
- version
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 24
- 230000023555 blood coagulation Effects 0.000 title description 16
- 230000002265 prevention Effects 0.000 title description 3
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims abstract description 111
- 230000003449 preventive effect Effects 0.000 claims abstract description 87
- 239000003814 drug Substances 0.000 claims abstract description 85
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 80
- 201000005665 thrombophilia Diseases 0.000 claims abstract description 51
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 206010047249 Venous thrombosis Diseases 0.000 claims abstract description 17
- 206010003178 Arterial thrombosis Diseases 0.000 claims abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 230000002085 persistent effect Effects 0.000 claims abstract description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 17
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 17
- 230000008719 thickening Effects 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 abstract description 7
- 210000004231 tunica media Anatomy 0.000 abstract description 6
- 200000000007 Arterial disease Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 175
- 108010000499 Thromboplastin Proteins 0.000 description 134
- 102000002262 Thromboplastin Human genes 0.000 description 134
- 239000013612 plasmid Substances 0.000 description 128
- 108020004414 DNA Proteins 0.000 description 124
- 108090000623 proteins and genes Proteins 0.000 description 106
- 239000013615 primer Substances 0.000 description 98
- 241000282414 Homo sapiens Species 0.000 description 81
- 239000012634 fragment Substances 0.000 description 81
- 238000000034 method Methods 0.000 description 79
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 62
- 230000000694 effects Effects 0.000 description 59
- 239000000427 antigen Substances 0.000 description 55
- 102000036639 antigens Human genes 0.000 description 55
- 108091007433 antigens Proteins 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000002299 complementary DNA Substances 0.000 description 50
- 230000027455 binding Effects 0.000 description 49
- 125000003275 alpha amino acid group Chemical group 0.000 description 45
- 239000002773 nucleotide Substances 0.000 description 44
- 125000003729 nucleotide group Chemical group 0.000 description 44
- 229920000936 Agarose Polymers 0.000 description 43
- 239000002609 medium Substances 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 38
- 230000003472 neutralizing effect Effects 0.000 description 36
- 241000588724 Escherichia coli Species 0.000 description 35
- 239000013604 expression vector Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 108091008146 restriction endonucleases Proteins 0.000 description 29
- 210000004408 hybridoma Anatomy 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 26
- 238000005345 coagulation Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000015271 coagulation Effects 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 24
- 239000013598 vector Substances 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 208000007536 Thrombosis Diseases 0.000 description 21
- 239000012228 culture supernatant Substances 0.000 description 21
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 210000004204 blood vessel Anatomy 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 230000036470 plasma concentration Effects 0.000 description 17
- 238000000246 agarose gel electrophoresis Methods 0.000 description 16
- 238000010276 construction Methods 0.000 description 16
- 239000003656 tris buffered saline Substances 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 15
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 15
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 description 15
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 201000000050 myeloid neoplasm Diseases 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 108020004491 Antisense DNA Proteins 0.000 description 13
- 241000283707 Capra Species 0.000 description 13
- 239000003816 antisense DNA Substances 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 12
- 108010049003 Fibrinogen Proteins 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 229940012952 fibrinogen Drugs 0.000 description 12
- 238000002513 implantation Methods 0.000 description 12
- 229910001629 magnesium chloride Inorganic materials 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 235000010419 agar Nutrition 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 230000002688 persistence Effects 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004102 animal cell Anatomy 0.000 description 10
- 238000012869 ethanol precipitation Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 230000001235 sensitizing effect Effects 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000007910 cell fusion Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000013613 expression plasmid Substances 0.000 description 9
- 108010073651 fibrinmonomer Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 210000002826 placenta Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 108010054265 Factor VIIa Proteins 0.000 description 8
- 108010014173 Factor X Proteins 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 229940012414 factor viia Drugs 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 210000001168 carotid artery common Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 6
- 108020001019 DNA Primers Proteins 0.000 description 6
- 239000003155 DNA primer Substances 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 102100027378 Prothrombin Human genes 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003593 chromogenic compound Substances 0.000 description 6
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 6
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 6
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 210000004731 jugular vein Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229940039716 prothrombin Drugs 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 206010053648 Vascular occlusion Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000001376 precipitating effect Effects 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 208000021331 vascular occlusion disease Diseases 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229960004676 antithrombotic agent Drugs 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000208 fibrin degradation product Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- KQJTXYQXRHCWKW-PJSBSAQXSA-N (4s)-4-[[(2s,3s)-2-benzamido-3-methylpentanoyl]amino]-5-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid;hydrochloride Chemical compound Cl.N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 KQJTXYQXRHCWKW-PJSBSAQXSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 101150074155 DHFR gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 229920001363 Polidocanol Polymers 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 108010031969 benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide Proteins 0.000 description 3
- 201000001531 bladder carcinoma Diseases 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 3
- 229960002226 polidocanol Drugs 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 201000002282 venous insufficiency Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 206010009192 Circulatory collapse Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- -1 Vaseline Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101100482144 Homo sapiens TF gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000635833 Mus musculus Tissue factor Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 101150025711 TF gene Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a method of generating an animal model having a persistently hypercoagulable state, preventive or therapeutic agents for diseases having a persistent hypercoagulable state, preventive or therapeutic agents for a hypercoagulable state resulting from infections, preventive or therapeutic agents for venous or arterial thrombosis, and preventive or therapeutic agents for diseases resulting from the hypertrophy of vascular media.
- Blood coagulation is a reaction in which serine protease precursors are successively activated by activated-form proteases, which finally generate thrombin thereby leading to fibrin formation.
- Thrombosis arises as a consequence of an excessively enhanced blood coagulation reaction that was caused by changes in the plasma coagulation and fibrinolytic system, and in the functions of platelets, leucocytes and vascular endothelial cells associated with the progression of various disease states.
- the initiating factor of the blood coagulation reaction is tissue factor.
- the blood coagulation reaction is triggered when tissue factor occurring in abundance in the plaques formed after the progression of arterial sclerosis is exposed to the blood due to the rhexis of plaques.
- tissue factor or tumor cells express tissue factor thereby causing enhanced blood coagulation.
- tissue factor comes into contact with the blood, the blood coagulation reaction proceeds in a very short period of time and leads to the formation of blood clots.
- an experimental model that exhibits a hypercoagulable state on a persistent basis is essential for the development of effective anti-thrombotic agents.
- thrombus formation is induced in a short, period of time.
- an experimental model in which a hypercoagulable state persists by bringing human tissue factor into contact with the blood on a persistent basis.
- Blood coagulation is a reaction in which serine protease precursors are successively activated by activated-form proteases, which finally generate thrombin thereby leading to fibrin formation.
- Thrombosis arises as a consequence of an excessively enhanced blood coagulation reaction that was caused by changes in the plasma coagulation and fibrinolytic system, and in the functions of platelets, leucocytes and vascular endothelial cells associated with the progression of various disease states.
- the initiating factor of the blood coagulation reaction is tissue factor (TF).
- the blood coagulation reaction is triggered when tissue factor occurring in abundance in the plaques formed after the progression of arterial sclerosis is exposed to the blood due to the rupture of plaques.
- activated monocytes and macrophages express TF or tumor cells express TF thereby leading to enhanced blood coagulation and this state persists.
- the blood coagulation reaction proceeds in a very short period of time leading to the formation of blood clots.
- Severe infections are often associated with abnormal coagulation, which induces disease states such as multiple organ failure and the disseminated intravascular coagulation syndrome, and represents a factor that aggravates the prognosis of the patient.
- the measures employed are thus considered to be important.
- systemic infections such as sepsis and, among them, lesions in the vascular endothelial cells have been implicated as the onset mechanism of organ disorders.
- a cellular component, lipopolysaccharide (LPS) plays an important role.
- LPS liberated into the blood not only activates monocytes and thereby produces tissue factor (TF) leading to a hypercoagulable state, but produces and liberates cytokines such as TNF, IL-1 ⁇ and IL-8 and thereby activates neutrophils and vascular endothelial cells.
- cytokines such as TNF, IL-1 ⁇ and IL-8
- the activated neutrophils adhere to the vascular endothelial cells to liberate cytotoxic substances such as active enzymes and elastases, which injure the vascular endothelial cells.
- the production of TF is enhanced which further progresses the hypercoagulable state.
- microthrombi occur systemically, which elicits circulatory failures in the organs leading to multiple organ failure.
- venous stasis As a mechanism leading to the onset of venous thrombosis, venous stasis, damages to the venous wall, and hypercoagulabilyty are thought to play an important role.
- invasive events such as surgery, childbirth and trauma induce physical injuries to the vascular wall and abnormalities in the coagulation and fibrinolysis system, and decubitus after surgery induces a renous stasis.
- the resulting blood clots in the vein induce circulatory failure in the limbs but the clots themselves enter into the blood circulation and flows into the pulmonary artery leading to fatal pulmonary embolism.
- the prevention of venous thrombosis itself is considered to be important.
- agents that can effectively prevent or treat venous thrombosis.
- tissue factor an initiating factor for thrombus formation
- tissue factor an initiating factor for thrombus formation
- PTCA Percutaneous transluminal coronary angioplasty
- the growth of the blood vessel tissue per se and the constriction of the blood vessel diameter also contribute to the narrowing of the area of the lumen in the blood vessel, and they provide a direct factor for restenosis.
- a novel drug that can prevent or treat restenosis.
- the inventors of the present invention After intensive and extensive research to resolve the above first problem, the inventors of the present invention have found out that by implanting, into an experimental animal, an animal cell capable of constantly expressing human tissue factor by introducing therein the gene of a human tissue factor (TF) and thereby increasing the concentration of human tissue factor in the animal, the hypercoagulable state of said animal can be maintained for a long period of time, and thereby have completed the present invention.
- TF human tissue factor
- the present invention provides an experimental animal having implanted therein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene, said animal being a non-human animal in which a hypercoagulable state persists for a long period of time.
- TF human tissue factor
- the part of said human tissue factor is for example a human tissue factor that lacks the intracellular region.
- Said animal cell is preferably a mammalian cell.
- Said mammalian cell is preferably a human myeloma cell.
- Said animal is preferably a mouse.
- Said hypercoagulable state is indicated by at least one of the phenomena comprising an increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex.
- the present invention also provides a method of generating the above animal, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected.
- TF human tissue factor
- the present invention also provides a method of screening an anti-thrombotic agent which method comprises using the above animal.
- an antibody anti-human TF antibody, or sometimes referred to as anti-TF antibody
- an antibody against human tissue factor can prevent the persistence of a hypercoagulable state.
- the present invention provides a preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody against human tissue factor (human TF).
- the above antibody is for example a polyclonal antibody.
- the above antibody is preferably a monoclonal antibody.
- the above antibody is preferably a recombinant antibody.
- the above antibody is preferably an altered antibody.
- the above altered antibody is preferably a chimeric antibody or a humanized antibody.
- the above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- the above antibody is for example an antibody modification.
- the above antibody modification is for example an antibody fragment Fab, F(ab') 2 , or Fv, or a single chain Fv (scFv).
- an antibody against human tissue factor can prevent or treat a hypercoagulable state resulting from infections.
- the present invention provides a preventive or therapeutic agent for a hypercoagulable state resulting from infections, said agent comprising an antibody against human tissue factor (human TF).
- the above antibody is for example a polyclonal antibody.
- the above antibody is preferably a monoclonal antibody.
- the above antibody is preferably a recombinant antibody.
- the above antibody is preferably an altered antibody.
- the above altered antibody is preferably a chimeric antibody or a humanized antibody.
- the above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- the above antibody is for example an antibody modification.
- the above modified antibody is for example an antibody fragment Fab, F(ab') 2 , or Fv, or a single chain Fv (scFv).
- an antibody against human tissue factor can prevent or treat venous thrombosis.
- the present invention provides a preventive or therapeutic agent for venous thrombosis, said agent comprising an antibody against human tissue factor (human TF).
- the above antibody is for example a polyclonal antibody.
- the above antibody is preferably a monoclonal antibody.
- the above antibody is preferably a Recombinant antibody.
- the above antibody is preferably an altered antibody.
- the above altered antibody is preferably a chimeric antibody or a humanized antibody.
- the above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- the above antibody is for example an antibody modification.
- the above antibody modification is for example an antibody fragment Fab, F(ab') 2 , or Fv, or a single chain Fv (scFv).
- an antibody against human tissue factor can prevent or treat arterial thrombosis.
- the present invention provides a preventive or therapeutic agent for arterial thrombosis, said agent comprising an antibody against human tissue factor (human TF).
- the above antibody is for example a polyclonal antibody.
- the above antibody is preferably a monoclonal antibody.
- the above antibody is preferably a recombinant antibody.
- the above antibody is preferably an altered antibody.
- the above altered antibody is preferably a chimeric antibody or a humanized antibody.
- the above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- the above antibody is for example an antibody modification.
- the above antibody modification is for example an antibody fragment Fab, F(ab') 2 , or Fv, or a single chain Fv (scFv).
- an antibody against human tissue factor can prevent or treat diseases caused by the hypertrophy of vascular media.
- the present invention provides a preventive or therapeutic agent for diseases caused by the hypertrophy of vascular media, said agent comprising an antibody against human tissue factor (human TF).
- the above antibody is for example a polyclonal antibody.
- the above antibody is preferably a monoclonal antibody.
- the above antibody is preferably a recombinant antibody.
- the above antibody is preferably an altered antibody.
- the above altered antibody is preferably a chimeric antibody or a humanized antibody.
- the above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- the above antibody is for example an antibody modification.
- the above antibody modification is for example an antibody fragment Fab, F(ab') 2 , or Fv, or a single chain Fv (scFv).
- TF human tissue factor
- the gene that encodes human tissue factor (TF) for use in the first aspect of the present invention has already been cloned, and the base sequence and the amino acid sequence encoded thereby are also known ( H. Morrissey et al., Cell, Vol. 50, p. 129-135 (1987 )).
- the base sequence encoding the full-length human tissue factor and the corresponding amino acid sequence are set forth in SEQ ID NO: 103 and 104.
- any expression vector that functions in animal cells can be used, including, for example, PCOS1, pSV2-neo, pMAM-neo, and pSG5.
- a commonly used useful promoter, the human tissue factor gene, and a poly A signal, to 3'-end downstream thereof, can be functionally linked and can be expressed.
- human cytomegalovirus immediate early promoter/enhancer viral promoters such as promoters of retrovirus, polyoma virus, adenovirus, and simian virus 40 (SV40), and promoters/enhancers derived from mammalian cells such as human elongation factor 1 ⁇ (HEF1 ⁇ ).
- viral promoters such as promoters of retrovirus, polyoma virus, adenovirus, and simian virus 40 (SV40)
- promoters/enhancers derived from mammalian cells such as human elongation factor 1 ⁇ (HEF1 ⁇ ).
- HEF1 ⁇ human elongation factor 1 ⁇
- replicator there can be used those derived from SV40, polyoma virus, adenovirus and the like.
- the expression vector can be contained as selectable markers the phosphotransferase APH (3') II or I (neo) gene, the thymidine kinase (TK) gene, the dihydrofolate reductase (dhfr) gene and the like.
- the method of introducing a gene into a cell there can be used the electroporation method, the calcium phosphate method, the lipofection method and the like.
- the cell for introducing the expression vector any cell can be used as long as it can be grafted to an animal cell.
- various cultured cells may be used, including for example a mammalian cell such as a cultured cell derived from human, mice, rats, hamsters, and monkeys, with tumor cells being most preferred.
- a human myeloma cell line such as KPMM2 and ARH-77
- a mouse leukemia cell line such as P815, P388, and L1210.
- the experimental animals for use in the present invention are mammals other than the human and are preferably small experimental animals such as mice, rats, and hamsters with the mice being most preferred.
- the hypercoagulable state means a physical condition induced by human TF, and give signs as a decrease in platelet counts and fibrinogen concentration, an increase in the concentration of soluble fibrin monomer complex (SFMC) and thrombin-antithrombin III complex (TAT).
- SFMC soluble fibrin monomer complex
- TAT thrombin-antithrombin III complex
- the antibody used in the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferably.
- monoclonal antibody is preferably.
- chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- the antibody used in the third aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable.
- monoclonal antibody is preferable.
- chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- the antibody used in the fourth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable.
- monoclonal antibody is preferable.
- chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- the antibody used in the fifth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable.
- monoclonal antibody is preferable.
- chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- the antibody used in the sixth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferably.
- monoclonal antibody is preferably.
- chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- the anti-human TF antibody used in the present invention may be of any origin, type (monoclonal or polyclonal) and form provided it has the effect of preventing or treating viral hemorrhagic fever.
- the anti-human TF antibody used in the present invention can be obtained as polyclonal or monoclonal antibody using a known means.
- Monoclonal antibody of mammalian origin is particularly preferable as the anti-human TF antibody used in the present invention.
- Monoclonal antibody of mammalian origin includes that produced in hybridomas as well as that produced in a host transformed with an expression vector containing antibody gene by genetic engineering techniques. This antibody is an antibody that inhibits the induction of thrombus by human TF by binding with human TF.
- Monoclonal antibody-producing hybridoma can basically be produced in the following manner using known technology. Namely, using human TF or a portion (fragment) of it as sensitizing antigen, this is immunized in accordance with ordinary immunization methods, the resulting immunocytes are fused with known parent cells in accordance with ordinary cell fusion methods, and those cells that produce monoclonal antibody are screened in accordance with ordinary screening methods to produce monoclonal antibody.
- monoclonal antibody should be produced in the manner described below.
- human TF used as sensitizing antigen for antibody acquisition is obtained by expressing the TF gene/amino acid sequence disclosed in J.H. Morissey, et. al., Cell, Vol. 50, p. 129-135 (1987 ). Namely, gene sequence coding for human TF is inserted into a known expression vector to transform suitable host cells followed by purifying the target human TF protein present in the host cells or culture supernatant using a known method. This method is described in Reference Example 1 of the present specification. Moreover, the human TF used as antigen can be used by extracting and purifying from a TF-containing biological material such as human placenta according to the method described in Reference Example 2.
- this purified human TF protein is used as sensitizing antigen.
- soluble TF from which the membrane permeating region of the C-terminal of human TF has been removed can be produced by, for example, genetic recombination, and this can also be used as sensitizing antigen.
- a mammal in consideration of compatibility with the parent cells used in cell fusion, typical examples of which include rodents such as mice, rats, hamsters, or rabbits and monkeys.
- Immunization of animals with sensitizing antigen is performed in accordance with known methods.
- immunization is performed by injecting sensitizing antigen into the abdominal cavity or under the skin of the mammal. More specifically, sensitizing antigen is diluted to a suitable volume with phosphate-buffered saline (PBS) or physiological saline, and the resulting suspension is mixed with a suitable amount of ordinary adjuvant such as Freund's complete adjuvant as desired followed by emulsifying and administering in multiple doses to mammals every 4-21 days.
- PBS phosphate-buffered saline
- physiological saline physiological saline
- a suitable carrier can also be used when immunizing with sensitizing antigen.
- immunocytes After immunizing the mammals in this manner and confirming that antibody has risen to the desired level in the serum, immunocytes are sampled from the mammals and applied to cell fusion.
- spleen cells are a particularly preferable example of immunocytes.
- Mammalian myeloma cells are used for the other parent cells fused with the above immunocytes.
- Various known cell lines are used for these myeloma cells, preferable examples of which include P3 (P3x63Ag8.653) ( Kearney, J.F. et al., J. Immunol. (1979) 123, 1548-1550 ), P3x63Ag8U.1 ( Yelton, D.E. et al., Current Topics in Microbiology and Immunology (1978) 81, 1-7 ), NS-1 ( Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6, 511-519 ), MPC-11 ( Margulies, D.H.
- Cell fusion of the above immunocytes and myeloma cells can basically be carried out in compliance with known methods such as the method of Milstein, et al. ( Galfre G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46 ).
- cell fusion is carried out, for example, in ordinary nutrient culture media in the presence of cell fusion promoter.
- cell fusion promoters include polyethylene glycol (PEG) and Sendai virus (HVJ).
- an assistant such as dimethylsulfoxide can be added to further enhance fusion efficiency as desired.
- the usage ratio of immunocytes and myeloma cells can be set arbitrarily.
- the number of immunocytes is preferably 1-10 times the number of myeloma cells.
- culture media used in the above cell fusion include RPMI1640 culture medium, MEM culture medium and other ordinary culture media used in this type of cell culturing that is suitable for growth of the above myeloma cell lines.
- serum supplement such as fetal calf serum (FCS) can also be used in combination with the above media.
- Cell fusion is carried out by adequately mixing prescribed amounts of the above immunocytes and myeloma cells in the above culture media, adding PEG solution (for example, that having a molecular weight of about 1000-6000) warmed in advance to about 37°C at a concentration of usually 30-60% (w/v) and mixing to form the target fused cells (hybridoma). Subsequently, a suitable amount of culture media is sequentially added, and cell fusion agents and so forth undesirable for hybridoma growth are removed by repeated removal of supernatant by centrifugation.
- PEG solution for example, that having a molecular weight of about 1000-6000
- w/v concentration of usually 30-60%
- the hybridoma obtained in this manner is selected by culturing in an ordinary selective culture medium such as HAT culture medium (culture medium containing hypoxanthine, aminopterin and thymidine). Culturing in the above HAT culture medium is continued for an adequate amount of time (normally from several days to several weeks) for killing cells other than the target hybridoma cells (non-fused cells). Next, routine critical dilution is performed followed by screening for hybridoma that produces the target antibody and monocloning.
- an ordinary selective culture medium such as HAT culture medium (culture medium containing hypoxanthine, aminopterin and thymidine).
- HAT culture medium culture medium containing hypoxanthine, aminopterin and thymidine
- Culturing in the above HAT culture medium is continued for an adequate amount of time (normally from several days to several weeks) for killing cells other than the target hybridoma cells (non-fused cells).
- routine critical dilution is performed followed by screening for
- a desired human antibody having binding activity to human TF can be obtained by sensitizing human lymphocytes to human TF in vitro, and fusing the sensitized lymphocytes with human myeloma cells such as myeloma cell line U266 having permanent mitotic ability (refer to Japanese Examined Patent Publication No. 1-59878 ).
- human antibody to anti-human TF may also be acquired from attenuated cells by administering human TF serving as antigen to transgenic animals having all or a portion of the human antibody gene repertoire, acquiring anti-human TF antibody-producing cells and attenuating those cells (refer to International Unexamined Patent Application No. WO 94/25585 , NO 93/12227 , WO 92/03918 , WO 94/02602 , WO 96/34096 and WO 96/33735 ).
- Hybridoma that produces monoclonal antibody obtained in this manner can be sub-cultured in ordinary culture media, and can be stored for a long period of time in liquid nitrogen.
- said hybridoma is cultured in accordance with routine methods followed by obtaining the culture supernatant, or the hybridoma can be administered to a compatible mammal to proliferate in that mammal followed by obtaining in the form of the ascites.
- the former method is suitable for obtaining highly pure antibody, while the latter method is suitable for large volume production of antibody.
- ATR-2 monoclonal antibody production
- 3, 4, 5, 7 and 8 monoclonal antibodies
- ATR-5 is particularly preferable.
- recombinant antibody produced using genetic recombination technology by cloning antibody gene from hybridoma, incorporating in a suitable vector and introducing this into a host can be used as monoclonal antibody (refer to, for example, Vandamme, A.M. et al., Eur. J. Biochem. (1990) 192, 767-775 ).
- mRNA that codes for the variable region (V) of anti-human TF antibody is isolated from hybridoma that produces anti-human TF antibody. Isolation of mRNA is carried out by a known method such as guanidine ultracentrifugation ( Chirgwin, J.M. et al., Biochemistry (1979) 18, 5294-5299 ) or the AGPC method ( Chomczynski, P. and Sacchi, N., Anal. Biochem. (1987) 162, 156-159 ) to prepare total RNA, followed by preparation of the target mRNA using an mRNA Purification Kit (Pharmacia). In addition, mRNA can also be prepared directly by using the QuickPrep mRNA Purification Kit (Pharmacia).
- cDNA of the antibody V region is synthesized from the resulting mRNA using reverse transcriptase.
- Synthesis of cDNA is carried out using the AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Co.).
- synthesis and amplification of cDNA can also be carried out by using the 5'-Ampli FINDER RACE Kit (Clontech) and the 5'-RACE method using PCR ( Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002 , Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932 ).
- the target DNA fragment is purified from the resulting PCR product and linked with vector DNA. Moreover, a recombinant vector is produced from this, introduced into Escherichia coli and so forth, and colonies are selected to prepare the desired recombinant vector. The base sequence of the target DNA is then confirmed by a known method such as deoxyribonucleotide chain termination.
- an antibody gene is incorporated into an expression vector under the control of an expression control region such as an enhancer or promoter.
- an expression control region such as an enhancer or promoter.
- the host cells are transformed by this expression vector to express antibody.
- Expression of antibody gene may be carried out either by separately incorporating DNA that codes for antibody heavy chain (H chain) or light chain (L chain) into expression vectors and then simultaneously transforming the host cells, or by incorporating DNA that codes for H chain and L chain into a single expression vector and transforming the host cells (refer to the publication of WO 94/11523 ).
- transgenic animals can also be used in addition to the above host cells to produce recombinant antibody.
- recombinant antibody is produced in the form of a fused gene by inserting antibody gene at an intermediate location of a gene that codes for protein characteristically produced in breast milk.
- a DNA fragment containing fused gene into which antibody gene has been inserted is injected into a goat embryo, and this embryo is then introduced into a female goat.
- the desired antibody is obtained from the mother's milk produced by the transgenic goat born from the goat that received the embryo, or its offspring.
- a suitable hormone may be used in the transgenic goat to increase the amount of breast milk containing the desired antibody produced by that transgenic goat ( Ebert, K.M. et al., Bio/Technology (1994) 12, 699-702 ).
- genetic recombinant antibody that has been artificially altered for the purpose of decreasing heterogenic antigenicity with respect to humans can also be used, examples of which include chimeric antibody and humanized antibody. These altered antibodies can be produced using known methods.
- Chimeric antibody is obtained by linking DNA that codes for the antibody V region in the manner described above and DNA that codes for human antibody C region, incorporating this in an expression vector and introducing into a host to produce antibody. Chimeric antibody that is useful in the present invention can be obtained using this known method.
- Humanized antibody is also referred to as reshaped human antibody. This is the result of transplanting the complementarity determining region (CDR) of antibody of a mammal other than a human, such as mouse antibody, into the complementarity determining region of human antibody, and typical genetic recombination techniques are known for this (refer to European Unexamined Patent Publication No. EP 125023 and WO 96/02576 ).
- CDR complementarity determining region
- a DNA sequence designed so as to link the CDR of mouse antibody with the framework region (FR) of human antibody is synthesized by PCR using as primer a plurality of oligonucleotides prepared so as to have a portion that overlaps the terminal regions of both CDR and FR (refer to the method described in the publication of WO 98/13388 ).
- a region in which the complementarity determining region forms a satisfactory antigen binding site is selected for the framework region of the human antibody that is linked by way of CDR.
- the amino acids of the framework region in the variable region of the antibody may be substituted as necessary so that the complementarity determining region of reshaped human antibody forms an appropriate antigen binding site ( Sato, K. et al., Cancer Res. (1993) 53, 851-856 ).
- the C region of human antibody is used for the C region of chimeric antibody and humanized antibody, and for example, C ⁇ 1, C ⁇ 2, C ⁇ 3 and C ⁇ 4 can be used in the H chain, while C ⁇ and C ⁇ can be used in the L chain.
- human antibody C region may be modified to improve the stability of the antibody or its production.
- Chimeric antibody is composed of the variable region of antibody originating in a mammal other than humans and the constant region of human antibody.
- humanized antibody is composed of the complementarity determining region of an antibody originating in a mammal other than humans and the framework region and C region of human antibody. Since humanized antibody has decreased antigenicity in the human body, it is useful as an effective ingredient of the therapeutic agent of the present invention.
- versions a, b, c, b1 and b2 having the amino acid sequences shown in Table 3 were used as the humanized light chain (L chain) V region.
- the antibody used in the present invention may be an antibody fragment or modified antibody substance provided it binds to human TF and inhibits human TF activity.
- antibody fragments include single chain Fv (scFv) in which Fab, F(ab') 2 , Fv or H chain or L chain Fv is linked with a suitable linker.
- either antibody is treated with an enzyme such as papain or pepsin to produce antibody fragments, or a gene is constructed that codes for these antibody fragments, after which a fragment is inserted into an expression vector and expressed in a suitable host (refer to, for example, Co, M.S. et al., J. Immunol. (1994) 152, 2968-2976 , Better, M. & Horowitz, A.H., Methods in Enzymology (1989) 178, 476-496 , Plueckthun, A.
- an enzyme such as papain or pepsin
- scFv is obtained by linking antibody H chain V region and L chain V region.
- the H chain V region and L chain V region are linked by means of a linker, and preferably by means of a peptide linker ( Huston, J.B. et al., Proc. Natl. Acad. Sci., USA (1988) 85, 5879-5883 ).
- the H chain V region and L chain V region in scFv may be of any origin described as antibody in the present specification.
- An arbitrary single chain peptide comprised of, for example, 12-19 amino acid residues is used for the peptide linker that links the V regions.
- DNA that codes for scFv is obtained by using as template the portion of DNA coding for H chain or H chain V region and DNA coding for L chain or L chain V region of the above antibody that codes for the entire or desired amino acid sequence of those sequences, amplifying by PCR using a primer pair that defines both of its ends, and combining and amplifying DNA that codes for a peptide linker portion and primer pair defined such that both of its ends are linked with each H chain and L chain.
- DNA that codes for scFv is produced, an expression vector that contains them and a host that is transformed by said expression vector can be obtained in accordance with routine methods, and scFv can be obtained in accordance with routine methods by using that host.
- antibody fragments can be produced from a host by acquiring the gene in the same manner as previously described and expressing that gene.
- the term "antibody” in the present invention includes these antibody fragments.
- Anti-human TF antibody coupled with various molecules such as polyethylene glycol can also be used as modified antibody substances. These modified antibody substances are also included in the "antibody” of the present invention. These modified antibody substances can be obtained by performing chemical modification on the resulting antibody. Furthermore, antibody modification methods have already been established in this field.
- Antibody gene constructed in the manner previously described can be expressed and acquired by known methods.
- antibody gene can be expressed by functionally coupling a commonly used useful promoter, antibody gene to be expressed and a poly A signal downstream from its 3'-side.
- a promoter/enhancer is human cytomegalovirus immediate early promoter/enhancer.
- promoter/enhancer examples include virus promoter/enhancer such as retrovirus, poliovirus, adenovirus, and simean virus 40 (sV40), as well as promoter/enhancer originating in mammalian cells such as human elongation factor 1 ⁇ (HEF1 ⁇ ).
- virus promoter/enhancer such as retrovirus, poliovirus, adenovirus, and simean virus 40 (sV40)
- V40 simean virus 40
- promoter/enhancer originating in mammalian cells such as human elongation factor 1 ⁇ (HEF1 ⁇ ).
- Gene expression can be carried out easily according to the method of Mulligan, et al. (Nature (1979) 277, 108-114 ) in the case of using SV40 promoter/enhancer, or according to the method of Mizushima, et al. (Nucleic Acid Res. (1990) 18, 5322 ) in the case of using HEF1 ⁇ promoter/enhancer.
- said gene can be expressed by functionally coupling a commonly used useful promoter, signal sequence for antibody secretion and the antibody gene to be expressed.
- promoters include lacz promoter and araB promoter.
- Gene can be expressed according to the method of Ward, et al. ( Nature (1989) 341, 544-546 ; FASEB J. (1992) 6, 2422-2427 ) in the case of using lacz promoter, or according to the method of Better, et al. (Science (1988) 240, 1041-1043 ) in the case of using araB promoter.
- the pelB signal sequence ( Lei, S.P. et al., J. Bacteriol. (1987) 169, 4379-4383 ) should be used as the signal sequence for antibody secretion in the case of producing in periplasm of E. coli. After isolating the antibody produced in periplasm, the antibody is used after suitably refolding the antibody structure.
- Replication origins originating in SV40, poliovirus, adenovirus or bovine papilloma virus (BPV) and so forth can be used as replication origins.
- the expression vector can contain as selection marker aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine guanine phosphoribosyl transferase (Ecogpt) gene or dihydrofolate reductase (dhfr) gene.
- An arbitrary expression system such as a eucaryotic cell or procaryotic cell system, can be used to produce the antibody used in the present invention.
- eucaryotic cells include established mammalian cell systems, insect cell systems and fungal cells such as mold cells and yeast cells, while examples of procaryotic cells include bacterial cells such as E. coli cells.
- the antibody used in the present invention is preferably expressed in mammalian cells such as CHO, COS, myeloma, BHK, Vero and HeLa cells.
- the transformed host cells are cultured in vitro or in vivo to produce the target antibody.
- Culturing of host cells is carried out in accordance with known methods.
- DMEM, MEM, RPMI1640 or IMDM can be used for the culture medium
- a serum supplement such as fetal calf serum (FCS) can be used in combination with the above media.
- FCS fetal calf serum
- Antibody expressed and produced as described above can be isolated from cells or host animal and purified until homogeneous. Isolation and purification of antibody used in the present invention can be carried out using an affinity column. Examples of columns using a protein A column include Hyper D, POROS and Sepharose F.F. (Pharmacia). In addition, isolation and purification methods used with ordinary proteins should be used, and there are no restrictions whatsoever on these methods. For example, antibody can be isolated and purified by suitably selecting and combining, in addition to above affinity columns, a chromatography column, filter, ultrafiltration, salting out or dialysis and so forth ( Antibodies: A Laboratory Manual, Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988 ).
- Example 2 The result of the experiment that used the above humanized anti-human TF antibody version "i-b2" is shown in Example 2 and Figures 11 to 13 .
- 1 mg/kg of the humanized anti-human TF antibody version "i-b2" was repeatedly administered intravenously once a week, with a result that the platelet count was maintained at a level equal to that in the mice that were not implanted with the tumor cell till the end of the experiment, i.e., three weeks after the start of the administration.
- the administration of the humanized anti-human TF antibody of the present invention suppressed the increase in the concentrations of soluble fibrin monomer complex (sFMC) and thrombin-antithrombin III complex (TAT). The result confirmed that the administration of anti-human TF antibody of the present invention prevents the persistence of a hypercoagulable state and maintains a normal state.
- sFMC soluble fibrin monomer complex
- TAT thrombin-antithrombin III complex
- An elongation of prothrombin time, a decrease in the plasma concentration of fibrinogen, an increase in the serum concentration of fibrin degradation products, and the like can be ascribed to the hypercoagulable state.
- the administration of anti-human TF antibody of the present invention suppressed the elongation of prothrombin time, the decrease in plasma concentration of fibrinogen, and the increase in the serum concentration of fibrin degradation products induced by the continuous infusion of LPS. This result demonstrates that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on the hypercoagulable state resulting from infections.
- Example 3 this effect is described in detail. 8-3. Confirmation of the preventive and/or therapeutic effect on venous thrombosis
- Example 4 it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on venous thrombosis.
- Example 5 it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on arterial thrombosis.
- Example 6 it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on diseases resulting from the medial thickening of blood vessels.
- the therapeutic agent of the present invention is used for the purpose of preventing, treating or improving diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media.
- Effective dosage per administration is selected from the range of 0.001 mg to 1.000 mg/kg body weight. Alternatively, the dosage of 0.01 to 100 mg/kg, preferably 0.1 to 10 mg/kg may be selected. However, the therapeutic agent containing anti-human TF antibody of the present invention is not limited to these dosages.
- the method of administration is, but is not limited to, intravenous injection, intravenous drip, and the like.
- the therapeutic agent of the present invention comprising anti-human TF antibody as an active ingredient may be formulated using a standard method ( Remington's Pharmaceutical Science, the latest edition, Mark Publishing Company, Easton, USA ), and may contain pharmaceutically acceptable carriers and/or additives.
- Such carriers or additives include water, a pharmaceutically acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like.
- a pharmaceutically acceptable organic solvent collagen
- polyvinyl alcohol polyvinylpyrrolidone
- a carboxyvinyl polymer carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pe
- Additives used are chosen from, but are not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present invention.
- purified anti-human TF antibody when used as injections, purified anti-human TF antibody may be dissolved in a solvent such as physiological saline, a buffer, and a glucose solution, to which an anti-adsorbent such as Tween 80, Tween 20, gelatin, and human serum albumin may be added.
- a solvent such as physiological saline, a buffer, and a glucose solution
- an anti-adsorbent such as Tween 80, Tween 20, gelatin, and human serum albumin
- they may be lyophilized so as to be dissolved and reconstituted into a dosage form before use.
- sugar alcohols and sugars such as mannitol and glucose may be used.
- pCOS1. was constructed by removing the antibody gene from HEF-PMh-g ⁇ 1 ( WO 92/19759 ) by digesting with EcoRI and SmaI and then by ligating the EcoRI-NotI-BamHI adaptor (Takara Shuzo). This was cultured in a RPMI1640 medium (containing 20% FCS hIL-6: 4 ng/ml) containing 1 mg/ml G418, and the cells that grew were confirmed to be the expression of human tissue factor using anti-human tissue factor antibody (American Diganostica) by flow cytometry. This gave a cell line KPMM2/TF226 that has introduced a human tissue factor gene therein.
- the parent strain (KPMM2/parent) before the introduction of the above human tissue factor gene and the gene-introduced strain KPMM2/TF226 were cultured in a RPMI-1640 medium containing 4 ng/ml human IL-6 and 20% bovine fetal serum.
- SCID mice available from CLEA Japan, male, 7-week old, mean body weight: about 22 g
- tumor volume increased with time in all mice.
- the plasma concentration of human tissue factor increased with time in the mice having implanted therein cells to which the human tissue factor gene had been introduced, but did not increase at all in the mice having implatned therein cells to which the human tissue factor gene had not been introduced.
- Figure 7 and Figure 8 in the mice having implanted therein cells to which the human tissue factor gene had been introduced, each of platelets and fibrinogen decreased with time, indicating that these coagulation components in the blood were consumed. In contrast, in the mice having implanted therein cells to which the human tissue factor gene had not been introduced, no decrease (consumption) in these coagulation components in the blood was noted.
- the effect of the humanized anti-human TF antibody version "i-b2" was investigated in the model described in Example 1. Five to six weeks after the implantation of KPMM2/TF226 to SCID mice (CLEA Japan, male, 7-week old, mean body weight: about 22 g), at when platelet counts fell to about half that of the non-tumor-implanted group, confirming the persistence of a hypercoagulable state, and thus from day 45 after the implanted 1 mg/kg of humanized anti-human TF antibody version "i-b2" was intravenously administered once a week.
- humanized anti-human TF antibody version "i-b2" On day 6 after the third administration of humanized anti-human TF antibody version "i-b2" , the plasma concentrations of soluble fibrin monomer complex (sFMC) and of thrombin-antithrombin III complex (TAT) were determined, and it was found that the administration of the antibody suppressed their increases ( Figure 12 and Figure 13 ). These results indicated that humanized anti-human TF antibody version "i-b2" had the effect of stably maintaining coagulation at a normal level, by a once-per-week administration in the model in which a hypercoagulable state persists for a long period.
- sFMC soluble fibrin monomer complex
- TAT thrombin-antithrombin III complex
- LPS dissolved in physiological saline was continuously injected into a vein at a done of 1 mg/kg/hr (2 ml/kg/hr) for 6 hours to cynomolgus monkeys (imported from Chuang Primates Experimental Animal Research Center, Nanning, the People's Republic of China, equal numbers of males and females, estimated age: 5-7 years old, body weight: 2.99-5.81 kg) under isoflurane anesthesia.
- Intravenous administration of humanized anti-human TF antibody "version i-b2" at 0.3 mg/kg (1 ml/kg) to monkeys of the humanized anti-human TF antibody-administration group, and that of a solvent (20 mM sodium acetate/150 mM NaCl, pH 6.0) to monkeys of the control group were made respectively 10 minutes before the start of continuous injection of LPS.
- Cynomolgus monkeys with an estimated age of 3-4 years old, weighing 2.97-3.99 kg were used in the venous thrombosis model.
- the monkeys were anesthetized with mixture of isoflurane and nitrous oxide to expose the bilateral jugular veins.
- a segment of the exposed jugular vein was completely ligated with suture around the site proximal to the heart, and was reversibly legated with suture around the site nearer to the head so as to be loosened afterward.
- a catheter was inserted into the segment between the both ligation of the exposed jugular vein, from the nearer site to the heart in the direction toward the head.
- Blood in the segment between the ligations of the exposed jugular vein was removed through the catheter and the inside was washed with physiological saline. Via the catheter, 0.5% polidocanol was injected into the segment between the ligations of the exposed blood vessel. The catheter was removed and, at the same time, the segment of the blood vessel was reversibly ligated at the immediate upper part of the catheter insertion site.
- the reversible ligation at the heart side was loosened to remove polidocanol.
- the reversible ligation at the head side was loosened to drain a smoll amount of blood, and then the segment of the exposed blood vessel was completely at the immediate upper part of the catheter insertion site. After the segment was filled with blood, the exposed jugular vein was completely ligated at the part nearer to the head. The segment between the both complete ligations was adjusted to be 1.5 cm in length.
- the wet weight of the formed clots was measured. For the assessment, the sum of the wet weight of the clots in the bilateral jugular veins was used.
- Humanized anti-human TF antibody "version i-b2" was intravenously administered at a dose of 0.3 mg/kg and 1.5 mg/kg 2 hours before the start of the venous thrombus formation.
- Cynomolgus monkeys with an estimated age of 3-5 years old, weighing 3.55-3.99 kg were used in the arterial thrombosis model.
- the monkeys were anesthetized with ketamine hydrochloride (intramuscular administration) and butofanol (intramuscular administration) to expose the right common carotid artery.
- the probe of a doppler flowmeter was placed around the exposed blood vessel, and blood flow was monitored for about 5 minutes. After confirming the constant flow of the bloodstream, angiostenosis and the arterial wall injury were induced around the proximal site to the head side of the probe.
- Cynomolgus monkeys (purchased from KEARI Inc., monkeys raised in Vietnam, the estimated age of 4-5 years) were anesthetized under 5-10 mg/kg of Ketalar, im, and 15-20 mg/kg of pentobarbital, iv, and the neck was incised to expose the carotid artery.
- a Fogarty catheter (3-5F) was inserted and the balloon was inflated to scrape the vascular intima for five times. After scraping, the catheter was extracted and the wound was sutured.
- the animals were euthanized and the carotid artery was removed. At this time, the contralateral carotid artery that was not balloon-injured was extracted in a similar manner.
- Humanized anti-human TF antibody "version i-b2" was intravenously administered at a dose of 0.3 mg/kg over 1 minutes, 10 minutes before the vascular injury.
- the extracted artery was fixed in formalin, histological specimens were prepared, and stained with a HE stain and Elastica van Gieson stain, followed by image analysis to measure the area of the intima.
- humanized anti-human TF antibody "version i-b2" strongly suppressed the hypertrophy of the intima.
- Soluble human TF was prepared in the following manner.
- the gene encoding the human TF penetrating region in which amino acids at position 220 and thereafter had been replaced with the FLAG peptide M2 was inserted to a mammalian cell expression vector (containing the neomycin resistant gene and the DHFR gene), and introduced into CHO cells.
- a mammalian cell expression vector containing the neomycin resistant gene and the DHFR gene
- the gene sequence and the amino acid sequence of this soluble human TF are shown in SEQ ID NOs: 101 and 102. After drug selection with G418, the expressed cells were selected, which were then subjected to expression amplification with methotrexate, and the shTF-expressing cells were established.
- the cells were cultured in the serum-free medium CHO-S-SFMII (GIBCO) to obtain a culture supernatant containing shTF. It was diluted 2-fold with an equal volume of a 40 mM Tris-HCl buffer (pH 8.5), which was added to the Q-Sepharose Fast Flow column (100 ml, Pharmacia Biotech) equilibrated with a 20 mM Tris-HCl buffer (pH 8.5). After washing with the same buffer containing 0.1 M NaCl, the concentration of NaCl was changed to 0,3 M, and shTF was eluted from the column.
- CHO-S-SFMII GEBCO
- TF from human placenta was carried out according to the method of Ito ( Ito, T. et al., J. Biol. Chem., 114: 691-696, 1993 ).
- human placenta was homogenized in Tris buffered saline (TBS, pH 7.5) containing 1.0 mM benzamidine hydrochloride, 1 mM phenylmethylsulfonyl fluoride, 1 mM diisopropylfluoro phosphate, and 0.02% sodium azide, and then the precipitate was defatted with cold acetone.
- the defatted powder obtained was suspended in the above buffer containing 2% Triton X-100 to solubilize TF.
- the supernatant was subjected to affinity chromatography using Concanavalin A-Sepharose 4B column (Pharmacia) and anti-TF antibody-bound Sepharose 4B column (Pharmacia), and purified TF was obtained. This was concentrated with an ultrafiltration membrane (PM-10, Amicon) and was stored as the purified sample at 4°C.
- TF content in the purified sample was quantitated by Sandwich ELISA that combined a commercially available anti-TF monoclonal antibody (American Diagnostica) and polyclonal antibody (American Diagnostica) with Recombinant TF as a standard.
- the purity in the purified sample was confirmed by subjecting the sample to SDS-PAGE using a 4-20% density gradient polyacrylamide gel, and silver-staining the product.
- the spleen cells were prepared from four mice, and were fused to the mouse myeloma cell line P3U1 at 1/5 cell count thereof by the polyethylene glycol method.
- the fused cells were suspended into the RPMI-1640 medium (hereinafter referred to as RPMI-medium) (Lifetech Oriental) containing 10% fetal bovine serum, which was inoculated in 400 wells per mouse (about 400 cells/well) of a 96-well plate.
- HAT-medium RPMI-medium
- HAT Dainippon Seiyaku
- condimed H1 Boehringer Mannheim GmbH
- hybridomas selected by the screening method described below were cloned by conducting limiting dilution twice.
- 0.8 cells was inoculated per well in two 96-well plates.
- clones were selected by the following measurement of the binding activity to TF and neutralizing activity against TF. The clones obtained were acclaimed from the HAT-medium to the RPMI-medium. After the absence of reduction in antibody production ability due to acclimation was confirmed, limiting dilution was performed again for complete cloning.
- hybridomas that produce six antibodies (ATR-2, 3, 4, 5, 7, and 8) that strongly inhibit the binding of TF/Factor VIIa complex and Factor X were established.
- the ascites formation of the established hybridomas were carried out according to the standard method.
- 10 6 hybridomas that were subcultured in vitro were intraperitoneally grafted into BALB/c male mice that had previously received twice intravenous administration of mineral oil.
- Ascites was collected from the mice that showed a bloated abdomen 1-2 weeks after the grafting.
- Human bladder carcinoma cells J82 ( Fair D. S. et al., J. Biol. Chem., 262: 11692-11698, 1987 ) that are known to express TF at a high level were obtained from ATCC, and subcultured and maintained in the RPMI-medium under the condition of 37°C, 5% CO 2 , and 100% humidity.
- Cell-ELISA plates were prepared by inoculating J82 cells to a 96-well plate at 10 5 cells/well, culturing for one day under the above condition, removing the medium and then washing twice with phosphate buffered saline (PBS), adding a 4% paraformaldehyde solution (PFA), and allowing to stand on ice for 10 minutes for immobilization. After PFA was removed, the plate was washed with PBS, the Tris buffer (Blocking buffer) containing 1% BSA and 0.02% sodium azide was added thereto, and the plate was stored at 4°C until use.
- PBS phosphate buffered saline
- PFA paraformaldehyde solution
- Blocking buffer was removed from the plate prepared as above, to which an anti-TF antibody solution or a hybridoma culture supernatant was added and was reacted at room temperature for 1.5 hours. After washing with PBS containing 0.05% Tween 20, alkaline phosphatase-conjugated goat anti-mouse IgG (H+L) (Zymed) was reacted for 1 hour. After washing, 1 mg/ml p-nitrophenyl phosphate disodium (Sigma) was added, and one hour later absorbance at 405/655 nm was measured to determine the amount of anti-TF antibody that bound to the J82 cells.
- Tris buffered saline TBS: pH 7.6
- bovine serum albumin 10 ⁇ l
- a human placenta-derived thromboplastin solution 5 mg/ml
- Thromborel S Thromborel S
- 10 ⁇ l of a Factor VIIa solution 82.5 ng/ml
- mRNA was prepared from hybridoma ATR-5 (IgG1 ⁇ ) obtained in Reference Example 2 using the QuickPrep mRNA Purification Kit (Pharmacia Biotech). Each hybridoma cell was completely homogenized in the extraction buffer according to instructions attached to the kit, and then mRNA was purified by the oligo (dT)-cellulose spun column, followed by ethanol precipitation. The mRNA precipitate was dissolved in the elution buffer.
- the cloning of the gene encoding the H chain V region of a mouse monoclonal antibody against human TF was carried out using the 5'-RACE method ( Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002, 1988 ; Belyavsky, A. et al., Nucleic Acids Res. 17: 2919-2932, 1989 ).
- the Marathon cDNA Amplification Kit (CLONTECH) was used and the procedure carried out according to the instructions attached to the kit.
- the cDNA synthesis primer attached to the kit was added, which was reacted with a reverse transcriptase at 42°C for 60 minutes to effect reverse transcription to cDNA. This was reacted with DNA polymerase I, DNA ligase, and RNaseH at 16°C for 1.5 hour, and with T4 DNA polymerase at 16°C for 45 minutes thereby to synthesize a double stranded cDNA.
- the double stranded cDNA was extracted with phenol and chloroform, and recovered by ethanol precipitation.
- a cDNA adapter was ligated to both ends of the double stranded cDNA.
- the reaction mixture was diluted 50-fold with a 10 mM Tricine-KOH (pH 8.5) containing 0.1 mM EDTA.
- the gene encoding the H chain V region was amplified by PCR.
- the adapter primer 1 attached to the kit was used for the 5'-end primer, and for the 3'-end primer the MHC-G1 primer (SEQ ID NO: 1) ( S. T. Jones, et al., Biotechnology, 9: 88-89, 1991 ) were used.
- PCR solutions for the ATR-5 antibody H chain V region contained, in 100 ⁇ l, 120 mM Tris-HCl (pH 8.0),10 mM KCl, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), 30-50 pmole of adapter primer 1, as well as MHC-G1 primer, and 1-5 ⁇ l of a reaction mixture of cDNA to which the cDNA adapter was ligated.
- PCRs were carried out using the DNA Thermal Cycler 480 (Perkin-Elmer), and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- the cloning of the gene encoding the L chain V region of a mouse monoclonal antibody against human TF was carried out using the 5'-RACE method ( Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002, 1988 ; Belyavsky, A. et al., Nucleic Acids Res. 17: 2919-2932, 1989 ).
- the Marathon cDNA Amplification Kit (CLONTECH) was used and carried out according to the instructions attached to the kit.
- the cDNA synthesis primer was added, which was reacted with a reverse transcriptase at 42°C for 60 minutes to effect reverse transcription to cDNA.
- the gene encoding the L chain V region was amplified by PCR.
- the adapter primer 1 was used for the 5'-end primer, and for the 3'-end primer the MKC primer (SEQ ID NO: 2) ( S. T. Jones, et al., Biotechnology, 9: 88-89, 1991 ) was used.
- PCR solutions contained, in 100 ⁇ l, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), 30-50 pmole of adapter primer 1, as well as MKC primer, and 1 ⁇ l of a reaction mixture of cDNA to which the cDNA adapter was ligated.
- PCRs were carried out using the DNA Thermal Cycler 480 (Perkin-Elmer), and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- the above PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation.
- DNA fragments were digested with the restriction enzyme XmaI (New England Biolabs) at 37°C for 1 hour.
- the XmaI-digestion mixture was separated by agarose gel electrophoresis using 2%-3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 500 bp long DNA fragments as the H chain V region and about 500 bp Long DNA fragments as the L chain V region were excised.
- TE 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA
- the XmaI-digested DNA fragments prepared as above containing a genes encoding a mouse H chain V region and L chain V region and the pUC19 plasmid vector prepared by digesting with XmaI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli J1M109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C.
- the transformant was cultured overnight in 3 ml or 4 ml of a LB medium containing 50 ⁇ g/ml ampicillin (hereinafter referred to as LBA medium) at 37°C, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN), and then the nucleotide sequence was determined.
- LBA medium a LB medium containing 50 ⁇ g/ml ampicillin
- the nucleotide sequence of the cDNA coding region in the above plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) (SEQ ID NO: 3) and M13 Primer RV (Takara Shuzo) (SEQ ID NO: 4) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- nucleotide sequences of the genes encoding the H chain V region of each mouse antibody contained in the plasmid ATR-5Hv/pUC19 is shown in SEQ ID NO: 5 and 99, respectively, and the nucleotide sequences of the genes encoding the L chain V region of each mouse antibody contained in the plasmid ATR-5Lv/pUC19 (including the corresponding amino acid sequences) is shown in SEQ ID NO: 6 and 100, respectively.
- a chimeric ATR-5 antibody was generated in which the mouse ATR-5 antibody V region was ligated to the human antibody C region.
- a chimeric antibody expression vector was constructed by ligating the gene encoding the ATR-5 antibody V region to an expression vector encoding the human antibody C region.
- the ATR-5 antibody H chain V region was modified by the PCR method in order to ligate it to an expression vector encoding the human antibody H chain C region.
- the 5'-end primer ch5HS (SEQ ID NO: 7) was designed so as to hybridize the 5'-end of DNA encoding the V region and to have the Kozak consensus sequence ( Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987 ) and a recognition sequence of the restriction enzyme SalI.
- the 3'-end primer ch5HA was designed so as to hybridize 3'-end of DNA encoding the J region and to have a recognition sequence of the restriction enzyme NheI.
- the PCR solutions contained, in 100 #1, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the ch5HS primer and the ch5HA primer, as well as 1 ⁇ l of the plasmid ATR5Hv/pUC19 as a template DNA.
- the DNA Thermal Cycler 480 Perkin-Elmer
- the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- the PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation.
- the DNA fragments were digested with the restriction enzyme NheI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme SalI (Takara Shuzo) at 37°C for 1 hour.
- the digestion mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 450 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- an altered promoter vector (hereinafter referred to as CVIDEC) was used in which the recognition sequences of the restriction enzymes NheI, SalI, and SplI, BglII were introduced.
- the gene fragment prepared as above encoding the mouse H chain V region and the CVIDEC vector prepared by digesting with NheI and SalI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 2°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle. Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA sequencer 373A (Ferkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) (SEQ ID NO: 3) and M13 Primer RV (Takara Shuzo) (SEQ ID NO: 4) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- the plasmid that contains the gene encoding the ATR-5 antibody H chain V region, a SalI recognition sequence and the Kozak consensus sequence at the 5'-end, and a NheI recognition sequence at the 3'-end was designated as chATR5Hv/CVIDEC.
- the ATR-5 antibody L chain V region was modified by the PCR method in order to ligate it to an expression vector encoding the human antibody L chain C region.
- the 5'-end primer ch5LS (SEQ ID NO: 9) was designed so as to hybridize to the 5'-end of the DNA encoding the V region and to have the Kozak consensus sequence ( Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987 ) and a recognition sequence of the restriction enzyme BgIII.
- the 3'-end primer ch5LA was designed so as to hybridize to the 3'-end of the DNA encoding the J region and to have a recognition sequence of the restriction enzyme SplI.
- the PCR solutions contained, in 100 ⁇ l, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the ch5LS primer and the ch5LA primer, as well as 1 ⁇ l of the plasmid ATR5Lv/pUC19 as a template DNA.
- the DNA Thermal Cycle 480 Perkin-Elmer
- the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- the PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation.
- the DNA fragments were digested with the restriction enzyme SplI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme BglI (Takara Shuzo) at 37°C for 1 hour.
- the digestion mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, the DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- the gene fragment prepared as above encoding the mouse L chain V region and the CVIDEC vector prepared by digesting with SplI and BglI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 ⁇ g/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- the plasmid that contains the gene encoding the ATR-5 antibody L chain V region and that has a BglII recognition sequence and the Kozak consensus sequence at the 5'-end and a SplI recognition sequence at the 3'-end was designated as chATR5Lv/CVIDEC.
- a chimeric antibody expression vector was constructed using an antibody expression vector introduced from IDEC Pharmaceuticals.
- the TgGl-type antibody expression vector H5KG1(V) and the IgG4-type antibody expression vector N5KG4P were used.
- the chimeric ATR-5 antibody expression vector was generated by ligating a gene encoding the H chain V region of ATR-5 to the SalI-NheI site located immediately before the human antibody H chain C region of the expression vector N5KG1(V) or N5KG4P and ligating a gene encoding the L chain V region of ATR-5 to the BglII-SplI site located immediately before the human antibody L chain c region of the expression vector N5KG1(V) or N5KG4P.
- the plasmid chATR5Hv/CVIDEC was digested with the restriction enzyme NheI (Takara Shuzo) at 37°C for 3 hours, and with the restriction enzyme SalI (Takara Shuzo) at 37°C for 3 hours.
- the digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 450 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- the expression vector N5KG1(V) and N5KG4P were digested with the restriction enzyme Nhel (Takara Shuzo) at 37°C for 3 hours, and with the restriction enzyme SalI (Takara Shuzo) at 37°C for 3 hours.
- the digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 9000 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- the SalI-NheI DNA fragment prepared as above containing the gene encoding the H chain V region and N5KG1(V) or N5KG4P digested with SalI and NheI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the attached instructions.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 ⁇ g/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN). These plasmids containing the genes encoding the chimeric ATR-5 antibody H chain were designated as chATR5v/N5KG1(V) and chATR5Hv/N5KG4P, respectively.
- the plasmid chATR5Lv/cVIDEC was digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 1.5 hour.
- the digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- the plasmids chATR5Hv/N5KG1(V) and chATR5Hv/N5KG4P were digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 1.5 hour.
- the digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 9400 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, DNA fragments were precipitated with ethanol, which were then dissolved in 20 ⁇ l of TE.
- the SplI-BglII DNA fragment prepared as above containing the gene encoding the L chain V region and chATR5Hv/N5KG1(V) or chATR5Hv/N5KG4P digested with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the attached instructions.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 ⁇ g/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant.
- the transformant was cultured overnight at 37°C in 1 l of the 2xYT medium containing 50 ⁇ g/ml ampicillin, and from the cell fractions, plasmid DNA was prepared using the Plasmid Maxi Kit (QIAGEN). These plasmids containing the gene encoding the chimeric ATR-5 antibody were designated as chATR5/N5KG1(V) and chATR5/N5KG4P, respectively.
- the above expression plasmid was transected to COS-7 cells and the antibody was transient expressed.
- the plasmid chATR5/NSKG1(V) or chATR5/N5KG4P was transduced into COS-7 cells by electroporation using the Gene Pulser instrument (Bio Rad). Fifty ⁇ g of the plasmid was added to 0.78 ml of the COS-7 cells suspended in the Dulbecco PBS (-) (hereinafter referred to as PBS) at a cell concentration of 1 ⁇ 10 7 cells/ml, which was subjected to pulses of 1,500 V and 25 ⁇ F capacity.
- PBS Dulbecco PBS
- the electroporated cells were suspended in a DMEM medium containing 5% Ultra low IgG fetal bovine serum (GIBCO), and cultured using a 10 cm culture dish in a 5% CO 2 incubator. After culturing for 24 hours, the culture supernatant was aspirated off, and then a serum-free medium HBCHO (Irvine Scientific) was added. After further culturing for 72 hours, the culture supernatant was collected and centrifuged to remove cell debris.
- a DMEM medium containing 5% Ultra low IgG fetal bovine serum GGIBCO
- a serum-free medium HBCHO Irvine Scientific
- chimeric antibody was purified using the rProtein A Sepharose Fast Flow (Pharmacia Biotech) as follows.
- the adsorbed antibody fraction was then eluted by 13.5 ml of 2.5 mM HCl (pH 3.0), and the eluate was immediately neutralized by adding 1.5 ml of 1 M Tris-HCl (pH 8.0).
- the above expression plasmid was introduced into CHO cells (DG44) acclimated to the CHO-S-SFMII serum-free medium (GIBCO).
- the plasmid chATR5/N5KG1(V) or chATR5/N5KG4P was cleaved with the restriction enzyme SspI (Takara Shuzo) to linearize DNA, and after extraction with phenol and chloroform, DNA was recovered by ethanol precipitation.
- the linearized plasmid was transduced into the DG44 cells by electroporation using the Gene Pulser instrument (Bio Rad). Ten ⁇ g of the plasmid was added to 0.78 ml of DG44 cells suspended in PBS at a cell concentration of 1 ⁇ 10 7 cells/ml, which was subjected to pulses of 1,500 V and 25 ⁇ F capacity.
- the electroporated cells were suspended in a CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO), and cultured using two 96-well plates (Falcon) in a 5% CO 2 incubator.
- the medium was changed to a selection medium containing the CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO) and 500 ⁇ g/ml GENETICIN (G418Sulfate, GIBCO) to select cells into which the antibody gene had been introduced.
- the cells were examined under a microscope about two weeks later. After a favorable cell growth was observed, the amount of antibody produced was measured by the ELISA described below for determining antibody concentration, and cells having a high production yield of antibody were selected.
- Humanized ATR-5 antibody H chain was generated using CDR-grafting by the PCR method.
- the humanized antibody H chain version "a" having the FRs derived from human antibody L39130 (DDBJ, Gao L. et al., unpublished, 1995)
- seven PCR primers were used.
- the CDR-grafting primers hR5Hv1S (SEQ ID NO: 11), hR5Hv2S (SEQ ID NO: 12), and hR5Hv4S (SEQ ID NO: 13) have a sense DNA sequence
- hR5Hv1S was designed to have the Kozak consensus sequence ( Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987 ) and a SalI recognition site
- hR5Hv5A was designed to have a NheI recognition site.
- the exogenous primer hR5HvPrS (SEQ ID NO: 16) has a homology with the CDR-grafting primer hR5Hv1S
- hR5HvPrA SEQ ID NO: 17
- the CDR-grafting primers hR5Hv1S, hR5Hv2S, hR5Hv3A, hR5Hv4S, and hR5Hv5A, and exogenous primers hR5HvPrS and hR5HvPrA were synthesized and purified by Pharmacia Biotech.
- PCR was performed using the KOD DNA polymerase (Toyo Boseki) and using the attached buffer under the condition of containing 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), and 5 pmole each of the CDR-grafting primers hR5Hv1S, hR5Hv2S, hR5Hv3A, hR5Hv4S, and hR5Hv5A in 98 ⁇ l, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute.
- PCR was performed for 25 cycles in a system of 100 ⁇ l with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts).
- the agarose strips containing about 430 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 17 ⁇ l of water.
- the PCR reaction mixture obtained was digested with NheI and SalI, and was ligated to the plasmid vector CVIDEC prepared by digesting with NheI and SalI, using the DNA ligation kit ver.2 (Takara Shuzo) according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- each of fragments having the correct sequence was ligated and then subcloned again to CVIDEC to determine the nucleotide sequence.
- the plasmid having the correct sequence was designated as hATR5Hva/CVIDEC.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "a" contained in the plasmid hATR5Hva/CVIDEC are shown in SEQ ID NO: 18.
- the amino acid sequence of version "a” is also shown in SEQ ID NO: 19.
- Versions "b” and “c” were generated by replacing the FR3 of version "a” with the FR3 derived from another human antibody using the FR-shuffling method.
- the four DNA primers encoding the FR3 were generated.
- the FR-shuffling primers F3RFFS (SEQ ID NO: 20) and F3RFBS (SEQ ID NO: 21) have a sense DNA sequence and F3RFFA (SEQ ID NO: 22) and F3RFBA (SEQ ID NO: 23) have an antisense DNA sequence.
- F3RFFS and F3RFFA have a sequence complementary to each other, and have BalI and XhoI recognition sequences on both ends.
- the FR-shuffling primers F3NMFS (SEQ ID NO: 24) and F3NMBS (SEQ ID NO: 25) have a sense DNA sequence and F3NMFA (SEQ ID NO: 26) and F3NMBA (SEQ ID NO: 27) have an antisense DNA sequence.
- F3RFBS and F3RFBA have a sequence complementary to each other, and have XhoI and NcoI recognition sequences on both ends.
- F3RFFS, F3RFBS, F3RFFA, F3RFBA, F3NMFS, F3NMBS, F3NMFA, and F3NMBA were synthesized by Pharmacia Biotech.
- F3RFFS and F3RFFA, and F3RFBS and F3RFBA were annealed, and were digested with BalI and XhoI, and NcoI and XhoI, respectively. They were introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmid having the correct sequence was designated as hATR5Hvb/CVIDEC.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b" contained in the plasmid hATR5Hvb/CVIDEC are shown in SEQ ID NO: 28.
- amino acid sequence of version "b” is also shown in SEQ ID NO: 29.
- F3NMFS and F3NMFA, and F3NMBS and F3NMBA were annealed, and were digested with BalI and XhoI, and NcoI and XhoI, respectively. They were introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmid having the correct sequence was designated as hATR5Hvc/CVIDEC.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "c" contained in the plasmid hATR5Hvc/CVIDEC are shown in SEQ ID NO: 30.
- the amino acid sequence of version "c" is also shown in SEQ ID NO: 31.
- Versions "d” and “e” were generated by replacing the FR3 of version "a” with the FR3 derived from another human antibody using the FR-shuffling method.
- the FR-shuffling primer F3EPS (SEQ ID NO: 32) has a sense DNA sequence and F3EPA (SEQ ID NO: 33) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- Exogenous primers F3PrS (SEQ ID NO: 34) and F3PrA (SEQ ID NO: 35) have a homology with the For-shuffling primers F3EPS and F3EPA, and can also be used for other FR3's FR-shuffling.
- F3EPS and F3EPA for-shuffling primers
- F3EPA for-shuffling primers
- F3PrA SEQ ID NO: 35
- the for-shuffling primers F3VHS (SEQ ID NO: 36) has a sense DNA sequence and F3VHA (SEQ ID NO: 37) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3EPS, F3EPA, F3PrS, F3PrA, F3VHS and F3VHA were synthesized by Pharmacia Biotech.
- PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 ⁇ l each of 1 ⁇ M FR-shuffling primers F3EPS and F3EPA, or F3VHS and F3VHA, 0.2 mM dNTPs, 1.0 mM MgCl 2 , and 2.5 units of KOD DNA polymerase in 100 ⁇ l of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% Nu Sieve GTG agarose (FMC BioProducts).
- the agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 ⁇ l of water.
- the PCR reaction mixture obtained was digested with Ball and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmids having the correct sequence were designated as hATR5Hvd/CVIDEC and hATR5Hve/CVIDEC.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "d" contained in the plasmid hATR5Hvd/CVIDEC are shown in SEQ ID NO: 38, and the amino acid sequence of version "d” is also shown in SEQ ID NO: 39.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "e” contained in the plasmid hATR5Hve/CVIDEC are shown in SEQ ID NO: 40, and the amino acid sequence of version "e” is also shown in SEQ ID NO: 41.
- Versions "f” and “g” were generated by replacing the FR3 of version "a” with the FR3 derived from another human antibody using the FR-shuffling method.
- the FR3 in version "f” with one derived from human antibody L04345 (DDBJ, Hillson JL. et. al., J. Exp. Med., 178: 331-336, 1993 ) and to replace the FR3 in version "g” with one derived from human antibody S78322 (DDBJ, Bejcek BE. et al., Cancer Res., 55: 2346-2351, 1995 )
- two primers each encoding the FR3 were synthesized.
- the FR-shuffling primer F3SSS (SEQ ID NO: 42) of version "f” has a sense DNA sequence and F3SSA (SEQ ID NO: 43) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3CDS (SEQ ID NO: 44) of version "g” has a sense DNA sequence and F3CDA (SEQ ID NO: 45) has an antisense DNA sequence, and the 3 ⁇ -end of the primers has a complementary sequence of 18 bp.
- F3SSS, F3SSA, F3CDS, and F3CDA were synthesized and purified by Pharmacia Biotech.
- PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 ⁇ l each of 1 ⁇ M FR-shuffling primers F3SSS and F3SSA, or F3CDS and F3CDA, 0.2 mM dNTPs, 1.0 mM MgCl 2 , and 2.5 units of KOD DNA polymerase in 100 ⁇ l of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts).
- the agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 ⁇ l of water.
- the PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmids having the correct sequence were designated as hATR5Hvf/CVIDEC and hATR5Hvg/CVIDEC.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "f" contained in the plasmid hATR5Hvf/CVIDEC, and the amino acid sequence of version "f” are shown in SEQ ID NO: 46 and 47.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "g" contained in the plasmid hATR5Hvg/CVIDEC, and the amino acid sequence of version "g” are shown in SEQ ID NO: 48 and 49.
- versions "h” was generated by replacing the FR3 of version "a” with the FR3 derived from another human antibody using the FR-shuffling method.
- FR-shuffling primer F3ADS SEQ ID NO: 50
- F3ADA SEQ ID NO: 51
- F3ADS and F3ADA were synthesized and purified by Pharmacia Biotech. PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 ⁇ l each of 1 ⁇ M FR-shuffling primers F3ADS and F3ADA, 0.2 mM dNTPs, 1.0 mM MgCl 2 , and 2.5 units of KOD DNA polymerase in 100 ⁇ l of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74C for 1 minute.
- KOD DNA polymerase Toyo Boseki
- PCR was performed for 25 cycles with the same temperature cycle. DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts).
- the agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 ⁇ l of water.
- the PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmids having the correct sequence were designated as hATR5Hvh/CVIDEC.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "h" contained in the plasmid hATR5Hvh/CVIDEC, and the amino acid sequence of version "h” are shown in SEQ ID NO: 52.
- amino acid sequence of version "h” is shown in SEQ ID NO: 53.
- Versions "i” and “j” were generated by replacing the FR3 of version "a” with the FR3 derived from another human antibody using the FR-shuffling method.
- DDBJ Human antibody U95239
- FR3 in version "j” one derived from the human antibody L03147
- two primers each encoding the FR3 were synthesized.
- the FR-shuffling primer F3MHS (SEQ ID NO: 54) of version "i" has a sense DNA sequence and F3MMA (SEQ ID NO: 55) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3BMS (SEQ ID NO: 56) of version "j" has a sense DNA sequence and F3BMA (SEQ ID NO: 57) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3MMS, F3MMA, F3BMS, and F3BMA were synthesized and purified by Pharmacia Biotech.
- PCR was performed using the Ampli Taq Gold (Perkin-Elmer) using the attached buffer under the condition of containing 5 ⁇ l each of 1 ⁇ M FR-shuffling primers F3MMS and F3MMA, or F3BMS and F3BMA, 0.2 mM dNTPs, 1.0 mM MgCl 2 , and 2.5 units of Ampli Taq Gold in 100 ⁇ l of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- Ampli Taq Gold Perkin-Elmer
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% Nu Sieve GTG agarose (FMC BioProducts).
- the agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 ⁇ l of water.
- the PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- the plasmids having the correct sequence were designated as hATR5Hvi/cVIDEC and hATR5Hvj/CVIDEC.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "i" contained in the plasmid hATR5Hvi/CVIDEC, and the amino acid sequence of version "i” are shown in SEQ ID NO: 58 and 59.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "j" contained in the plasmid hATR5Hvj/CVIDEC, and the amino acid sequence of version "j” are shown in SEQ ID NO: 60 and 61.
- Versions "b1" and “dl” were generated by replacing the FR2 of versions "b” and “d” with the FR2 derived from another human antibody using the FR-shuffling method.
- the FR-shuffling vector F2MPS (SEQ ID NO: 62) has a sense DNA sequence and F2MPA (SEQ ID NO: 63) has an antisense DNA sequence. They also have a sequence complementary to each other, and have recognition sequences of EcoT221 and BalI on both ends thereof.
- F2MPS and F2MPA were synthesized and purified by Pharmacia Biotech. F2MPS and F2MPA were annealed and were digested with EcoT22I and BalI. They were introduced to plasmids hATR5Hvb/CVIDEC (EcoT22I/BalI) and hATR5Hvd/CVIDEC (EcoT22I/BalI) prepared by digesting with EcoT22I and BalI, and the nucleotide sequence was determined. The plasmids having the correct sequence were designated as hATR5Hvbl/CVIDEC and hATR5Bvd1/CVIDEC.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b1" contained in the plasmid hATR5Hvb1/CVIDEC, and the amino acid sequence of version "b1" are shown in SEQ ID NO: 64 and 65.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "dl” contained in the plasmid hATR5Hvdl/CVIDEC, and the amino acid sequence of version "dl” are shown in SEQ ID NO: 66 and 67.
- Versions "b3" and “d3” were generated by replacing the FR2 of versions "b” and “d” with the FR2 derived from another human antibody using the FR-shuffling method.
- the FR-shuffling vector F2VHS (SEQ ID NO: 68) has a sense DNA sequence and F2VHA (SEQ ID NO: 69) has an antisense DNA sequence. They also have a sequence complementary to each other, and have recognition sequences of EcoT221 and BalI on both ends thereof.
- the synthesis and purification of F2VHS and F2VHA was referred to Pharmacia Biotech.
- F2VHS and F2VHA were annealed and were digested with EcoT22I and BalI. They were introduced to plasmids hATR5Hvb/CVIDEC (EcoT22I/BalI) and hATR5Hvd/CVIDEC (EcoT22I/BalI) prepared by digesting with EcoT22I and BalI, and the nucleotide sequence was determined. The plasmids having the correct sequence were designated as hATR5Hvb3/CVIDEC and hATR5Hvd3/CVIDEC.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b3" contained in the plasmid hATR5Hvb3/CVIDEC, and the amino acid sequence of version "b3” are shown in SEQ ID NO: 70 and 71.
- nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "d3" contained in the plasmid hATR5Hvd3/CVIDEC, and the amino acid sequence of version "d3" are shown in SEQ ID NO: 72 and 73.
- the humanized ATR-5 antibody L chain V region was generated by the CDR-grafting using the PCR method.
- a humanized antibody L chain (version "a") having framework regions derived from human antibody Z37332 (DDBJ, Welschof M. et al., J. Immunol. Methods, 179: 203-214, 1995 )
- seven PCR primers were used.
- CDR-grafting primers h5Lv1S (SEQ ID NO: 74) and h5Lv4S (SEQ ID NO: 75) have a sense DNA sequence
- CDR-grafting primers h5Lv2A (SEQ ID NO: 76), h5Lv3A (SEQ ID NO: 77), and h5Lv5A (SEQ ID NO: 78) have an antisense DNA sequence, and each primer has 20 bp complementary sequences on both ends thereof.
- Exogenous primers h5LvS (SEQ ID NO: 79) and h5LvA (SEQ ID NO: 80) have a homology with CDR-grafting primers h5Lv1S and h5Lv5A.
- CDR-grafting primers h5Lv1S, h5Lv4S, h5Lv2A, h5Lv3A, h5Lv5A, h5LvS, and h5LvA were referred to Pharmacia Biotech.
- the PCR solutions contain, in 100 ⁇ l, 120 mM Tris-HC1 (pH 8.0), 10 mM KC1, 6 mM (NH 4 ) 2 SO 4 , 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, DCTP, dTTP), 1 mM MgCl 2 , 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the CDR-grafting primers h5Lv1S, h5Lv2A, h5Lv3A, h5Lv4S, and h5Lv5A.
- PCR was performed using the DNA Thermal Cycler 480 (Perkin-Elmer) for 5 cycles with the temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute to assemble 5 CDR-grafting primers. After further addition of 100 pmole of exogenous primers h5LvS and h5LvA to the reaction mixture, PCR was performed for 30 cycles with the temperature cycle of 94°C for 30 seconds, 52°C for 1 minute, and 72°C for 1 minute to amplify the assembled DNA fragments.
- DNA Thermal Cycler 480 Perkin-Elmer
- the PCR reaction mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, DNA fragments were recovered by ethanol precipitation.
- the recovered DNA fragments were digested with the restriction enzymes SplI (akara Shuzo) and BglII (Takara Shuzo) at 37°C for 4 hours.
- the digestion mixture was extracted with phenol and chloroform, and after the ethanol precipitation of the DNA fragments, they were dissolved in 10 ⁇ l of TE.
- the SplI-BglII DNA fragment prepared as above encoding the humanized L chain V region and the CVIDEC vector prepared by digesting with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 3'7°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- the plasmid that contains the gene encoding the humanized antibody L chain V region and that has a BglII recognition sequence and the Kozak sequence at the 5'-end, and a SplI recognition sequence at the 3'-end was designated as hATR5Lva/CVIDEC.
- the nucleotide sequence (including the corresponding amino acid sequence) of the humanized L chain version "a” is shown in SEQ ID NO: 81.
- the amino acid sequence of version "a” is also shown in SEQ ID NO: 82.
- Versions "b” and “c” were generated by replacing (FR-shuffling) the FR3 of version "a".
- version "b” the FR3 derived from human antibody S68699 (DDBJ, Hougs L. et al., Exp. Clin. Immunogen et., 10: 141-151, 1993 ) was used, and for version "c” the FR3 derived from human antibody P01607 (SWISS-PROT, Epp O et al., Biochemistry, 14: 4943-4952, 1975 ) was used, respectively.
- Primers F3SS (SEQ ID NO: 83) and F3SA (SEQ ID NO: 84) encoding the FR3 of version "b", or primers F3RS (SEQ ID NO: 85) and F3RA (SEQ ID NO: 86) encoding the FR3 of version "c" have a sequence complementary to each other, and have the recognition sequences of the restriction enzymes KpnI and PstI on both ends thereof.
- the synthesis and purification of F3SS, F3SA, F3RS, and F3RA were referred to Pharmacia Biotech. 100 pmole each of F3SS and F3SA, or F3RS and F3RA were annealed by treating at 96°C for 2 minutes and at 50°C for 2 minutes and the double stranded DNA fragments were generated.
- the plasmid hATR5Lva/CVIDEC was digested with the restriction enzyme KpnI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme PstI (Takara Shuzo) at 37°e for 1 hour.
- the digestion mixture was separated by agarose gel electrophoresis using a 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 3000 bp long DNA fragments were excised.
- the agarose strip was extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- the KpnI-PstI DNA fragment prepared as above encoding the FR3 of versions "b” or “c” and the hATR5Lva/CVIDEC vector in which the FR3 was removed by digesting with KpnI and PstI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- the plasmids that contain the gene encoding version "b” or version "c” in which the FR3 of humanized antibody L chain version "a” was replaced was designated as hATR5Lvb/CVIDEC or hATR5Lvc/CVIDEC, respectively.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b” contained in plasmid hATR5Lvb/CVIDEC and the amino acid sequence of version "b” are shown in SEQ ID NO: 87 and 88.
- nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "c" contained in plasmid hATR5Lvc/CVIDEC and the amino acid sequence of version "c" are shown in SEQ ID NO: 89 and 90.
- Versions "b1" and “b2” were generated by replacing the FR2 of version "b".
- version "b1” the FR2 derived from human antibody S65921 (DDBJ, Tonge DW et al., Year Immunol., 7: 56-62, 1993 ) was used, and for version "b2” the FR2 derived from human antibody X93625 (DDBJ, Cox JP et al., Eur. J. Immunol., 24: 827-836, 1994 ) was used, respectively.
- Primers F2SS (SEQ ID NO: 91) and F2SA (SEQ ID NO: 92) encoding the FR2 of version "b1", or primers F2XS (SEQ ID NO: 93) and F2XA (SEQ ID NO: 94) encoding the FR2 of version "b2" have a sequence complementary to each other, and have the recognition sequences of the restriction enzymes AflII and SpeI on both ends thereof.
- F2SS, F2SA, F2XS, and F2XA were synthesized by Pharmacia Biotech. 100 pmole each of F2SS and F2SA, or F2XS and F2XA were annealed by treating at 96°C for 2 minutes and at 50°C for 2 minutes, and the double stranded DNA fragments were generated.
- the plasmid hATR5Lvb/CVIDEC was digested with the restriction enzymes AflII (Takara Shuzo) and SpeI (Takara Shuzo) at 37°C for 1 hour.
- the digestion mixture was separated by agarose gel electrophoresis using a 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 3000 bp long DNA fragments were excised.
- the agarose strip was extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- the AflII-SpeI DNA fragment prepared as above encoding the FR2 of version "b1" or “b2" and the hATR5Lvb/CVIDEC vector in which the FR2 was removed by digesting with AflII and SpeI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 4 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- the nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmex).
- As the sequencing primer M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- the plasmids that contain the gene encoding version "b1" or "b2" in which the FR2 of humanized antibody L chain version "b” was replaced was designated as hATR5Lvbl/CVIDEC and hATR5Lv2/CVIDEC, respectively.
- the nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b1" contained in plasmid hATR5Lvbl/CVIDEC and the amino acid sequence of version "b1" are shown in SEQ ID NO: 95 and 96.
- nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b2" contained in plasmid hATR5Lvb2/CVIDEC and the amino acid sequence of version "b2" are shown in SEQ ID NO: 97 and 98.
- the plasmid hATB5Hva/CVIDEC containing a H chain V region was digested with NheI and SalI, and a DNA fragment of the humanized H chain V region was recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATRS/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmid thus generated was designated as hFiva-chLv/N5KG4P.
- the plasmid hATR5Hvb/CVIDEC containing a H chain V region was digested with NheI and SalI, and a DNA fragment of the humanized H chain V region was recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmid thus generated was designated as hHvb-chLv/N5KG4P.
- the plasmids hATR5Hvc/CVIDEC, hATR5Hvd/CVIDEC, and hATR5Hve/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmids thus generated were designated as hHvc-chLv/N5KG4P, hHvd-chLv/N5KG4P, and hHve-chLv/N5KG4P.
- the plasmids hATR5Hvf/CVIDEC and hATR5Hvh/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmids thus generated were designated as hHvf-chLv/N5KG4P and hHvh-chLv/N5KG4P.
- the plasmids hATR5Hvi/CVIDEC and hATR5Hvj/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5XG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmids thus generated were designated as hHvi-chLv/N5KG4P and hHvj-chLv/N5KG4P.
- the plasmids hATR5Hbl/CVIDEC and hATR5Hvdl/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI.
- the plasmids thus generated were designated as hHvb1 chLv/N5KG4P and hHvdl-chLv/N5KG4P.
- the plasmids hATR5Lva/CVIDEC, hATR5Lvb/CVIDEC, hATR5Lvc/CVIDEC, hATR5Lvbl/CVIDEC, and hATR5Lvb2/CVIDEC were digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 2-3 hours.
- the digestion mixture was separated by agarose gel electrophoresis using a 1.5% or 2% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 400 bp long DNA fragments were excised.
- the agarose strips were extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- the SplI-BglII DNA fragment containing the gene encoding the a humanized L chain V region of each of these versions and the hATR5Hv/N5KG4P digested with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- the ligation mixture was added to 100 ⁇ l of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 ⁇ l of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant.
- the transformant was cultured overnight at 37°C in 250 ml or 500 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the Plasmid Maxi Kit (QIAGEN).
- the plasmid in which a gene encoding the chimeric H chain and humanized L chain was introduced were designated as chHv-hLva/N5KG4P, chHv-hLvb/N5KG4P, chHv-hLvc/N5KG4P, chHv-hLvbl/N5KG4P, and chHv-hLvb2/N5KG4P.
- the plasmid hATR5Hva/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLva/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv,-hLva/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "a" with NheI and SalI.
- the plasmid thus generated was designated as hHva-hLva/N5KG4P.
- the plasmids hATR5Hvb/CVTIDEC and hATR5Hvc/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLva/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLva/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "a" with NheI and SalI.
- the plasmids thus generated were designated as hRvb-hLva/N5KG4P and hHvc-hLva/N5KG4P.
- the plasmids hATR5Hvb/CVIDEC, hATR5Hvd/CVIDEC, and hATR5Hve/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI.
- the plasmids thus generated were designated as hHvb-hLvb/N5KG4P, hHvd-hLvb/N5KG4P, and hHve-hLvb/N5KG4P.
- the plasmids hATR5Hvf/CVIDEC, hATR5Hvg/CVIDEC, and hATR5Hvh/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/NSKG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI.
- the plasmids thus generated were designated as hHvf-hLvb/N5KG4P, hHvg-hLvb/N5KG4P, and hHvh-hLvb/N5KG4P.
- the plasmids hATR5Hvi/CVIDEC and hATR5Hvj/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI.
- the plasmids thus generated were designated as hHvi-hLvb/N5KG4P and hHvj-hLvb/N5KG4P.
- the plasmids hATR5Hvbl/CVIDEC and hATR5Hvdl/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI.
- the plasmids thus generated were designated as hHvb1-bLvb/N5KG4P and hHvdl-hLvb/N5KG4P.
- the plasmids hATR5Hvb3/CVIDEC and hATR5Hvd3/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI.
- the plasmids thus generated were designated as hHvb3-hLvb/N5KG4P and hHvd3-hLvb/N5KG4P.
- the plasmid hATR5Hvb/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLvbl/N5KG4P (SalI/NheI) and hLvb2/N5KG4P (SalI/NheI) prepared by digesting plasmids chHv-hLvb1/N5KG4P and chHv-hLvb2/N5KG4P containing the DNA sequence of humanized ATR-5 antibody L chain versions "b1" and "b2" with NheI and SalI.
- the plasmids thus generated were designated as hHvb-hLvb1/N5KG4P and hHvb-hLvb2/N5KG4P.
- the plasmid hATR5Hvi/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLvb1/N5KG4P (SalI/NheI) and hLvb2/N5KG4P (SalI/NheI) prepared by digesting plasmids chHv-hLvb1/N5KG4P and chHv-hLvb2/N5KG4P containing the DNA sequence of humanized ATR-5 antibody L chain versions "b1" and "b2" with NheI and SalI.
- the plasmids thus generated were designated as hHvi-hLvb1/N5KG4P and hHvi-hLvb2/N5KG4P.
- the above antibody was transiently expressed in COS-7 cells.
- the constructed expression plasmid vector was transduced into COS-7 cells by electroporation using the Gene Pulser instrument (Bio Rad). Fifty ⁇ g or 20 ⁇ g of the plasmid was added to 0.78 ml of COS-7 cells suspended in PBS at a cell concentration of 1 ⁇ 10 7 cells/ml, which was subjected to pulses of 1,500 V and 25 ⁇ F capacity.
- the electroporated cells were suspended in a DMEM medium (GIBCO) containing 5% Ultra low IgG fetal bovine serum (GIBCO), and cultured using a 10 cm culture dish or 15 cm culture dish in a 5% CO 2 incubator. After culturing for 24 hours, the culture supernatant was aspirated off, and then a serum-free medium HBCHO (Irvine Scientific) was added. After further culturing for 72 hours or 96 hours, the culture supernatant was collected and centrifuged to remove cell debris.
- a DMEM medium containing 5% Ultra low IgG fetal bovine serum (GIBCO)
- a serum-free medium HBCHO Irvine Scientific
- the antibody was purified using the AffiGel Protein A MAPSII kit (Bio Rad) or the rProtein A Sepharose Fast Flow (Pharmacia Biotech). Purification using the AffiGel Protein A MAPSII kit was carried out according to the instructions attached to the kit. Purification using the rProtein A Sepharose Fast Flow was carried out as follows:
- ELISA plates for measurement of antibody concentration were prepared as follows: Each well of a 96-well ELISA plate (Maxisorp, NUNC) was immobilized by 100 ⁇ l of goat anti-human IgG ⁇ antibody (BIO SOURCE) prepared to a concentration of 1 ⁇ g/ml in the immobilization buffer (0.1 M NaHCO 3 , 0.02% NaN 3 , pH 9.6) (hereinafter referred to as CB).
- BIO SOURCE goat anti-human IgG ⁇ antibody
- the culture supernatant of the COS-7 cells in which antibody was expressed or purified antibody were serially diluted with DB, and then added to each well.
- Cell ELISA plates for measurement of antigen binding were prepared as follows.
- Cells used were human bladder carcinoma cells J82 (ATCC HTB-1).
- PFA/PBS paraformaldehyde
- the neutralizing activity of mouse antibody, chimeric antibody, and humanized antibody was measured with the inhibiting activity against the Factor Xa-production activity by human placenta-derived thromboplastin, Thromborel S (Boehringer AG), as an index.
- 60 ⁇ l of the buffer TBS containing 5 mM CaCl 2 and 0.1% BSA
- 10 ⁇ l of 1.25 mg/ml Thromborel S and 10 ⁇ l of appropriately diluted antibody was then incubated in a 96-well plate at room temperature for 1 hour.
- the neutralizing activity may be determined by calculating the residual activity (%) from each change in absorbance with the hourly absorbance change at no antibody addition as a 100% activity.
- the chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, diluting 2-fold with purified water and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- An antibody (a-ch) which is the humanized H chain version "a” combined with a chimeric L chain was generated, and was tested for the binding activity to the antigen by the cell ELISA. The amount bound to the antigen was found to be decreased at the high concentration. The neutralizing activity against the antigen by FXa production-inhibition was weak as compared that of to the positive control chimeric antibody (ch-ch). Therefore, it was decided to perform the version-up of the humanized H chain by FR-shuffling.
- the chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- ch-a which is the humanized L chain version "a” combined with a chimeric H chain was generated, and was tested for the binding activity to the antigen by the cell ELISA. It was found to have the binding activity equal to or higher than that of the chimeric antibody. On the other hand, the neutralizing activity against the antigen was weak as compared to that of the positive control chimeric antibody. Therefore, it was decided to perform the version-up of the humanized L chain by FR-shuffling.
- the chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- An antibody (a-a) which is the humanized H chain version "a” combined with the humanized L chain version "a” was generated, and was tested for the binding activity to the antigen by the cell ELISA.
- the amount bound to the antigen was found to be decreased in the high concentration side.
- the neutralizing activity against the antigen by FXa production-inhibition was weak as compared to that of the positive control chimeric antibody. Therefore, it was decided to perform the version-up of the humanized H chain and L chain by FR-shuffling.
- the chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- Antibodies ("b-ch”, “c-ch”, and “d-ch”, respectively) which are the humanized H chain subjected to version-up by FR-shuffling combined with a chimeric L chain were generated, and were tested for the binding activity to the antigen by the cell ELISA.
- "d-ch” exhibited a binding activity equal to that of the chimeric antibody
- "b-ch” and "c-ch” exhibited a slightly lower biding activity.
- the neutralizing activity against the antigen as compared to the that of positive control chimeric antibody was almost equal in “b-ch”, and slightly weak in "d-ch”. In version "c-ch", it was significantly weaker than that of the chimeric antibody. Therefore, the humanized H chain versions "b” and “d” were considered the ones of the humanized H chain to exhibit a high activity.
- Antibodies which are the humanized L chain versions "b” and “c” combined with a chimeric H chain were generated, and both of them were found to have the binding activity to the antigen and the neutralizing activity against the antigen equal to the chimeric antibody. Therefore, versions "b” and “c” were chosen as a candidate for a humanized antibody L chain.
- Mouse antibody-derived version "b” which is one amino acid fewer in the amino acid residue number is considered to be superior to version "c” in terms of antigenicity.
- the chimeric antibody used herein was the one that was expressed in CHO cells DG44, purified, and evaluated. In the evaluation hereinafter the antibody was used as the positive control.
- Antibodies ("b-b” and “b-c”, respectively) which are the humanized H chain version "b” combined with the humanized L chain versions "b” and “c” were generated, and tested for the binding activity to the antigen and the neutralizing activity against the antigen. Both of them had a slightly lower activity than that of the chimeric antibody in both the binding activity and the neutralizing activity.
- Antibodies ("b-b” and “d-b”, respectively) which are the humanized H chain subjected to version-up by FR-shuffling combined with the humanized L chain version "b” were generated, and were tested for the binding activity to the antigen by the cell ELISA.
- "d-b” exhibited a binding activity equal to that of the chimeric antibody, and "b-b” exhibited a slightly lower binding activity at the high concentration.
- the neutralizing activity against the antigen as compared to that of the positive control chimeric antibody was slightly low in “b-b” , and significantly weak in "d-b”. Therefore, it was shown that "b-b” is a high neutralizing activity version, whereas “d-b” is a high binding activity version.
- Antibodies which are the humanized L chain version "e” combined with a chimeric L chain and the humanized version "b” were generated.
- “e-ch” exhibited a binding activity to the antigen equal to that of the chimeric antibody, but in “e-b” the amount of antibody expressed was very little and most of the binding activity was lost.
- the neutralizing activity against the antigen of "e-ch” was significantly low as compared to that of the chimeric antibody. Therefore, it was concluded that the H chain version "e” combined with L chain version "b” did not work well.
- Antibodies which are the humanized H chain versions "f”, “g”, and “h” combined with the humanized L chain version "b” were generated.
- “f-b” and “h-b” antibody the amount of antibody expressed was very little.
- versions "f” and “h” antibodies combined with the Chimeric L chain were generated, but were not expressed.
- "g-b” reached saturation at a low concentration, and exhibited a binding activity weaker than that of the chimeric antibody.
- the neutralizing activity against the antigen of "g-b” was significantly weak as compared to that of the chimeric antibody.
- Antibodies (b1-b” and “d1-b”, respectively) which are the humanized H chain versions “b1” and “d1” combined with the humanized L chain version "b” were generated. Almost no antibody was expressed in any of them. For these, antibodies combined with a chimeric L chain were generated, but were not expressed.
- Antibodies ("b3-b” and “d3-b”, respectively) which are the humanized H chain versions “b3” and “d3” combined with the humanized L chain version "b” were generated.
- the binding activity to the antigen of "d3-b” was slightly lower than that of the chimeric antibody, and that of "b3-b” was much lower.
- the neutralizing activity against the antigen of "b3-b” was higher than that of "b-b”, but was lower than that of the chimeric antibody, and "d3-b” and "b-b” remained equal in activity.
- Antibodies which are the humanized H chain versions "i” and “j” combined with a chimeric L chain, and antibodies (“i-b” and “j-b”, respectively) combined with the humanized L chain version "b” were generated, and were tested for the binding activity to the antigen and the neutralizing activity against the antigen.
- the binding activity of any of the antibodies was almost equal to that of the chimeric antibody.
- "i-ch” exhibited the neutralizing activity higher than that of the chimeric antibody, and “j-ch” was significantly lower than that of the chimeric antibody.
- “i-b” exhibited the neutralizing activity equal to that of the chimeric antibody, and "j-b” exhibited a significantly weaker neutralizing activity than that of that of the chimeric antibody.
- Antibodies (I-b1" and “i-b2", respectively) which are the humanized H chain version "i” combined with the humanized L chain version "b1” or “b2" were generated, and were tested for the binding activity to the antigen and the neutralizing activity against the antigen.
- the binding activity of "i-b2” was almost equal to that of the chimeric antibody, and that of "i-b1” was slightly lower than that of chimeric antibody.
- the neutralizing activity of "i-b1” and “i-b2” was higher than that of the chimeric antibody and "i-b” , which was in a decreasing order of "i-b2" > "i-b1".
- an antibody expression gene vector was introduced into CHO cells (DG44) aimed to a serum-free medium.
- Plasmid DNA, hHvb-hLvb/N5KG4P, hHvi-hLvb/N5KG4P, and hHvi--hLvb2/N5KG4P were digested with the restriction enzyme Sspl (Takara Shuzo) and linearized, which was extracted with phenol and chloroform, and purified by ethanol precipitation.
- the linearized expression gene vector was introduced into the DG44 cells using the electroporation instrument (Gene Pulser; Bio Rad).
- the DG44 cells were suspended in PBS at a cell concentration of 1 ⁇ 10 7 cells/ml, and to about 0.8 ml of this suspension 10 or 50 ⁇ g of the DNA was added, which was subjected to pulses of 1,500 V and 25 ⁇ F capacity.
- the treated cells were suspended in a CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO) (hereinafter referred to as HT), which was inoculated on two 96-well plates (Falcon) at 100 ⁇ l/well, and cultured in a CO 2 incubator.
- a CHO-S-SFMII medium containing hypoxanthine/thymidine (GIBCO) (hereinafter referred to as HT)
- Falcon hypoxanthine/thymidine
- GIBCQ 1 mg/ml GENETICIN
- the medium was changed with a fresh one once every 3-4 days with 1/2 the volume.
- an aliquot of the culture supernatant was recovered from the well in which a favorable cell growth was observed 4-5 days later.
- the concentration of antibody expressed in the culture supernatant was measured by the ELISA described above for measuring antibody concentration, and cells having a high production yield of antibody were selected.
- ELISA plates for measurement of antibody concentration were prepared as follows: Each well of a 96-well ELISA plate (Maxisorp, NUNC) was immobilized with 100 ⁇ l of goat anti-human IgG ⁇ antibody (BioSource) prepared to a concentration of 1 ⁇ g/ml with CB. After blocking with 200 ⁇ l of DB, the culture supernatant of the CHO cells in which antibody had been expressed or the purified antibody was serially diluted with DB, and added to each well.
- Cell ELISA plates for measurement of antigen binding were prepared as follows.
- Cells used were human bladder carcinoma cells J82 (ATCC HTB-1), which were inoculated onto a 96-well cell culture plate at a cell count of 1 ⁇ 10 5 cells. This was cultured (RPMI1640 medium containing 10% fetal bovine serum (GIBCO)) for one day in a CO 2 incubator to allow the cells to be attached thereto. After discarding the culture liquid, each well was washed twice with PBS. 100 ⁇ l of PFA/PBS was added to each well, and placed on ice for 10 minutes to immobilize the cells.
- RPMI1640 medium containing 10% fetal bovine serum (GIBCO) fetal bovine serum
- the purified antibody was serially diluted with DB starting at 10 ⁇ g/ml by a factor of 2, 100 ⁇ l of which was added to each well. After incubating at room temperature for 2 hours and washing with RB, 100 ⁇ l of alkaline phosphatase-conjugated goat anti-human IgG ⁇ antibody (BioSource) diluted 1000-fold with DB was added. After incubating at room temperature for 1 hour and washing with RB, 100 ⁇ l of the substrate solution was added, and then absorbance at 405/655 nm was measured using the Microplate Reader (Bio-Rad).
- the Factor Xa production-inhibiting activity of humanized antibody was measured with the inhibiting activity against the Factor Xa production activity by the human placenta-derived thromboplastin, Thromborel S (Boehringer AG), as an index.
- 60 ⁇ l of the buffer TBS containing 5 mM CaCl 2 , and 0.1% BSA
- 10 ⁇ l of 5 mg/ml Thromborel S and 10 ⁇ l of the antibody was then incubated in a 96-well plate at room temperature for 1 hour.
- the antibody was serially diluted with the buffer starting at 200 ⁇ g/ml by a factor of 5.
- the chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- the inhibiting activity against the FX-binding of humanized antibody was measured using the human placenta-derived thromboplastin, Thrombore1 S (Boehringer AG), in which a complex of TF and Factor VIIa had previously been formed and the inhibiting activity against the FX-binding was measured with the Factor Xa production activity of the TF-FVIIa complex as an index.
- the chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- the neutralizing activity against TF (inhibiting activity against the plasma coagulation) of humanized antibody was measured using, as an index, prothrombin time determined using the human placenta-derived thromboplastin, Thromborel S (Boehringer AG).
- prothrombin time determined using the human placenta-derived thromboplastin, Thromborel S (Boehringer AG).
- 100 ⁇ l of human plasma (Cosmo Bio) was placed into a sample cup, to which 50 ⁇ l of antibody diluted at various concentrations was added, and heated at 37°C for 3 minutes.
- Fifty ⁇ l of 1.25 mg/ml Thromborel S that had previously been preheated at 37°C was added to start plasma coagulation.
- the coagulation time was measured using the Amelung KC-10A connected to the Amelung CR-A (both from M. C. Medical).
- the antibody was serially diluted with TBS containing 0.1% BSA (hereinafter referred to as BSA-TBS) starting at 80 ⁇ g/ml by a factor of 2.
- BSA-TBS 0.1% BSA
- the residual TF activity was calculated from each coagulation time at antibody addition based on a standard curve obtained by plotting the concentration of Thromborel S and the coagulation time.
- the standard curve was created from the various concentration of Thromborel S and the coagulation time was measured. Fifty ⁇ l of BSA-TBS was added to 50 ⁇ l of appropriately diluted Thromborel S, which was heated at 37°C for 3 minutes, 100 ⁇ l of human plasma preheated at 37°C was added to start coagulation, and the coagulation time was determined. Thromborel S was serially diluted with the Hank's buffer (GIBCO) containing 25 mM caCl 2 starting at 6.25 mg/ml by a factor of 2. The Thromborel S concentration was plotted on the abscissa, and the coagulation time on the ordinate on a log-log paper, which was rendered a standard curve.
- GEBCO Hank's buffer
- the invention also relates to the following aspects as defined in the following numbered paragraphs:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
Abstract
Description
- The present invention relates to a method of generating an animal model having a persistently hypercoagulable state, preventive or therapeutic agents for diseases having a persistent hypercoagulable state, preventive or therapeutic agents for a hypercoagulable state resulting from infections, preventive or therapeutic agents for venous or arterial thrombosis, and preventive or therapeutic agents for diseases resulting from the hypertrophy of vascular media.
- Blood coagulation is a reaction in which serine protease precursors are successively activated by activated-form proteases, which finally generate thrombin thereby leading to fibrin formation. Thrombosis arises as a consequence of an excessively enhanced blood coagulation reaction that was caused by changes in the plasma coagulation and fibrinolytic system, and in the functions of platelets, leucocytes and vascular endothelial cells associated with the progression of various disease states. The initiating factor of the blood coagulation reaction is tissue factor. In acute coronary syndromes such as acute myocardial infarction and unstable angina, the blood coagulation reaction is triggered when tissue factor occurring in abundance in the plaques formed after the progression of arterial sclerosis is exposed to the blood due to the rhexis of plaques.
- In the disseminated intravascular coagulation syndrome associated with sepsis and malignant tumors, activated monocytes and macrophages express tissue factor or tumor cells express tissue factor thereby causing enhanced blood coagulation. Once tissue factor comes into contact with the blood, the blood coagulation reaction proceeds in a very short period of time and leads to the formation of blood clots. Thus, in order to prevent thrombus formation, it is necessary to block blood coagulation reactions that may be triggered at any time or that may be constantly occurring. Therefore, an experimental model that exhibits a hypercoagulable state on a persistent basis is essential for the development of effective anti-thrombotic agents. In any of the conventionally known thrombotic models, thrombus formation is induced in a short, period of time.
- Thus, according to one aspect of the present invention, there is provided an experimental model in which a hypercoagulable state persists by bringing human tissue factor into contact with the blood on a persistent basis.
- Blood coagulation is a reaction in which serine protease precursors are successively activated by activated-form proteases, which finally generate thrombin thereby leading to fibrin formation. Thrombosis arises as a consequence of an excessively enhanced blood coagulation reaction that was caused by changes in the plasma coagulation and fibrinolytic system, and in the functions of platelets, leucocytes and vascular endothelial cells associated with the progression of various disease states. The initiating factor of the blood coagulation reaction is tissue factor (TF).
- In acute coronary syndromes such as acute myocardial infarction and unstable angina, the blood coagulation reaction is triggered when tissue factor occurring in abundance in the plaques formed after the progression of arterial sclerosis is exposed to the blood due to the rupture of plaques. In disseminated intravascular coagulation syndrome associated with sepsis and malignant tumors, activated monocytes and macrophages express TF or tumor cells express TF thereby leading to enhanced blood coagulation and this state persists. Once TF comes into contact with the blood, the blood coagulation reaction proceeds in a very short period of time leading to the formation of blood clots. Thus, in order to prevent thrombus formation, it is necessary to block blood coagulation reactions that may be triggered at any time or that may be constantly occurring. Therefore, as an effective anti-thrombotic agent, a drug is required that can block the persistence of the hypercoagulable state that is occurring on a constant basis.
- Thus, according to the second aspect of the present invention, there is provided a novel preventive or therapeutic agent for diseases having a persistent hypercoagulable state.
- Severe infections are often associated with abnormal coagulation, which induces disease states such as multiple organ failure and the disseminated intravascular coagulation syndrome, and represents a factor that aggravates the prognosis of the patient. The measures employed are thus considered to be important. In severe infections, systemic infections such as sepsis and, among them, lesions in the vascular endothelial cells have been implicated as the onset mechanism of organ disorders. In sepsis, and particular in sepsis caused by gram negative bacteria, a cellular component, lipopolysaccharide (LPS), plays an important role.
- LPS liberated into the blood, not only activates monocytes and thereby produces tissue factor (TF) leading to a hypercoagulable state, but produces and liberates cytokines such as TNF, IL-1β and IL-8 and thereby activates neutrophils and vascular endothelial cells. The activated neutrophils adhere to the vascular endothelial cells to liberate cytotoxic substances such as active enzymes and elastases, which injure the vascular endothelial cells. In the vascular endothelial cells activated by cytokines or injured by neutrophils, the production of TF is enhanced which further progresses the hypercoagulable state. As a result, microthrombi occur systemically, which elicits circulatory failures in the organs leading to multiple organ failure.
- Thus, there is a great need for the development of preventive or therapeutic agents for blood coagulable states caused by infections.
- Thus, according to the third aspect of the present invention, there is provided a novel preventive or therapeutic agent for blood coagulable states caused by infections.
- As a mechanism leading to the onset of venous thrombosis, venous stasis, damages to the venous wall, and hypercoagulabilyty are thought to play an important role. In particular, invasive events such as surgery, childbirth and trauma induce physical injuries to the vascular wall and abnormalities in the coagulation and fibrinolysis system, and decubitus after surgery induces a renous stasis. Not only the resulting blood clots in the vein induce circulatory failure in the limbs but the clots themselves enter into the blood circulation and flows into the pulmonary artery leading to fatal pulmonary embolism. Hence, the prevention of venous thrombosis itself is considered to be important. Thus, there is a need for the development of agents that can effectively prevent or treat venous thrombosis.
- Thus, according to the fourth aspect of the present invention, there is provided a novel preventive or therapeutic agent for the treatment of venous thrombosis.
- In arterial thrombosis, blood clots occur in the blood vessel having an advanced sclerosis, and the onset of the disease in the important organs such as the brain and the heart would be fatal in most cases. In particular, acute coronary syndromes such as unstable angina and acute myocardial infarction are believed to be dangerous disease states that could easily cause sudden death. Recently it was demonstrated that the rhexis of the arteriosclerotic plaques and the ensuing thrombus formation is an important factor in the onset mechanism of the disease.
- It has also been demonstrated that tissue factor (TF), an initiating factor for thrombus formation, is being excessively expressed on the cell surface and the extracellular interstitium in the plaque, and thus it is believed that the exposure of tissue factor (TF) to the blood resulting from the rupture of plaques is a major factor for thrombus formation.
- Thus, there is a great need for the development of a novel drug for preventing or treating arterial thrombosis.
- Thus, according to the fifth aspect of the present invention, there is provided a novel preventive or therapeutic agent for arterial thrombosis.
- Percutaneous transluminal coronary angioplasty (PTCA) occupies an important position in the treatment of coronary heart diseases. But restenosis that occurs several months after the operation hinders the effectiveness of the treating method and thus is posing a problem. As a cause of restenosis, it is becoming increasingly clear, thrombus formation during the acute phase and the subacute phase resulting from the injuries to endothelial cells is important. The contact with the blood of tissue factor (TF) expressed by the injured endothelial cells and the smooth muscles and fibroblasts in the subendothelial tissue is important for thrombus formation. The cells in the blood vessel wall grow so as to cover the resulting thrombi and thereby narrow the area of the lumen in the blood vessel. The growth of the blood vessel tissue per se and the constriction of the blood vessel diameter also contribute to the narrowing of the area of the lumen in the blood vessel, and they provide a direct factor for restenosis. Thus, there is a great need for a novel drug that can prevent or treat restenosis.
- Thus, according to the sixth aspect of the present invention, there is provided a novel preventive or therapeutic agent for diseases caused by the hypertrophy of vascular media.
- After intensive and extensive research to resolve the above first problem, the inventors of the present invention have found out that by implanting, into an experimental animal, an animal cell capable of constantly expressing human tissue factor by introducing therein the gene of a human tissue factor (TF) and thereby increasing the concentration of human tissue factor in the animal, the hypercoagulable state of said animal can be maintained for a long period of time, and thereby have completed the present invention.
- Thus, according to the first aspect, the present invention provides an experimental animal having implanted therein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene, said animal being a non-human animal in which a hypercoagulable state persists for a long period of time.
- The part of said human tissue factor is for example a human tissue factor that lacks the intracellular region. Said animal cell is preferably a mammalian cell. Said mammalian cell is preferably a human myeloma cell. Said animal is preferably a mouse. Said hypercoagulable state is indicated by at least one of the phenomena comprising an increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex.
- The present invention also provides a method of generating the above animal, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected.
- The present invention also provides a method of screening an anti-thrombotic agent which method comprises using the above animal.
- After intensive and extensive research to resolve the above second problem, the inventors of the present invention have found out that an antibody (anti-human TF antibody, or sometimes referred to as anti-TF antibody) against human tissue factor can prevent the persistence of a hypercoagulable state.
- Thus, according to the second aspect, the present invention provides a preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody against human tissue factor (human TF).
- The above antibody is for example a polyclonal antibody. The above antibody is preferably a monoclonal antibody. The above antibody is preferably a recombinant antibody. The above antibody is preferably an altered antibody. The above altered antibody is preferably a chimeric antibody or a humanized antibody. The above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. The above antibody is for example an antibody modification. The above antibody modification is for example an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
- After intensive and extensive research to resolve the above third problem, the inventors of the present invention have found out that an antibody (anti-human TF antibody, or sometimes referred to as anti-TF antibody) against human tissue factor can prevent or treat a hypercoagulable state resulting from infections.
- Thus, according to the third aspect, the present invention provides a preventive or therapeutic agent for a hypercoagulable state resulting from infections, said agent comprising an antibody against human tissue factor (human TF).
- The above antibody is for example a polyclonal antibody. The above antibody is preferably a monoclonal antibody. The above antibody is preferably a recombinant antibody. The above antibody is preferably an altered antibody. The above altered antibody is preferably a chimeric antibody or a humanized antibody. The above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. The above antibody is for example an antibody modification. The above modified antibody is for example an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
- After intensive and extensive research to resolve the above fourth problem, the inventors of the present invention have found out that an antibody (anti-human TF antibody, or sometimes referred to as anti-TF antibody) against human tissue factor can prevent or treat venous thrombosis.
- Thus, according to the fourth aspect, the present invention provides a preventive or therapeutic agent for venous thrombosis, said agent comprising an antibody against human tissue factor (human TF).
- The above antibody is for example a polyclonal antibody. The above antibody is preferably a monoclonal antibody. The above antibody is preferably a Recombinant antibody. The above antibody is preferably an altered antibody. The above altered antibody is preferably a chimeric antibody or a humanized antibody. The above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. The above antibody is for example an antibody modification. The above antibody modification is for example an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
- After intensive and extensive research to resolve the above fifth problem, the inventors of the present invention have found out that an antibody (anti-human TF antibody, or sometimes referred to as anti-TF antibody) against human tissue factor can prevent or treat arterial thrombosis.
- Thus, according to the fifth aspect, the present invention provides a preventive or therapeutic agent for arterial thrombosis, said agent comprising an antibody against human tissue factor (human TF).
- The above antibody is for example a polyclonal antibody. The above antibody is preferably a monoclonal antibody. The above antibody is preferably a recombinant antibody. The above antibody is preferably an altered antibody. The above altered antibody is preferably a chimeric antibody or a humanized antibody. The above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. The above antibody is for example an antibody modification. The above antibody modification is for example an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
- After intensive and extensive research to resolve the above sixth problem, the inventors of the present invention have found out that an antibody (anti-human TF antibody, or sometimes referred to as anti-TF antibody) against human tissue factor can prevent or treat diseases caused by the hypertrophy of vascular media.
- Thus, according to the sixth aspect, the present invention provides a preventive or therapeutic agent for diseases caused by the hypertrophy of vascular media, said agent comprising an antibody against human tissue factor (human TF).
- The above antibody is for example a polyclonal antibody. The above antibody is preferably a monoclonal antibody. The above antibody is preferably a recombinant antibody. The above antibody is preferably an altered antibody. The above altered antibody is preferably a chimeric antibody or a humanized antibody. The above humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. The above antibody is for example an antibody modification. The above antibody modification is for example an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
-
-
Figure 1 is a graph that compares the antigen binding activity of a H chain chimeric/L chain chimeric antibody, a H chain humanized version b/L chain humanized version b antibody, a H chain humanized version i/L chain humanized version b antibody, and a H chain humanized version i/L chain humanized version b2 antibody. -
Figure 2 is a graph that compares the activity of neutralizing human TF (the activity of TF to inhibit the production of Factor Xa) of a H chain chimeric/L chain chimeric antibody, a H chain humanized version b/L chain humanized version b antibody, a H chain humanized version i/L chain humanized version b antibody, and a H chain humanized version i/L chain humanized version b2 antibody. -
Figure 3 is a graph that compares the activity of neutralizing human TF (the activity of TF to inhibit the production of Factor X) of a H chain chimeric/L chain chimeric antibody, a H chain humanized version b/L chain humanized version b antibody, a H chain humanized version i/L chain humanized version b antibody, and a H chain humanized version i/L chain humanized version b2 antibody. -
Figure 4 is a graph that compares the activity of neutralizing human TF (the activity of TF to inhibit plasma coagulation) of a H chain chimeric/L chain chimeric antibody, a H chain humanized version b/L chain humanized version b antibody, a H chain humanized version i/L chain humanized version b antibody, and a H chain humanized version i/L chain humanized version b2 antibody. -
Figure 5 is a graph showing changes in tumor volume with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). -
Figure 6 is a graph showing changes in the plasma concentration of human tissue factor with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). -
Figure 7 is a graph showing changes in platelet counts with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). -
Figure 8 is a graph showing changes in the plasma concentration of fibrinogen with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). The points indicate relative values, in which the concentration of fibrinogen in the control mice to which tumor cells have not been implanted (normal) is expressed as 100%. -
Figure 9 is a graph showing changes in the plasma concentration of soluble fibrin monomer complex (sFMC) with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). -
Figure 10 is a graph showing changes in the plasma concentration of thrombin-antithrombin III complex (TAT) with time after the implantation of tumor cells in the mice implanted with the cells to which gene of human tissue factor has been introduced (dotted line) and in the mice implanted with the cells to which said gene has not been introduced (solid line). -
Figure 11 is a graph showing changes in platelet counts with time in the mice that are administered anti-human tissue factor antibody at 1 mg/kg once weekly for three weeks from day 45 after implantation of tumor cells to which gene of human tissue factor has been introduced. -
Figure 12 is a graph showing the plasma concentration of soluble fibrin monomer complex (sFMC) on day 6 after the final administration of anti-human tissue factor antibody in the mice that are administered said antibody at 1 mg/kg once weekly for three weeks from day 45 after implantation of tumor cells to which gene of human tissue factor has been introduced. -
Figure 13 is a graph showing the plasma concentration of thrombin-antithrombin. III complex (TAT) on day 6 after the final administration of anti-human tissue factor antibody in the mice that are administered said antibody at 1 mg/kg once weekly for three weeks from day 45 after implantation of tumor cells to which gene of human tissue factor has been introduced. -
Figure 14 is a graph showing changes in platelet counts with time in the mice that received the single administration of anti-human tissue factor antibody at 1 mg/kg or in the mice that received the 24-hour continuous administration of low molecular weight heparin at 601.5 IU/kg, 1900.3 IU/kg, or 6487.3 IU/kg using an osmotic pump onday 49 after implantation of tumor cells to which gene of human tissue factor has been introduced. - The gene that encodes human tissue factor (TF) for use in the first aspect of the present invention has already been cloned, and the base sequence and the amino acid sequence encoded thereby are also known (H. Morrissey et al., Cell, Vol. 50, p. 129-135 (1987)). The base sequence encoding the full-length human tissue factor and the corresponding amino acid sequence are set forth in SEQ ID NO: 103 and 104. According to the present invention, there may be used a gene encoding TF from which the intracellular region has been removed or a gene encoding the portion that retains the activity of initiating the blood coagulation system.
- As a vector for introducing this gene into an animal cell and expressing it, any expression vector that functions in animal cells can be used, including, for example, PCOS1, pSV2-neo, pMAM-neo, and pSG5. In accordance with the present invention, a commonly used useful promoter, the human tissue factor gene, and a poly A signal, to 3'-end downstream thereof, can be functionally linked and can be expressed. As the promoter/enhancer, there can be mentioned human cytomegalovirus immediate early promoter/enhancer, viral promoters such as promoters of retrovirus, polyoma virus, adenovirus, and simian virus 40 (SV40), and promoters/enhancers derived from mammalian cells such as human elongation factor 1α (HEF1α). For expression vectors, as the replicator, there can be used those derived from SV40, polyoma virus, adenovirus and the like. Furthermore, for the expression vector can be contained as selectable markers the phosphotransferase APH (3') II or I (neo) gene, the thymidine kinase (TK) gene, the dihydrofolate reductase (dhfr) gene and the like.
- As the method of introducing a gene into a cell, there can be used the electroporation method, the calcium phosphate method, the lipofection method and the like. As the cell for introducing the expression vector, any cell can be used as long as it can be grafted to an animal cell. For this purpose, various cultured cells may be used, including for example a mammalian cell such as a cultured cell derived from human, mice, rats, hamsters, and monkeys, with tumor cells being most preferred. As specific examples of the cell, there can be used a human myeloma cell line such as KPMM2 and ARH-77, a mouse leukemia cell line such as P815, P388, and L1210.
- The experimental animals for use in the present invention are mammals other than the human and are preferably small experimental animals such as mice, rats, and hamsters with the mice being most preferred.
- In accordance with the second aspect of the present invention, the hypercoagulable state means a physical condition induced by human TF, and give signs as a decrease in platelet counts and fibrinogen concentration, an increase in the concentration of soluble fibrin monomer complex (SFMC) and thrombin-antithrombin III complex (TAT).
- Although the antibody used in the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferably. In addition, chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- Although the antibody used in the third aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable. In addition, chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- Although the antibody used in the fourth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable. In addition, chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- Although the antibody used in the fifth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferable. In addition, chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- Although the antibody used in the sixth aspect of the present invention may be either polyclonal antibody or monoclonal antibody provided it has a preventive or therapeutic effect on the persistence of a hypercoagulable state due to TF, monoclonal antibody is preferably. In addition, chimeric antibody, humanized antibody or single chain Fv and so forth based on monoclonal antibody can also be used, while humanized antibody is particularly preferable.
- The anti-human TF antibody used in the present invention may be of any origin, type (monoclonal or polyclonal) and form provided it has the effect of preventing or treating viral hemorrhagic fever.
- The anti-human TF antibody used in the present invention can be obtained as polyclonal or monoclonal antibody using a known means. Monoclonal antibody of mammalian origin is particularly preferable as the anti-human TF antibody used in the present invention. Monoclonal antibody of mammalian origin includes that produced in hybridomas as well as that produced in a host transformed with an expression vector containing antibody gene by genetic engineering techniques. This antibody is an antibody that inhibits the induction of thrombus by human TF by binding with human TF.
- Monoclonal antibody-producing hybridoma can basically be produced in the following manner using known technology. Namely, using human TF or a portion (fragment) of it as sensitizing antigen, this is immunized in accordance with ordinary immunization methods, the resulting immunocytes are fused with known parent cells in accordance with ordinary cell fusion methods, and those cells that produce monoclonal antibody are screened in accordance with ordinary screening methods to produce monoclonal antibody.
- More specifically, monoclonal antibody should be produced in the manner described below.
- To begin with, human TF used as sensitizing antigen for antibody acquisition is obtained by expressing the TF gene/amino acid sequence disclosed in J.H. Morissey, et. al., Cell, Vol. 50, p. 129-135 (1987). Namely, gene sequence coding for human TF is inserted into a known expression vector to transform suitable host cells followed by purifying the target human TF protein present in the host cells or culture supernatant using a known method. This method is described in Reference Example 1 of the present specification. Moreover, the human TF used as antigen can be used by extracting and purifying from a TF-containing biological material such as human placenta according to the method described in Reference Example 2.
- Next, this purified human TF protein is used as sensitizing antigen. Alternatively, soluble TF from which the membrane permeating region of the C-terminal of human TF has been removed can be produced by, for example, genetic recombination, and this can also be used as sensitizing antigen.
- Although there are no particular restrictions on the mammal that is sensitized with sensitizing antigen, it is preferable to select a mammal in consideration of compatibility with the parent cells used in cell fusion, typical examples of which include rodents such as mice, rats, hamsters, or rabbits and monkeys.
- Immunization of animals with sensitizing antigen is performed in accordance with known methods. For example, as a typical immunization method, immunization is performed by injecting sensitizing antigen into the abdominal cavity or under the skin of the mammal. More specifically, sensitizing antigen is diluted to a suitable volume with phosphate-buffered saline (PBS) or physiological saline, and the resulting suspension is mixed with a suitable amount of ordinary adjuvant such as Freund's complete adjuvant as desired followed by emulsifying and administering in multiple doses to mammals every 4-21 days. In addition, a suitable carrier can also be used when immunizing with sensitizing antigen.
- After immunizing the mammals in this manner and confirming that antibody has risen to the desired level in the serum, immunocytes are sampled from the mammals and applied to cell fusion. However, spleen cells are a particularly preferable example of immunocytes.
- Mammalian myeloma cells are used for the other parent cells fused with the above immunocytes. Various known cell lines are used for these myeloma cells, preferable examples of which include P3 (P3x63Ag8.653) (Kearney, J.F. et al., J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Yelton, D.E. et al., Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies, D.H. et al., Cell (1976) 8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), F0 (de St. Groth, S.F. and Scheidegger, D.J., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I.S., J. Exp. Med. (1978) 148, 313-323) and R210 (Galfre, G. et al., Nature (1979) 277, 131-133).
- Cell fusion of the above immunocytes and myeloma cells can basically be carried out in compliance with known methods such as the method of Milstein, et al. (Galfre G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).
- More specifically, the above cell fusion is carried out, for example, in ordinary nutrient culture media in the presence of cell fusion promoter. Examples of cell fusion promoters used include polyethylene glycol (PEG) and Sendai virus (HVJ). Moreover, an assistant such as dimethylsulfoxide can be added to further enhance fusion efficiency as desired.
- The usage ratio of immunocytes and myeloma cells can be set arbitrarily. For example, the number of immunocytes is preferably 1-10 times the number of myeloma cells. Examples of culture media used in the above cell fusion include RPMI1640 culture medium, MEM culture medium and other ordinary culture media used in this type of cell culturing that is suitable for growth of the above myeloma cell lines. Moreover, serum supplement such as fetal calf serum (FCS) can also be used in combination with the above media.
- Cell fusion is carried out by adequately mixing prescribed amounts of the above immunocytes and myeloma cells in the above culture media, adding PEG solution (for example, that having a molecular weight of about 1000-6000) warmed in advance to about 37°C at a concentration of usually 30-60% (w/v) and mixing to form the target fused cells (hybridoma). Subsequently, a suitable amount of culture media is sequentially added, and cell fusion agents and so forth undesirable for hybridoma growth are removed by repeated removal of supernatant by centrifugation.
- The hybridoma obtained in this manner is selected by culturing in an ordinary selective culture medium such as HAT culture medium (culture medium containing hypoxanthine, aminopterin and thymidine). Culturing in the above HAT culture medium is continued for an adequate amount of time (normally from several days to several weeks) for killing cells other than the target hybridoma cells (non-fused cells). Next, routine critical dilution is performed followed by screening for hybridoma that produces the target antibody and monocloning.
- In addition, besides obtaining the above hybridoma by immunizing animals other than humans with antigen, a desired human antibody having binding activity to human TF can be obtained by sensitizing human lymphocytes to human TF in vitro, and fusing the sensitized lymphocytes with human myeloma cells such as myeloma cell line U266 having permanent mitotic ability (refer to Japanese Examined Patent Publication No.
1-59878 WO 94/25585 NO 93/12227 WO 92/03918 WO 94/02602 WO 96/34096 WO 96/33735 - Hybridoma that produces monoclonal antibody obtained in this manner can be sub-cultured in ordinary culture media, and can be stored for a long period of time in liquid nitrogen.
- In order to acquire monoclonal antibody from said hybridoma, said hybridoma is cultured in accordance with routine methods followed by obtaining the culture supernatant, or the hybridoma can be administered to a compatible mammal to proliferate in that mammal followed by obtaining in the form of the ascites. The former method is suitable for obtaining highly pure antibody, while the latter method is suitable for large volume production of antibody.
- An example of monoclonal antibody production is specifically described in Reference Example 2. In this example, six types of monoclonal antibodies referred to as ATR-2, 3, 4, 5, 7 and 8 are obtained. Although all of these can be used in the present invention, ATR-5 is particularly preferable.
- -In the present invention, recombinant antibody produced using genetic recombination technology by cloning antibody gene from hybridoma, incorporating in a suitable vector and introducing this into a host can be used as monoclonal antibody (refer to, for example, Vandamme, A.M. et al., Eur. J. Biochem. (1990) 192, 767-775).
- More specifically, mRNA that codes for the variable region (V) of anti-human TF antibody is isolated from hybridoma that produces anti-human TF antibody. Isolation of mRNA is carried out by a known method such as guanidine ultracentrifugation (Chirgwin, J.M. et al., Biochemistry (1979) 18, 5294-5299) or the AGPC method (Chomczynski, P. and Sacchi, N., Anal. Biochem. (1987) 162, 156-159) to prepare total RNA, followed by preparation of the target mRNA using an mRNA Purification Kit (Pharmacia). In addition, mRNA can also be prepared directly by using the QuickPrep mRNA Purification Kit (Pharmacia).
- cDNA of the antibody V region is synthesized from the resulting mRNA using reverse transcriptase. Synthesis of cDNA is carried out using the AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Co.). In addition, synthesis and amplification of cDNA can also be carried out by using the 5'-Ampli FINDER RACE Kit (Clontech) and the 5'-RACE method using PCR (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002, Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932).
- The target DNA fragment is purified from the resulting PCR product and linked with vector DNA. Moreover, a recombinant vector is produced from this, introduced into Escherichia coli and so forth, and colonies are selected to prepare the desired recombinant vector. The base sequence of the target DNA is then confirmed by a known method such as deoxyribonucleotide chain termination.
- After obtaining DNA that codes for the V region of the target anti-human TF antibody, this is incorporated into an expression vector containing DNA that codes for the desired antibody constant region (C region).
- In producing the anti-human TF antibody used in the present invention, an antibody gene is incorporated into an expression vector under the control of an expression control region such as an enhancer or promoter. Next, the host cells are transformed by this expression vector to express antibody.
- Expression of antibody gene may be carried out either by separately incorporating DNA that codes for antibody heavy chain (H chain) or light chain (L chain) into expression vectors and then simultaneously transforming the host cells, or by incorporating DNA that codes for H chain and L chain into a single expression vector and transforming the host cells (refer to the publication of
WO 94/11523 - In addition, transgenic animals can also be used in addition to the above host cells to produce recombinant antibody. For example, recombinant antibody is produced in the form of a fused gene by inserting antibody gene at an intermediate location of a gene that codes for protein characteristically produced in breast milk. A DNA fragment containing fused gene into which antibody gene has been inserted is injected into a goat embryo, and this embryo is then introduced into a female goat. The desired antibody is obtained from the mother's milk produced by the transgenic goat born from the goat that received the embryo, or its offspring. In addition, a suitable hormone may be used in the transgenic goat to increase the amount of breast milk containing the desired antibody produced by that transgenic goat (Ebert, K.M. et al., Bio/Technology (1994) 12, 699-702).
- An example of a production method of recombinant antibody is specifically described in Reference Example 3.
- In the present invention, in addition to the above-mentioned antibodies, genetic recombinant antibody that has been artificially altered for the purpose of decreasing heterogenic antigenicity with respect to humans can also be used, examples of which include chimeric antibody and humanized antibody. These altered antibodies can be produced using known methods.
- Chimeric antibody is obtained by linking DNA that codes for the antibody V region in the manner described above and DNA that codes for human antibody C region, incorporating this in an expression vector and introducing into a host to produce antibody. Chimeric antibody that is useful in the present invention can be obtained using this known method.
- Humanized antibody is also referred to as reshaped human antibody. This is the result of transplanting the complementarity determining region (CDR) of antibody of a mammal other than a human, such as mouse antibody, into the complementarity determining region of human antibody, and typical genetic recombination techniques are known for this (refer to European Unexamined Patent Publication No.
EP 125023 WO 96/02576 - More specifically, a DNA sequence designed so as to link the CDR of mouse antibody with the framework region (FR) of human antibody is synthesized by PCR using as primer a plurality of oligonucleotides prepared so as to have a portion that overlaps the terminal regions of both CDR and FR (refer to the method described in the publication of
WO 98/13388 - A region in which the complementarity determining region forms a satisfactory antigen binding site is selected for the framework region of the human antibody that is linked by way of CDR. The amino acids of the framework region in the variable region of the antibody may be substituted as necessary so that the complementarity determining region of reshaped human antibody forms an appropriate antigen binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).
- The C region of human antibody is used for the C region of chimeric antibody and humanized antibody, and for example, Cγ1, Cγ2, Cγ3 and Cγ4 can be used in the H chain, while Cκ and Cλ can be used in the L chain. In addition, human antibody C region may be modified to improve the stability of the antibody or its production.
- Chimeric antibody is composed of the variable region of antibody originating in a mammal other than humans and the constant region of human antibody. On the other hand, humanized antibody is composed of the complementarity determining region of an antibody originating in a mammal other than humans and the framework region and C region of human antibody. Since humanized antibody has decreased antigenicity in the human body, it is useful as an effective ingredient of the therapeutic agent of the present invention.
- The production method of chimeric antibody is specifically described in Reference Example 4.
- In addition, the production method of humanized antibody is specifically described in Reference Example 5. In this reference example, versions a, b, c, d, e, f, g, h, i, j, b1, d1, b3 and d3 having the amino acid sequences shown in Tables 1 and 2 were used as the humanized heavy chain (H chain) variable region (V region).
-
- As a result of evaluating antigen binding ability and TF neutralization activity by combining the above various versions of H chain V region and the various versions of L chain V region, as described in Reference Examples 6 and 7, in the case of indicating as "H chain V region version" - "L chain V region version", the combinations of "b-b", "i-b" and "i-b2" exhibited particularly high activity. Furthermore, the antigen binding ability of these humanized antibodies is shown in
Fig. 1 , human TF neutralization activity (TF Factor Xa production inhibitory activity) is shown inFig. 2 , human TF neutralization activity (Factor X binding inhibitory activity) is shown inFig. 3 , and human TF neutralization activity (TF plasma coagulation inhibitory activity) is shown inFig. 4 . - The antibody used in the present invention may be an antibody fragment or modified antibody substance provided it binds to human TF and inhibits human TF activity. For example, examples of antibody fragments include single chain Fv (scFv) in which Fab, F(ab')2, Fv or H chain or L chain Fv is linked with a suitable linker.
- More specifically, either antibody is treated with an enzyme such as papain or pepsin to produce antibody fragments, or a gene is constructed that codes for these antibody fragments, after which a fragment is inserted into an expression vector and expressed in a suitable host (refer to, for example, Co, M.S. et al., J. Immunol. (1994) 152, 2968-2976, Better, M. & Horowitz, A.H., Methods in Enzymology (1989) 178, 476-496, Plueckthun, A. & Skerra, A., Methods in Enzymology (1989) 178, 497-515, Lamoyi, E., Methods in Enzymology (1986) 121, 652-663, Rousseaux, J. et al., Methods in Enzymology (1986) 121, 663-669, and Bird, R.E. et al., TIBTECH (1991) 9, 132-137).
- scFv is obtained by linking antibody H chain V region and L chain V region. In this scfv, the H chain V region and L chain V region are linked by means of a linker, and preferably by means of a peptide linker (Huston, J.B. et al., Proc. Natl. Acad. Sci., USA (1988) 85, 5879-5883). The H chain V region and L chain V region in scFv may be of any origin described as antibody in the present specification. An arbitrary single chain peptide comprised of, for example, 12-19 amino acid residues is used for the peptide linker that links the V regions.
- DNA that codes for scFv is obtained by using as template the portion of DNA coding for H chain or H chain V region and DNA coding for L chain or L chain V region of the above antibody that codes for the entire or desired amino acid sequence of those sequences, amplifying by PCR using a primer pair that defines both of its ends, and combining and amplifying DNA that codes for a peptide linker portion and primer pair defined such that both of its ends are linked with each H chain and L chain.
- In addition, once DNA that codes for scFv is produced, an expression vector that contains them and a host that is transformed by said expression vector can be obtained in accordance with routine methods, and scFv can be obtained in accordance with routine methods by using that host.
- These antibody fragments can be produced from a host by acquiring the gene in the same manner as previously described and expressing that gene. The term "antibody" in the present invention includes these antibody fragments.
- Anti-human TF antibody coupled with various molecules such as polyethylene glycol can also be used as modified antibody substances. These modified antibody substances are also included in the "antibody" of the present invention. These modified antibody substances can be obtained by performing chemical modification on the resulting antibody. Furthermore, antibody modification methods have already been established in this field.
- Antibody gene constructed in the manner previously described can be expressed and acquired by known methods. In the case of mammalian cells, antibody gene can be expressed by functionally coupling a commonly used useful promoter, antibody gene to be expressed and a poly A signal downstream from its 3'-side. An example of a promoter/enhancer is human cytomegalovirus immediate early promoter/enhancer.
- In addition, other examples of promoter/enhancer that can be used to express antibody used in the present invention include virus promoter/enhancer such as retrovirus, poliovirus, adenovirus, and simean virus 40 (sV40), as well as promoter/enhancer originating in mammalian cells such as human elongation factor 1α (HEF1α).
- Gene expression can be carried out easily according to the method of Mulligan, et al. (Nature (1979) 277, 108-114) in the case of using SV40 promoter/enhancer, or according to the method of Mizushima, et al. (Nucleic Acid Res. (1990) 18, 5322) in the case of using HEF1α promoter/enhancer.
- In the case of E. coli, said gene can be expressed by functionally coupling a commonly used useful promoter, signal sequence for antibody secretion and the antibody gene to be expressed. Examples of promoters include lacz promoter and araB promoter. Gene can be expressed according to the method of Ward, et al. (Nature (1989) 341, 544-546; FASEB J. (1992) 6, 2422-2427) in the case of using lacz promoter, or according to the method of Better, et al. (Science (1988) 240, 1041-1043) in the case of using araB promoter.
- The pelB signal sequence (Lei, S.P. et al., J. Bacteriol. (1987) 169, 4379-4383) should be used as the signal sequence for antibody secretion in the case of producing in periplasm of E. coli. After isolating the antibody produced in periplasm, the antibody is used after suitably refolding the antibody structure.
- Replication origins originating in SV40, poliovirus, adenovirus or bovine papilloma virus (BPV) and so forth can be used as replication origins. Moreover, in order to amplify the number of gene copies in host cell systems, the expression vector can contain as selection marker aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine guanine phosphoribosyl transferase (Ecogpt) gene or dihydrofolate reductase (dhfr) gene.
- An arbitrary expression system, such as a eucaryotic cell or procaryotic cell system, can be used to produce the antibody used in the present invention. Examples of eucaryotic cells include established mammalian cell systems, insect cell systems and fungal cells such as mold cells and yeast cells, while examples of procaryotic cells include bacterial cells such as E. coli cells.
- The antibody used in the present invention is preferably expressed in mammalian cells such as CHO, COS, myeloma, BHK, Vero and HeLa cells.
- Next, the transformed host cells are cultured in vitro or in vivo to produce the target antibody. Culturing of host cells is carried out in accordance with known methods. For example, DMEM, MEM, RPMI1640 or IMDM can be used for the culture medium, and a serum supplement such as fetal calf serum (FCS) can be used in combination with the above media.
- Antibody expressed and produced as described above can be isolated from cells or host animal and purified until homogeneous. Isolation and purification of antibody used in the present invention can be carried out using an affinity column. Examples of columns using a protein A column include Hyper D, POROS and Sepharose F.F. (Pharmacia). In addition, isolation and purification methods used with ordinary proteins should be used, and there are no restrictions whatsoever on these methods. For example, antibody can be isolated and purified by suitably selecting and combining, in addition to above affinity columns, a chromatography column, filter, ultrafiltration, salting out or dialysis and so forth (Antibodies: A Laboratory Manual, Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988).
- In order to study the efficacy of prevention or treatment of the present invention for diseases having a chronic hypercoagulable state, a novel animal model is required, and the details of the evaluation method are described in the specification of the patent application entitled "An animal model of a chronic hypercoagulable state and a method of generating the same" by the same applicant as this invention. Specific examples of the evaluation method are described as Example 1 in this specification.
- The result of the experiment that used the above humanized anti-human TF antibody version "i-b2" is shown in Example 2 and
Figures 11 to 13 . According to this experiment, in the animal model system shown in Example 1, after the platelet count of the mice that were implanted with the tumor cell containing the human TF gene decreased to about half of that of the mice that were not implanted with the same (5 to 6 weeks after implantation), 1 mg/kg of the humanized anti-human TF antibody version "i-b2" was repeatedly administered intravenously once a week, with a result that the platelet count was maintained at a level equal to that in the mice that were not implanted with the tumor cell till the end of the experiment, i.e., three weeks after the start of the administration. - The administration of the humanized anti-human TF antibody of the present invention suppressed the increase in the concentrations of soluble fibrin monomer complex (sFMC) and thrombin-antithrombin III complex (TAT). The result confirmed that the administration of anti-human TF antibody of the present invention prevents the persistence of a hypercoagulable state and maintains a normal state.
- An elongation of prothrombin time, a decrease in the plasma concentration of fibrinogen, an increase in the serum concentration of fibrin degradation products, and the like can be ascribed to the hypercoagulable state. The administration of anti-human TF antibody of the present invention suppressed the elongation of prothrombin time, the decrease in plasma concentration of fibrinogen, and the increase in the serum concentration of fibrin degradation products induced by the continuous infusion of LPS. This result demonstrates that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on the hypercoagulable state resulting from infections.
- In Example 3, this effect is described in detail. 8-3. Confirmation of the preventive and/or therapeutic effect on venous thrombosis
- In Example 4, it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on venous thrombosis.
- In Example 5, it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on arterial thrombosis.
- In Example 6, it is described in detail that the anti-human TF antibody of the present invention has a preventive and/or therapeutic effect on diseases resulting from the medial thickening of blood vessels.
- The therapeutic agent of the present invention is used for the purpose of preventing, treating or improving diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media.
- Effective dosage per administration is selected from the range of 0.001 mg to 1.000 mg/kg body weight. Alternatively, the dosage of 0.01 to 100 mg/kg, preferably 0.1 to 10 mg/kg may be selected. However, the therapeutic agent containing anti-human TF antibody of the present invention is not limited to these dosages.
- Preferably the method of administration is, but is not limited to, intravenous injection, intravenous drip, and the like.
- The therapeutic agent of the present invention comprising anti-human TF antibody as an active ingredient may be formulated using a standard method (Remington's Pharmaceutical Science, the latest edition, Mark Publishing Company, Easton, USA), and may contain pharmaceutically acceptable carriers and/or additives.
- Examples of such carriers or additives include water, a pharmaceutically acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like.
- Additives used are chosen from, but are not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present invention. For example, when used as injections, purified anti-human TF antibody may be dissolved in a solvent such as physiological saline, a buffer, and a glucose solution, to which an anti-adsorbent such as Tween 80,
Tween 20, gelatin, and human serum albumin may be added. Alternatively, they may be lyophilized so as to be dissolved and reconstituted into a dosage form before use. As the excipient for lyophilization, sugar alcohols and sugars such as mannitol and glucose may be used. - The present invention will now be explained more specifically with reference to the examples.
- A vector in which a gene encoding human tissue factor (SEQ ID NO: 103) had been inserted into an animal expression vector pCOS1 (hTF-pCOS1) was digested with a restriction enzyme PruI and linearized, which was then introduced into a human myeloma cell line KPMM2 (FERM BP -7419) by electroporation.
- pCOS1. was constructed by removing the antibody gene from HEF-PMh-gγ1 (
WO 92/19759 - The parent strain (KPMM2/parent) before the introduction of the above human tissue factor gene and the gene-introduced strain KPMM2/TF226 were cultured in a RPMI-1640 medium containing 4 ng/ml human IL-6 and 20% bovine fetal serum. The thus-grown KPMM2/TF226 cells and the parent KPMM2/parent cells, separately, were implanted subcutaneously at 1 x 107 cells into the flanks of SCID mice (available from CLEA Japan, male, 7-week old, mean body weight: about 22 g), and changes with time in tumor volume, platelet counts in the blood, and plasma concentrations of human tissue factor, fibrinogen, soluble fibrin monomer complex (sFMC), and thrombin-antithrombin III complex (TAT) were investigated.
- As a result, as shown in
Figure 5 , tumor volume increased with time in all mice. As shown inFigure 6 , however, the plasma concentration of human tissue factor increased with time in the mice having implanted therein cells to which the human tissue factor gene had been introduced, but did not increase at all in the mice having implatned therein cells to which the human tissue factor gene had not been introduced. As shown inFigure 7 andFigure 8 , in the mice having implanted therein cells to which the human tissue factor gene had been introduced, each of platelets and fibrinogen decreased with time, indicating that these coagulation components in the blood were consumed. In contrast, in the mice having implanted therein cells to which the human tissue factor gene had not been introduced, no decrease (consumption) in these coagulation components in the blood was noted. - As shown in
Figure 9 andFigure 10 , in the mice having implanted therein cells to which the human tissue factor gene had been introduced, the plasma concentration of each of soluble fibrin monomer complex (sFMC) and thrombin-antithrombin III complex (TAT) increased with time, indicating that the hypercoagulable state is persistent. In contrast, in the mice having implanted therein cells to which the human tissue factor gene had not been introduced, no increases in the above coagulation components in the blood were noted. - From the above results, it was confirmed that, in the mice having implanted therein cells to which the human tissue factor gene had been introduced, the hypercoagulable state is persistent, confirming that the animal of the present invention is useful as a model of a chronic hypercoagulable state.
- The effect of the humanized anti-human TF antibody version "i-b2" was investigated in the model described in Example 1. Five to six weeks after the implantation of KPMM2/TF226 to SCID mice (CLEA Japan, male, 7-week old, mean body weight: about 22 g), at when platelet counts fell to about half that of the non-tumor-implanted group, confirming the persistence of a hypercoagulable state, and thus from day 45 after the implanted 1 mg/kg of humanized anti-human TF antibody version "i-b2" was intravenously administered once a week. As a result, on day 3 after the administration of humanized anti-human TF antibody version "i-b2", platelet counts recovered to a level higher than that in the non-tumor-implanted group, and platelet counts were maintained at a level equal to that in the non-tumor-implanted group during the period from the start of the administration to week 3 when the experiment ended.
- On day 6 after the third administration of humanized anti-human TF antibody version "i-b2" , the plasma concentrations of soluble fibrin monomer complex (sFMC) and of thrombin-antithrombin III complex (TAT) were determined, and it was found that the administration of the antibody suppressed their increases (
Figure 12 andFigure 13 ). These results indicated that humanized anti-human TF antibody version "i-b2" had the effect of stably maintaining coagulation at a normal level, by a once-per-week administration in the model in which a hypercoagulable state persists for a long period. - LPS dissolved in physiological saline was continuously injected into a vein at a done of 1 mg/kg/hr (2 ml/kg/hr) for 6 hours to cynomolgus monkeys (imported from Chuang Primates Experimental Animal Research Center, Nanning, the People's Republic of China, equal numbers of males and females, estimated age: 5-7 years old, body weight: 2.99-5.81 kg) under isoflurane anesthesia. Intravenous administration of humanized anti-human TF antibody "version i-b2" at 0.3 mg/kg (1 ml/kg) to monkeys of the humanized anti-human TF antibody-administration group, and that of a solvent (20 mM sodium acetate/150 mM NaCl, pH 6.0) to monkeys of the control group were made respectively 10 minutes before the start of continuous injection of LPS.
- At the end of continuos injection of LPS, citrated blood and normal blood were drawn via the catheter mounted to the femoral artery, and prothrombin time, plasma concentration of fibrinogen and serum concentration of fibrin degradation products were determined. As shown in Table 4, LPS injection resulted in the elongation of prothrombin time, decreases in plasma concentration of fibrinogen, and increases in serum concentration of fibrin degradation products, i.e. a hypercoagulable state, but in the monkeys that had received humanized anti-human TF antibody "version i-b2", these changes were strongly suppressed. These results reveal that humanized anti-human TF antibody "version i-b2" can suppress the hypercoagulable state resulting from infections.
Table 4 Effect of humanized anti-human TF antibody on hypercoagulability by LPS injection Control group (n=4) Humanized TF antibody administration group (n=4) Before LPS injection After LPS injection Before LPS injection After LPS injection Prothrombin time 11.1 ± 15.8 ± 10.9 ± 11.7 ± (seconds) 0.3 2.3 0.3 0.6 plasma concentration of fibrinogen (mg/dl) 150 ± 20 90 ± 20 170 ± 10 160 ± 20 Serum concentration of fibrin degradation (µg/ml) 0 ± 0 43 ± 14 0 ± 0 8 ± 4 * Mean ± standard error - In a model of venous thrombosis induced by venostasis and a venous wall injury, the effect of humanized anti-human TF antibody on the venous thrombosis was evaluated. The venostasis was created by the ligation of the blood vessel. The venous wall injury was induced using "polidocanol (a therapeutic agent for esophageal varices, Kreussler)".
- Cynomolgus monkeys with an estimated age of 3-4 years old, weighing 2.97-3.99 kg (obtained from Chuang Primate Experimental Animal Research Center, the people's Republic of China) were used in the venous thrombosis model. The monkeys were anesthetized with mixture of isoflurane and nitrous oxide to expose the bilateral jugular veins. A segment of the exposed jugular vein was completely ligated with suture around the site proximal to the heart, and was reversibly legated with suture around the site nearer to the head so as to be loosened afterward. A catheter was inserted into the segment between the both ligation of the exposed jugular vein, from the nearer site to the heart in the direction toward the head. Blood in the segment between the ligations of the exposed jugular vein was removed through the catheter and the inside was washed with physiological saline. Via the catheter, 0.5% polidocanol was injected into the segment between the ligations of the exposed blood vessel. The catheter was removed and, at the same time, the segment of the blood vessel was reversibly ligated at the immediate upper part of the catheter insertion site.
- Five minutes later, the reversible ligation at the heart side was loosened to remove polidocanol. The reversible ligation at the head side was loosened to drain a smoll amount of blood, and then the segment of the exposed blood vessel was completely at the immediate upper part of the catheter insertion site. After the segment was filled with blood, the exposed jugular vein was completely ligated at the part nearer to the head. The segment between the both complete ligations was adjusted to be 1.5 cm in length. Thirty minutes later, the wet weight of the formed clots was measured. For the assessment, the sum of the wet weight of the clots in the bilateral jugular veins was used. Humanized anti-human TF antibody "version i-b2" was intravenously administered at a dose of 0.3 mg/kg and 1.5 mg/kg 2 hours before the start of the venous thrombus formation.
- The results are shown in Table 5. The administration of humanized anti-human TF antibody led to the reduction in the weight of the clots formed. Therefore, these result indicate that humanized anti-human TF antibody has a prophylactic effect on the venous thrombus formation in this model.
Table 5 Effect of humanized anti-human TF antibody in the venous thrombosis cynomolgus monkey Test agent not administered (n=2) Humanized anti-human TF antibody 0.3 mg/kg i.v. (n=2) Humanized anti-human TF antibody 1.5 mg/kg i.v. (n=2) Sum of the wet 20.8 1.4 0.0 weight of venous clots in the left and right carotid veins (mg) 21.9 1.1 0.4 Mean 21.4 1.3 0.2 - In a model of arterial thrombosis induced by angiostenosis and an arterial wall injury, the effect of humanized anti-human TF antibody on the arterial thrombosis was evaluated. The angiostenosis and the arterial wall injury were made by tightly ligating a blood vessel with a 20G needle pinched therein with its tip rounded and then removing the needle. This is a model that mimics angiostenosis due to arteriosclerosis and the arterial wall injury due to the plaque rupture.
- Cynomolgus monkeys with an estimated age of 3-5 years old, weighing 3.55-3.99 kg (obtained from Chuang Primates Experimental Animal Research Center, the People's Republic of China) were used in the arterial thrombosis model. The monkeys were anesthetized with ketamine hydrochloride (intramuscular administration) and butofanol (intramuscular administration) to expose the right common carotid artery. The probe of a doppler flowmeter was placed around the exposed blood vessel, and blood flow was monitored for about 5 minutes. After confirming the constant flow of the bloodstream, angiostenosis and the arterial wall injury were induced around the proximal site to the head side of the probe.
- The blood flow was observed for the subsequent 15 minutes, and the time of vascular occlusion due to thrombus formation was determined. After loosening the ligation at the right common carotid artery, humanized anti-human TF antibody was administered to the monkeys of the antibody administration group. In the left common carotid artery as well, the time of vascular occlusion due to thrombus formation was determined. Humanized anti-human TF antibody "version i-b2" was intravenously administered at a dose of 0.3 mg/kg and 1.5 mg/kg one hour before the start of the thrombus formation at the left common carotid artery.
- The results are shown in Table 6. The administration of humanized anti-human TF antibody led to the reduction in the time of vascular occlusion. Therefore, these results indicate that humanized anti-human TF antibody has a prophylactic effect on the arterial thrombus formation in this model.
Table 6 Effect of humanized anti-human TF antibody in the arterial thrombosis cynomolgus monkey Test agent not administered (n=2) Humanized anti-human TF antibody 0.3 mg/kg i.v. (n=2) Humanized anti-human TF antibody 1.5 mg/kg i.v. (n=2) The time of vascular occlusion during 15-min observation after test agent administration (minutes) [left common carotid artery] 12.2 7.2 3.5 The time of vascular occlusion during 15-min observation after test agent administration (minutes) left common carotid artery - right common carotid artery] +0.9 -4.4 -6.2 * All are the mean of the group. - Cynomolgus monkeys (purchased from KEARI Inc., monkeys raised in Vietnam, the estimated age of 4-5 years) were anesthetized under 5-10 mg/kg of Ketalar, im, and 15-20 mg/kg of pentobarbital, iv, and the neck was incised to expose the carotid artery. Via the external carotid artery, a Fogarty catheter (3-5F) was inserted and the balloon was inflated to scrape the vascular intima for five times. After scraping, the catheter was extracted and the wound was sutured. One month later, the animals were euthanized and the carotid artery was removed. At this time, the contralateral carotid artery that was not balloon-injured was extracted in a similar manner.
- Humanized anti-human TF antibody "version i-b2" was intravenously administered at a dose of 0.3 mg/kg over 1 minutes, 10 minutes before the vascular injury. The extracted artery was fixed in formalin, histological specimens were prepared, and stained with a HE stain and Elastica van Gieson stain, followed by image analysis to measure the area of the intima. As a result, as shown in
Figure 7 , humanized anti-human TF antibody "version i-b2" strongly suppressed the hypertrophy of the intima. This indicated that humanized anti-human TF antibody "version i-b2" prevents the narrowing of the area of the lumen during the remote period by suppressing the growth of the blood vessel tissue itself, suggesting that it can effectively prevent restenosis.Table 7 Non-injured blood vessel Injured blood vessel Animal No. Area of media (mm2) Area of media (mm2) Control group 1 1.06 2.15 (203%) 2 0.74 1.45 (196%) 3 0.82 1.78 (217%) Anti-human TF antibody 4 0.75 1.15 (153%) 5 0.78 0.96 (123%) 6 0.86 0.98 (114%) (Percentage relative to the non-injured side) - The effect of humanized anti-human TF antibody "version i-b2" and low molecular weight heparin was investigated in the model described in Example 1. Six to seven weeks after the grafting of KPMM2/TF226 to SCID mice (CLEA Japan, male, 7 weeks old, mean body-weight: about 24 g), platelet counts reduced to about half that of the non-tumor-grafted group, confirming the persistence of the hypercoagulable state. Hence, from
day 49 after thegrafting 1 mg/kg of humanized anti-human TF antibody version "i-b2" was intravenously administered or low molecular weight heparin at 601.5 IU/kg, 1900.3 IU/kg, and 6487.3 IU/kg was continuously administered by subcutaneously embedding an osmotic pump that permits sustained release for 24 hours. As a result, onday 1 after the administration of humanized anti-human TF antibody version "i-b2", platelet counts recovered, and on day 3 platelet counts were higher than that in the non-tumor-grafted group, and day 3 the effect was maintained even afterday 7. In contrast, in the administration group of 6487,3 IU/kg of low molecular weight heparin, a slight recovery in platelet counts was observed one and two days after the start of the continuous administration, but on day 3 the effect disappeared though there was a slight recovery in platelets counts (Figure 14 ). - Soluble human TF (shTF) was prepared in the following manner.
- The gene encoding the human TF penetrating region in which amino acids at position 220 and thereafter had been replaced with the FLAG peptide M2 was inserted to a mammalian cell expression vector (containing the neomycin resistant gene and the DHFR gene), and introduced into CHO cells. For the cDNA sequence of human TF, reference was made to an article by James H. Morrissey et al. (Cell (1987) 50: 129-135). The gene sequence and the amino acid sequence of this soluble human TF are shown in SEQ ID NOs: 101 and 102. After drug selection with G418, the expressed cells were selected, which were then subjected to expression amplification with methotrexate, and the shTF-expressing cells were established.
- The cells were cultured in the serum-free medium CHO-S-SFMII (GIBCO) to obtain a culture supernatant containing shTF. It was diluted 2-fold with an equal volume of a 40 mM Tris-HCl buffer (pH 8.5), which was added to the Q-Sepharose Fast Flow column (100 ml, Pharmacia Biotech) equilibrated with a 20 mM Tris-HCl buffer (pH 8.5). After washing with the same buffer containing 0.1 M NaCl, the concentration of NaCl was changed to 0,3 M, and shTF was eluted from the column. To the shTF fraction obtained, ammonium sulfate was added to a final concentration of 2.5 M, and was centrifuged (10,000 rpm, 20 minutes) to precipitate the contaminating proteins. The supernatant was added to Butyl TOYOPEARL (30 ml, TOSOH), and then was washed with a 50 mM Tris-HCl buffer (pH 6.8) containing 2.5 M ammonium sulfate. In the 50 mM Tris-HCl buffer (pH 6.8), the concentration of ammonium sulfate was linearly reduced from 2.5 M to 0 M to permit the elution of shTF. The peak fractions containing shTF were concentrated by the Centri-Prep 10 (Amicon). The concentrate was added to the TSKgel G3000SWG column (21.5 × 600 mm, TOSOH) equilibrated with a 20 mM Tris-HCl buffer (pH 7.0) containing 150 mM NaCl, and the peak fraction of shTF was collected. It was filter sterilized with a 0.22 µm membrane filter and the product was set as the soluble human TF (shTF). The concentration of the sample was calculated assuming that the molar extinction coefficient of the sample ε = 40,130 and molecular weight = 43,210.
- The purification of TF from human placenta was carried out according to the method of Ito (Ito, T. et al., J. Biol. Chem., 114: 691-696, 1993). Thus, human placenta was homogenized in Tris buffered saline (TBS, pH 7.5) containing 1.0 mM benzamidine hydrochloride, 1 mM phenylmethylsulfonyl fluoride, 1 mM diisopropylfluoro phosphate, and 0.02% sodium azide, and then the precipitate was defatted with cold acetone. The defatted powder obtained was suspended in the above buffer containing 2% Triton X-100 to solubilize TF.
- The supernatant was subjected to affinity chromatography using Concanavalin A-Sepharose 4B column (Pharmacia) and anti-TF antibody-bound Sepharose 4B column (Pharmacia), and purified TF was obtained. This was concentrated with an ultrafiltration membrane (PM-10, Amicon) and was stored as the purified sample at 4°C.
- TF content in the purified sample was quantitated by Sandwich ELISA that combined a commercially available anti-TF monoclonal antibody (American Diagnostica) and polyclonal antibody (American Diagnostica) with Recombinant TF as a standard.
- The purity in the purified sample was confirmed by subjecting the sample to SDS-PAGE using a 4-20% density gradient polyacrylamide gel, and silver-staining the product.
- After mixing the purified human TF (about 70 µg/ml) with an equal volume of Freund's complete adjuvant (Difco), it was immunized subcutaneously into the abdomen of 5-week old Balb/c male mice (Nippon Charles River) at 10 µg TF/mouse. On
day 12, 18, and 25, TF mixed with Freund's incomplete adjuvant was subcutaneously boosted at 5 µg/mouse TF, and as a final immunization the TF solution diluted with PBS was intraperitoneally given at 5 µg/mouse on day 32. - Three days after the final immunization, the spleen cells were prepared from four mice, and were fused to the mouse myeloma cell line P3U1 at 1/5 cell count thereof by the polyethylene glycol method. The fused cells were suspended into the RPMI-1640 medium (hereinafter referred to as RPMI-medium) (Lifetech Oriental) containing 10% fetal bovine serum, which was inoculated in 400 wells per mouse (about 400 cells/well) of a 96-well plate. On
day 1, 2, 3, and 5 after the fusion, half the volume of the medium was exchanged with the RPMI-medium (hereinafter referred to as HAT-medium) containing HAT (Dainippon Seiyaku) and condimed H1 (Boehringer Mannheim GmbH) to perform HAT selection of the hybridoma. - The hybridomas selected by the screening method described below were cloned by conducting limiting dilution twice.
- For the limiting dilution, 0.8 cells was inoculated per well in two 96-well plates. For the wells in which single colony was confirmed by microscopic examination, clones were selected by the following measurement of the binding activity to TF and neutralizing activity against TF. The clones obtained were acclaimed from the HAT-medium to the RPMI-medium. After the absence of reduction in antibody production ability due to acclimation was confirmed, limiting dilution was performed again for complete cloning. By the foregoing procedure, hybridomas that produce six antibodies (ATR-2, 3, 4, 5, 7, and 8) that strongly inhibit the binding of TF/Factor VIIa complex and Factor X were established.
- The ascites formation of the established hybridomas were carried out according to the standard method. Thus, 106 hybridomas that were subcultured in vitro were intraperitoneally grafted into BALB/c male mice that had previously received twice intravenous administration of mineral oil. Ascites was collected from the mice that showed a bloated abdomen 1-2 weeks after the grafting.
- The purification of antibody from ascites was carried out using the ConSepLC100 system (Millipore) equipped with the Protein A column (Nippon Gaishi).
- Human bladder carcinoma cells J82 (Fair D. S. et al., J. Biol. Chem., 262: 11692-11698, 1987) that are known to express TF at a high level were obtained from ATCC, and subcultured and maintained in the RPMI-medium under the condition of 37°C, 5% CO2, and 100% humidity.
- Cell-ELISA plates were prepared by inoculating J82 cells to a 96-well plate at 105 cells/well, culturing for one day under the above condition, removing the medium and then washing twice with phosphate buffered saline (PBS), adding a 4% paraformaldehyde solution (PFA), and allowing to stand on ice for 10 minutes for immobilization. After PFA was removed, the plate was washed with PBS, the Tris buffer (Blocking buffer) containing 1% BSA and 0.02% sodium azide was added thereto, and the plate was stored at 4°C until use.
- Cell-ELISA was carried out in the following manner. Thus, the Blocking buffer was removed from the plate prepared as above, to which an anti-TF antibody solution or a hybridoma culture supernatant was added and was reacted at room temperature for 1.5 hours. After washing with PBS containing 0.05
% Tween 20, alkaline phosphatase-conjugated goat anti-mouse IgG (H+L) (Zymed) was reacted for 1 hour. After washing, 1 mg/ml p-nitrophenyl phosphate disodium (Sigma) was added, and one hour later absorbance at 405/655 nm was measured to determine the amount of anti-TF antibody that bound to the J82 cells. - To 50 µl of Tris buffered saline (TBS: pH 7.6) containing 5 mM Cacl2 and 0.1% bovine serum albumin, 10 µl of a human placenta-derived thromboplastin solution (5 mg/ml) (Thromborel S) (Boehring) and 10 µl of a Factor VIIa solution (82.5 ng/ml) (American Diagnostics) were added, and reacted at room temperature for 1 hour to permit the formation of the TF/Factor VIIa complex. After 10 µl of a predetermined concentration of a diluted anti-TF antibody solution or the hybridoma culture supernatant and 10 µl of a Factor X solution (3.245 µg/ml) (Celsus Laboratories) were added and reacted for 45 minutes, 10 µl of 0.5 M EDTA was added to stop the reaction. Fifty µl of 2 nM S-2222 solution (Daiichi Kagaku Yakuhin) was added thereto, and changes in absorbance at 405/655 nm over 30 minutes were measured and was set as the Factor X-producing activity of TF. In this method, the activity of antibody that inhibits the binding of the TF/Factor VIIa complex and Factor X can be determined.
- Fifty µl of an appropriately diluted anti-TF antibody solution was mixed with 100 µl of a commercially available normal human plasma (Kojin Bio) and reacted at 37°C for 3 minutes. Then 50 µl of human placenta-derived thromboplastin solution (1.25 mg/ml) was added thereto, and the time to coagulation of the plasma was measured using the plasma coagulation measuring instrument (CR-A: Amelung).
- For the culture supernatant of the hybridoma and the purified antibody, the mouse monoclonal antibody isotyping kit (manufactured by Amersham) was used to confirm the isotype of antibody. The result is shown below.
Table 5 Immunoglobulin isotype of anti-TF monoclonal antibody ATR-2 IgG1, k ATR-3 IgG1, k ATR-4 IgG1, k ATR-5 IgG1, k ATR-7 IgG2a, k ATR-8 IgG2a, k - mRNA was prepared from hybridoma ATR-5 (IgG1κ) obtained in Reference Example 2 using the QuickPrep mRNA Purification Kit (Pharmacia Biotech). Each hybridoma cell was completely homogenized in the extraction buffer according to instructions attached to the kit, and then mRNA was purified by the oligo (dT)-cellulose spun column, followed by ethanol precipitation. The mRNA precipitate was dissolved in the elution buffer.
- The cloning of the gene encoding the H chain V region of a mouse monoclonal antibody against human TF was carried out using the 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002, 1988; Belyavsky, A. et al., Nucleic Acids Res. 17: 2919-2932, 1989). For the 5'-RACE method, the Marathon cDNA Amplification Kit (CLONTECH) was used and the procedure carried out according to the instructions attached to the kit.
- Using about 1 µg of mRNA prepared as above as a template, the cDNA synthesis primer attached to the kit was added, which was reacted with a reverse transcriptase at 42°C for 60 minutes to effect reverse transcription to cDNA. This was reacted with DNA polymerase I, DNA ligase, and RNaseH at 16°C for 1.5 hour, and with T4 DNA polymerase at 16°C for 45 minutes thereby to synthesize a double stranded cDNA. The double stranded cDNA was extracted with phenol and chloroform, and recovered by ethanol precipitation.
- By overnight reaction with T4 DNA ligase at 16°C, a cDNA adapter was ligated to both ends of the double stranded cDNA. The reaction mixture was diluted 50-fold with a 10 mM Tricine-KOH (pH 8.5) containing 0.1 mM EDTA. Using this as a template, the gene encoding the H chain V region was amplified by PCR. The
adapter primer 1 attached to the kit was used for the 5'-end primer, and for the 3'-end primer the MHC-G1 primer (SEQ ID NO: 1) (S. T. Jones, et al., Biotechnology, 9: 88-89, 1991) were used. - PCR solutions for the ATR-5 antibody H chain V region contained, in 100 µl, 120 mM Tris-HCl (pH 8.0),10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), 30-50 pmole of
adapter primer 1, as well as MHC-G1 primer, and 1-5 µl of a reaction mixture of cDNA to which the cDNA adapter was ligated. - All PCRs were carried out using the DNA Thermal Cycler 480 (Perkin-Elmer), and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- The cloning of the gene encoding the L chain V region of a mouse monoclonal antibody against human TF was carried out using the 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002, 1988; Belyavsky, A. et al., Nucleic Acids Res. 17: 2919-2932, 1989). For the 5'-RACE method, the Marathon cDNA Amplification Kit (CLONTECH) was used and carried out according to the instructions attached to the kit. Using about 1 µg of mRNA prepared as above as a template, the cDNA synthesis primer was added, which was reacted with a reverse transcriptase at 42°C for 60 minutes to effect reverse transcription to cDNA.
- This was reacted with DNA polymerase I, DNA ligase, and RNaseH at 16°C for 1.5 hour, and with T4 DNA polymerase at 16°C for 45 minutes thereby to synthesize a double stranded cDNA. The double stranded cDNA was extracted with phenol and chloroform, and recovered by ethanol precipitation. By overnight reaction with T4 DNA ligase at 16°C, a cDNA adapter was ligated to both ends of the double stranded cDNA. The reaction mixture was diluted 50-fold with a 10 mM Tricine-KOH (pH 8.5) containing 0.1 mM EDTA. Using this as a template, the gene encoding the L chain V region was amplified by PCR. The
adapter primer 1 was used for the 5'-end primer, and for the 3'-end primer the MKC primer (SEQ ID NO: 2) (S. T. Jones, et al., Biotechnology, 9: 88-89, 1991) was used. - PCR solutions contained, in 100 µl, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), 30-50 pmole of
adapter primer 1, as well as MKC primer, and 1 µl of a reaction mixture of cDNA to which the cDNA adapter was ligated. - All PCRs were carried out using the DNA Thermal Cycler 480 (Perkin-Elmer), and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- The above PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation. DNA fragments were digested with the restriction enzyme XmaI (New England Biolabs) at 37°C for 1 hour. The XmaI-digestion mixture was separated by agarose gel electrophoresis using 2%-3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 500 bp long DNA fragments as the H chain V region and about 500 bp Long DNA fragments as the L chain V region were excised. The agarose strips were extracted with phenol and chloroform, DNA fragments were precipitated with ethanol, which were then dissolved in 10 µl of 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA (hereinafter referred to as TE).
- The XmaI-digested DNA fragments prepared as above containing a genes encoding a mouse H chain V region and L chain V region and the pUC19 plasmid vector prepared by digesting with XmaI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli J1M109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C.
- Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour. Then, Escherichia coli was plated on a LB agar medium (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) containing 100 µg/ml ampicillin (hereinafter referred to as LBA agar medium), and incubated overnight at 37°C to obtain an E. coli transformant.
- The transformant was cultured overnight in 3 ml or 4 ml of a LB medium containing 50 µg/ml ampicillin (hereinafter referred to as LBA medium) at 37°C, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN), and then the nucleotide sequence was determined.
- The nucleotide sequence of the cDNA coding region in the above plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) (SEQ ID NO: 3) and M13 Primer RV (Takara Shuzo) (SEQ ID NO: 4) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- Thus obtained plasmids containing the gene encoding the mouse H chain V region derived from the hybridoma ATR-5 was designated as ATR-5Hv/pUC19, and the thus obtained plasmids containing the gene encoding a mouse L chain V region derived from the hybridoma ATR-5 was designated as ATR-5Lv/pUC19. The nucleotide sequences of the genes encoding the H chain V region of each mouse antibody contained in the plasmid ATR-5Hv/pUC19 (including the corresponding amino acid sequences) is shown in SEQ ID NO: 5 and 99, respectively, and the nucleotide sequences of the genes encoding the L chain V region of each mouse antibody contained in the plasmid ATR-5Lv/pUC19 (including the corresponding amino acid sequences) is shown in SEQ ID NO: 6 and 100, respectively.
- A chimeric ATR-5 antibody was generated in which the mouse ATR-5 antibody V region was ligated to the human antibody C region. A chimeric antibody expression vector was constructed by ligating the gene encoding the ATR-5 antibody V region to an expression vector encoding the human antibody C region.
- The ATR-5 antibody H chain V region was modified by the PCR method in order to ligate it to an expression vector encoding the human antibody H chain C region. The 5'-end primer ch5HS (SEQ ID NO: 7) was designed so as to hybridize the 5'-end of DNA encoding the V region and to have the Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987) and a recognition sequence of the restriction enzyme SalI. The 3'-end primer ch5HA (SEQ ID NO: 8) was designed so as to hybridize 3'-end of DNA encoding the J region and to have a recognition sequence of the restriction enzyme NheI.
- The PCR solutions contained, in 100 #1, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the ch5HS primer and the ch5HA primer, as well as 1 µl of the plasmid ATR5Hv/pUC19 as a template DNA. For PCR, the DNA Thermal Cycler 480 (Perkin-Elmer) was used, and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- The PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation. The DNA fragments were digested with the restriction enzyme NheI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme SalI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 450 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- As the cloning vector, an altered promoter vector (hereinafter referred to as CVIDEC) was used in which the recognition sequences of the restriction enzymes NheI, SalI, and SplI, BglII were introduced. The gene fragment prepared as above encoding the mouse H chain V region and the CVIDEC vector prepared by digesting with NheI and SalI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 2°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle. Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA sequencer 373A (Ferkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) (SEQ ID NO: 3) and M13 Primer RV (Takara Shuzo) (SEQ ID NO: 4) were used, and the sequence was determined by confirming the nucleotide sequence in both directions. The plasmid that contains the gene encoding the ATR-5 antibody H chain V region, a SalI recognition sequence and the Kozak consensus sequence at the 5'-end, and a NheI recognition sequence at the 3'-end was designated as chATR5Hv/CVIDEC.
- The ATR-5 antibody L chain V region was modified by the PCR method in order to ligate it to an expression vector encoding the human antibody L chain C region. The 5'-end primer ch5LS (SEQ ID NO: 9) was designed so as to hybridize to the 5'-end of the DNA encoding the V region and to have the Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987) and a recognition sequence of the restriction enzyme BgIII. The 3'-end primer ch5LA (SEQ ID NO: 10) was designed so as to hybridize to the 3'-end of the DNA encoding the J region and to have a recognition sequence of the restriction enzyme SplI.
- The PCR solutions contained, in 100 µl, 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the ch5LS primer and the ch5LA primer, as well as 1 µl of the plasmid ATR5Lv/pUC19 as a template DNA. For PCR the DNA Thermal Cycle 480 (Perkin-Elmer) was used, and the PCR was performed for thirty cycles at a temperature cycle of 94°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute.
- The PCR reaction mixture was extracted with phenol and chloroform, and the amplified DNA fragments were recovered by ethanol precipitation. The DNA fragments, were digested with the restriction enzyme SplI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme BglI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, the DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- The gene fragment prepared as above encoding the mouse L chain V region and the CVIDEC vector prepared by digesting with SplI and BglI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 µg/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions. The plasmid that contains the gene encoding the ATR-5 antibody L chain V region and that has a BglII recognition sequence and the Kozak consensus sequence at the 5'-end and a SplI recognition sequence at the 3'-end was designated as chATR5Lv/CVIDEC.
- A chimeric antibody expression vector was constructed using an antibody expression vector introduced from IDEC Pharmaceuticals. As the vector, the TgGl-type antibody expression vector H5KG1(V) and the IgG4-type antibody expression vector N5KG4P were used. The chimeric ATR-5 antibody expression vector was generated by ligating a gene encoding the H chain V region of ATR-5 to the SalI-NheI site located immediately before the human antibody H chain C region of the expression vector N5KG1(V) or N5KG4P and ligating a gene encoding the L chain V region of ATR-5 to the BglII-SplI site located immediately before the human antibody L chain c region of the expression vector N5KG1(V) or N5KG4P.
- The plasmid chATR5Hv/CVIDEC was digested with the restriction enzyme NheI (Takara Shuzo) at 37°C for 3 hours, and with the restriction enzyme SalI (Takara Shuzo) at 37°C for 3 hours. The digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 450 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- The expression vector N5KG1(V) and N5KG4P were digested with the restriction enzyme Nhel (Takara Shuzo) at 37°C for 3 hours, and with the restriction enzyme SalI (Takara Shuzo) at 37°C for 3 hours. The digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 9000 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- The SalI-NheI DNA fragment prepared as above containing the gene encoding the H chain V region and N5KG1(V) or N5KG4P digested with SalI and NheI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the attached instructions.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 µg/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN). These plasmids containing the genes encoding the chimeric ATR-5 antibody H chain were designated as chATR5v/N5KG1(V) and chATR5Hv/N5KG4P, respectively.
- The plasmid chATR5Lv/cVIDEC was digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 1.5 hour. The digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, and the DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- The plasmids chATR5Hv/N5KG1(V) and chATR5Hv/N5KG4P were digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 1.5 hour. The digestion mixture was separated by agarose gel electrophoresis using 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 9400 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, DNA fragments were precipitated with ethanol, which were then dissolved in 20 µl of TE.
- The SplI-BglII DNA fragment prepared as above containing the gene encoding the L chain V region and chATR5Hv/N5KG1(V) or chATR5Hv/N5KG4P digested with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the attached instructions.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on a 100 µg/ml LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 1 l of the 2xYT medium containing 50 µg/ml ampicillin, and from the cell fractions, plasmid DNA was prepared using the Plasmid Maxi Kit (QIAGEN). These plasmids containing the gene encoding the chimeric ATR-5 antibody were designated as chATR5/N5KG1(V) and chATR5/N5KG4P, respectively.
- In order to evaluate the activity of binding to the antigen and the neutralizing activity of chimeric antibody, the above expression plasmid was transected to COS-7 cells and the antibody was transient expressed.
- The plasmid chATR5/NSKG1(V) or chATR5/N5KG4P was transduced into COS-7 cells by electroporation using the Gene Pulser instrument (Bio Rad). Fifty µg of the plasmid was added to 0.78 ml of the COS-7 cells suspended in the Dulbecco PBS (-) (hereinafter referred to as PBS) at a cell concentration of 1 × 107 cells/ml, which was subjected to pulses of 1,500 V and 25 µF capacity.
- After 10 minutes of the recovery period at room temperature, the electroporated cells were suspended in a DMEM medium containing 5% Ultra low IgG fetal bovine serum (GIBCO), and cultured using a 10 cm culture dish in a 5% CO2 incubator. After culturing for 24 hours, the culture supernatant was aspirated off, and then a serum-free medium HBCHO (Irvine Scientific) was added. After further culturing for 72 hours, the culture supernatant was collected and centrifuged to remove cell debris.
- From the culture supernatant of the COS-7 cells, chimeric antibody was purified using the rProtein A Sepharose Fast Flow (Pharmacia Biotech) as follows.
- One ml of rProtein A Sepharose Fast Flow was filled into a column and the column was equilibrated by 10 volumes of TBS. The culture supernatant of COS-7 cells was applied to the equilibrated column, which was then washed with 10 volumes of TBS.
- The adsorbed antibody fraction was then eluted by 13.5 ml of 2.5 mM HCl (pH 3.0), and the eluate was immediately neutralized by adding 1.5 ml of 1 M Tris-HCl (pH 8.0).
- By performing ultrafiltration twice for the purified antibody fraction using the Centriprep 100 (Amicon), the solvent was replaced to 50 mM Tris-HCl (pH 7.6) containing 150 mM NaCl (hereinafter referred to as TBS), and was finally concentrated to about 1.5 ml.
- In order to establish a cell line that stably produces chimeric antibody, the above expression plasmid was introduced into CHO cells (DG44) acclimated to the CHO-S-SFMII serum-free medium (GIBCO).
- The plasmid chATR5/N5KG1(V) or chATR5/N5KG4P was cleaved with the restriction enzyme SspI (Takara Shuzo) to linearize DNA, and after extraction with phenol and chloroform, DNA was recovered by ethanol precipitation. The linearized plasmid was transduced into the DG44 cells by electroporation using the Gene Pulser instrument (Bio Rad). Ten µg of the plasmid was added to 0.78 ml of DG44 cells suspended in PBS at a cell concentration of 1 × 107 cells/ml, which was subjected to pulses of 1,500 V and 25 µF capacity.
- After 10 minutes of the recovery period at room temperature, the electroporated cells were suspended in a CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO), and cultured using two 96-well plates (Falcon) in a 5% CO2 incubator. On the day after the start of culturing, the medium was changed to a selection medium containing the CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO) and 500 µg/ml GENETICIN (G418Sulfate, GIBCO) to select cells into which the antibody gene had been introduced. After changing the selection medium, the cells were examined under a microscope about two weeks later. After a favorable cell growth was observed, the amount of antibody produced was measured by the ELISA described below for determining antibody concentration, and cells having a high production yield of antibody were selected.
- Humanized ATR-5 antibody H chain was generated using CDR-grafting by the PCR method. In order to generate the humanized antibody H chain version "a" having the FRs derived from human antibody L39130 (DDBJ, Gao L. et al., unpublished, 1995), seven PCR primers were used. The CDR-grafting primers hR5Hv1S (SEQ ID NO: 11), hR5Hv2S (SEQ ID NO: 12), and hR5Hv4S (SEQ ID NO: 13) have a sense DNA sequence, and the CDR grafting primers hR5Hv3A (SEQ ID NO: 14) and hR5Hv5A (SEQ ID NO: 15) have an antisense DNA sequence, each primer having a 18-35 bp complementary sequence on both ends thereof.
- hR5Hv1S was designed to have the Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol. 196: 947-950, 1987) and a SalI recognition site, and hR5Hv5A was designed to have a NheI recognition site. The exogenous primer hR5HvPrS (SEQ ID NO: 16) has a homology with the CDR-grafting primer hR5Hv1S, and hR5HvPrA (SEQ ID NO: 17) has a homology with the CDR-grafting primer hR5Hv5A.
- The CDR-grafting primers hR5Hv1S, hR5Hv2S, hR5Hv3A, hR5Hv4S, and hR5Hv5A, and exogenous primers hR5HvPrS and hR5HvPrA were synthesized and purified by Pharmacia Biotech.
- PCR was performed using the KOD DNA polymerase (Toyo Boseki) and using the attached buffer under the condition of containing 120 mM Tris-HCl (pH 8.0), 10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), and 5 pmole each of the CDR-grafting primers hR5Hv1S, hR5Hv2S, hR5Hv3A, hR5Hv4S, and hR5Hv5A in 98 µl, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute. After further addition of 100 pmole of exogenous primers hR5HvPrS and hR5HvPrA, PCR was performed for 25 cycles in a system of 100 µl with the same temperature cycle. DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts).
- The agarose strips containing about 430 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 17 µl of water. The PCR reaction mixture obtained was digested with NheI and SalI, and was ligated to the plasmid vector CVIDEC prepared by digesting with NheI and SalI, using the DNA ligation kit ver.2 (Takara Shuzo) according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- Since mutation and/or deletion were observed before or after the EcoT221 recognition site, each of fragments having the correct sequence was ligated and then subcloned again to CVIDEC to determine the nucleotide sequence. The plasmid having the correct sequence was designated as hATR5Hva/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "a" contained in the plasmid hATR5Hva/CVIDEC are shown in SEQ ID NO: 18. The amino acid sequence of version "a" is also shown in SEQ ID NO: 19.
- Versions "b" and "c" were generated by replacing the FR3 of version "a" with the FR3 derived from another human antibody using the FR-shuffling method. In order to replace the FR3 in version "b" with one derived from human antibody Z34963 (DDBJ, Borretzen M. et al., Proc. Natl. Acad. Sci. USA, 91: 12917-12921, 1994), the four DNA primers encoding the FR3 were generated. The FR-shuffling primers F3RFFS (SEQ ID NO: 20) and F3RFBS (SEQ ID NO: 21) have a sense DNA sequence and F3RFFA (SEQ ID NO: 22) and F3RFBA (SEQ ID NO: 23) have an antisense DNA sequence.
- F3RFFS and F3RFFA have a sequence complementary to each other, and have BalI and XhoI recognition sequences on both ends. In order to replace the FR3 in version "c" with one derived from human antibody P01825 (SWISS-PROT, Poljak RJ. et al., Biochemistry, 16: 3412-3420, 1977), four DNA primers encoding the FR3 were generated. The FR-shuffling primers F3NMFS (SEQ ID NO: 24) and F3NMBS (SEQ ID NO: 25) have a sense DNA sequence and F3NMFA (SEQ ID NO: 26) and F3NMBA (SEQ ID NO: 27) have an antisense DNA sequence. F3RFBS and F3RFBA have a sequence complementary to each other, and have XhoI and NcoI recognition sequences on both ends.
- F3RFFS, F3RFBS, F3RFFA, F3RFBA, F3NMFS, F3NMBS, F3NMFA, and F3NMBA were synthesized by Pharmacia Biotech. F3RFFS and F3RFFA, and F3RFBS and F3RFBA were annealed, and were digested with BalI and XhoI, and NcoI and XhoI, respectively. They were introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined. The plasmid having the correct sequence was designated as hATR5Hvb/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b" contained in the plasmid hATR5Hvb/CVIDEC are shown in SEQ ID NO: 28. The amino acid sequence of version "b" is also shown in SEQ ID NO: 29.
- F3NMFS and F3NMFA, and F3NMBS and F3NMBA were annealed, and were digested with BalI and XhoI, and NcoI and XhoI, respectively. They were introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined. The plasmid having the correct sequence was designated as hATR5Hvc/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "c" contained in the plasmid hATR5Hvc/CVIDEC are shown in SEQ ID NO: 30. The amino acid sequence of version "c" is also shown in SEQ ID NO: 31.
- Versions "d" and "e" were generated by replacing the FR3 of version "a" with the FR3 derived from another human antibody using the FR-shuffling method. In order to replace the FR3 in version "d" with one derived from human antibody M62723 (DDBJ, Pascual V. et al., J. Clin. Invest., 86: 1320-1328, 1990), four DNA primers encoding the FR3 were generated. The FR-shuffling primer F3EPS (SEQ ID NO: 32) has a sense DNA sequence and F3EPA (SEQ ID NO: 33) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- Exogenous primers F3PrS (SEQ ID NO: 34) and F3PrA (SEQ ID NO: 35) have a homology with the For-shuffling primers F3EPS and F3EPA, and can also be used for other FR3's FR-shuffling. In order to replace the FR3 in version "e" with one derived from the human antibody Z80844 (DDBJ, Thomsett AR. et al., unpublished), two DNA primers encoding the FR3 were generated. The for-shuffling primers F3VHS (SEQ ID NO: 36) has a sense DNA sequence and F3VHA (SEQ ID NO: 37) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp. F3EPS, F3EPA, F3PrS, F3PrA, F3VHS and F3VHA were synthesized by Pharmacia Biotech.
- PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 µl each of 1 µM FR-shuffling primers F3EPS and F3EPA, or F3VHS and F3VHA, 0.2 mM dNTPs, 1.0 mM MgCl2, and 2.5 units of KOD DNA polymerase in 100 µl of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% Nu Sieve GTG agarose (FMC BioProducts). The agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 µl of water. The PCR reaction mixture obtained was digested with Ball and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- The plasmids having the correct sequence were designated as hATR5Hvd/CVIDEC and hATR5Hve/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "d" contained in the plasmid hATR5Hvd/CVIDEC are shown in SEQ ID NO: 38, and the amino acid sequence of version "d" is also shown in SEQ ID NO: 39. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "e" contained in the plasmid hATR5Hve/CVIDEC are shown in SEQ ID NO: 40, and the amino acid sequence of version "e" is also shown in SEQ ID NO: 41.
- Versions "f" and "g" were generated by replacing the FR3 of version "a" with the FR3 derived from another human antibody using the FR-shuffling method. In order to replace the FR3 in version "f" with one derived from human antibody L04345 (DDBJ, Hillson JL. et. al., J. Exp. Med., 178: 331-336, 1993) and to replace the FR3 in version "g" with one derived from human antibody S78322 (DDBJ, Bejcek BE. et al., Cancer Res., 55: 2346-2351, 1995), two primers each encoding the FR3 were synthesized. The FR-shuffling primer F3SSS (SEQ ID NO: 42) of version "f" has a sense DNA sequence and F3SSA (SEQ ID NO: 43) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3CDS (SEQ ID NO: 44) of version "g" has a sense DNA sequence and F3CDA (SEQ ID NO: 45) has an antisense DNA sequence, and the 3`-end of the primers has a complementary sequence of 18 bp. F3SSS, F3SSA, F3CDS, and F3CDA were synthesized and purified by Pharmacia Biotech. PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 µl each of 1 µM FR-shuffling primers F3SSS and F3SSA, or F3CDS and F3CDA, 0.2 mM dNTPs, 1.0 mM MgCl2, and 2.5 units of KOD DNA polymerase in 100 µl of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts). The agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 µl of water. The PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- The plasmids having the correct sequence were designated as hATR5Hvf/CVIDEC and hATR5Hvg/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "f" contained in the plasmid hATR5Hvf/CVIDEC, and the amino acid sequence of version "f" are shown in SEQ ID NO: 46 and 47. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "g" contained in the plasmid hATR5Hvg/CVIDEC, and the amino acid sequence of version "g" are shown in SEQ ID NO: 48 and 49.
- versions "h" was generated by replacing the FR3 of version "a" with the FR3 derived from another human antibody using the FR-shuffling method. In order to replace the FR3 in version "h" with one derived from the human antibody Z26827 (DDBJ, van Der Stoep et al., J. Exp. Med., 177; 99-107, 1993), two primers each encoding the FR3 were synthesized. The FR-shuffling primer F3ADS (SEQ ID NO: 50) of version "h" has a sense DNA sequence and F3ADA (SEQ ID NO: 51) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3ADS and F3ADA were synthesized and purified by Pharmacia Biotech. PCR was performed using the KOD DNA polymerase (Toyo Boseki) using the attached buffer under the condition of containing 5 µl each of 1 µM FR-shuffling primers F3ADS and F3ADA, 0.2 mM dNTPs, 1.0 mM MgCl2, and 2.5 units of KOD DNA polymerase in 100 µl of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74C for 1 minute. After further addition of 100 pmole of exogenous primers F3Pr5 and F3PrA, PCR was performed for 25 cycles with the same temperature cycle. DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% NuSieve GTG agarose (FMC BioProducts).
- The agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 µl of water. The PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined. The plasmids having the correct sequence were designated as hATR5Hvh/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "h" contained in the plasmid hATR5Hvh/CVIDEC, and the amino acid sequence of version "h" are shown in SEQ ID NO: 52. The amino acid sequence of version "h" is shown in SEQ ID NO: 53.
- Versions "i" and "j" were generated by replacing the FR3 of version "a" with the FR3 derived from another human antibody using the FR-shuffling method. In order to replace the FR3 in version "i" with one derived from the human antibody U95239 (DDBJ, Manheimer-Lory AAJ., unpublished) and to replace the FR3 in version "j" with one derived from the human antibody L03147 (DDBJ, Collect TA. et al., Proc. Natl. Acad. Sci, USA, 89: 10026-10030, 1992), two primers each encoding the FR3 were synthesized. The FR-shuffling primer F3MHS (SEQ ID NO: 54) of version "i" has a sense DNA sequence and F3MMA (SEQ ID NO: 55) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp.
- F3BMS (SEQ ID NO: 56) of version "j" has a sense DNA sequence and F3BMA (SEQ ID NO: 57) has an antisense DNA sequence, and the 3'-end of the primers has a complementary sequence of 18 bp. F3MMS, F3MMA, F3BMS, and F3BMA were synthesized and purified by Pharmacia Biotech. PCR was performed using the Ampli Taq Gold (Perkin-Elmer) using the attached buffer under the condition of containing 5 µl each of 1 µM FR-shuffling primers F3MMS and F3MMA, or F3BMS and F3BMA, 0.2 mM dNTPs, 1.0 mM MgCl2, and 2.5 units of Ampli Taq Gold in 100 µl of the reaction mixture, for 5 cycles at a temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 74°C for 1 minute. After further addition of 100 pmole of exogenous primers F3PrS and F3PrA, PCR was performed for 25 cycles with the same temperature cycle.
- DNA fragments amplified by the PCR method were separated by agarose gel electrophoresis using a 2% Nu Sieve GTG agarose (FMC BioProducts). The agarose strips containing about 424 bp long DNA fragments were excised, to which 3 volumes (ml/g) of TE was added, and then were extracted with phenol, phenol/chloroform, and chloroform to purify the DNA fragments. After precipitating the purified DNA with ethanol, one third the volume thereof was dissolved in 14 µl of water. The PCR reaction mixture obtained was digested with BalI and NcoI, and was introduced to the plasmid hATR5Hva/CVIDEC (BalI/NcoI) prepared by digesting with BalI and NcoI, and the nucleotide sequence was determined.
- The plasmids having the correct sequence were designated as hATR5Hvi/cVIDEC and hATR5Hvj/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "i" contained in the plasmid hATR5Hvi/CVIDEC, and the amino acid sequence of version "i" are shown in SEQ ID NO: 58 and 59. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "j" contained in the plasmid hATR5Hvj/CVIDEC, and the amino acid sequence of version "j" are shown in SEQ ID NO: 60 and 61.
- Versions "b1" and "dl" were generated by replacing the FR2 of versions "b" and "d" with the FR2 derived from another human antibody using the FR-shuffling method. In order to replace the FR2 with one derived from the human antibody P01742 (SWISS-PROT, Cunningham BA. et al., Biochemistry, 9: 3161-3170, 1970), two DNA primers encoding the FR2 were synthesized. The FR-shuffling vector F2MPS (SEQ ID NO: 62) has a sense DNA sequence and F2MPA (SEQ ID NO: 63) has an antisense DNA sequence. They also have a sequence complementary to each other, and have recognition sequences of EcoT221 and BalI on both ends thereof.
- F2MPS and F2MPA were synthesized and purified by Pharmacia Biotech. F2MPS and F2MPA were annealed and were digested with EcoT22I and BalI. They were introduced to plasmids hATR5Hvb/CVIDEC (EcoT22I/BalI) and hATR5Hvd/CVIDEC (EcoT22I/BalI) prepared by digesting with EcoT22I and BalI, and the nucleotide sequence was determined. The plasmids having the correct sequence were designated as hATR5Hvbl/CVIDEC and hATR5Bvd1/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b1" contained in the plasmid hATR5Hvb1/CVIDEC, and the amino acid sequence of version "b1" are shown in SEQ ID NO: 64 and 65. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "dl" contained in the plasmid hATR5Hvdl/CVIDEC, and the amino acid sequence of version "dl" are shown in SEQ ID NO: 66 and 67.
- Versions "b3" and "d3" were generated by replacing the FR2 of versions "b" and "d" with the FR2 derived from another human antibody using the FR-shuffling method. In order to replace the FR2 with one derived from the human antibody Z80844 (DDDJ, Thomsett AR. et al., unpublished), two DNA primers encoding the FR2 were synthesized. The FR-shuffling vector F2VHS (SEQ ID NO: 68) has a sense DNA sequence and F2VHA (SEQ ID NO: 69) has an antisense DNA sequence. They also have a sequence complementary to each other, and have recognition sequences of EcoT221 and BalI on both ends thereof. The synthesis and purification of F2VHS and F2VHA was referred to Pharmacia Biotech.
- F2VHS and F2VHA were annealed and were digested with EcoT22I and BalI. They were introduced to plasmids hATR5Hvb/CVIDEC (EcoT22I/BalI) and hATR5Hvd/CVIDEC (EcoT22I/BalI) prepared by digesting with EcoT22I and BalI, and the nucleotide sequence was determined. The plasmids having the correct sequence were designated as hATR5Hvb3/CVIDEC and hATR5Hvd3/CVIDEC. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "b3" contained in the plasmid hATR5Hvb3/CVIDEC, and the amino acid sequence of version "b3" are shown in SEQ ID NO: 70 and 71. The nucleotide sequence and the corresponding amino acid sequence of the humanized H chain version "d3" contained in the plasmid hATR5Hvd3/CVIDEC, and the amino acid sequence of version "d3" are shown in SEQ ID NO: 72 and 73.
- The humanized ATR-5 antibody L chain V region was generated by the CDR-grafting using the PCR method. For the generation of a humanized antibody L chain (version "a") having framework regions derived from human antibody Z37332 (DDBJ, Welschof M. et al., J. Immunol. Methods, 179: 203-214, 1995), seven PCR primers were used.
- CDR-grafting primers h5Lv1S (SEQ ID NO: 74) and h5Lv4S (SEQ ID NO: 75) have a sense DNA sequence, CDR-grafting primers h5Lv2A (SEQ ID NO: 76), h5Lv3A (SEQ ID NO: 77), and h5Lv5A (SEQ ID NO: 78) have an antisense DNA sequence, and each primer has 20 bp complementary sequences on both ends thereof. Exogenous primers h5LvS (SEQ ID NO: 79) and h5LvA (SEQ ID NO: 80) have a homology with CDR-grafting primers h5Lv1S and h5Lv5A. The synthesis and purification of CDR-grafting primers h5Lv1S, h5Lv4S, h5Lv2A, h5Lv3A, h5Lv5A, h5LvS, and h5LvA were referred to Pharmacia Biotech.
- The PCR solutions contain, in 100 µl, 120 mM Tris-HC1 (pH 8.0), 10 mM KC1, 6 mM (NH4)2SO4, 0.1% Triton X-100, 0.001% BSA, 0.2 mM dNTPs (dATP, dGTP, DCTP, dTTP), 1 mM MgCl2, 2.5 units of KOD DNA polymerase (Toyo Boseki), 50 pmole of the CDR-grafting primers h5Lv1S, h5Lv2A, h5Lv3A, h5Lv4S, and h5Lv5A.
- PCR was performed using the DNA Thermal Cycler 480 (Perkin-Elmer) for 5 cycles with the temperature cycle of 94°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute to assemble 5 CDR-grafting primers. After further addition of 100 pmole of exogenous primers h5LvS and h5LvA to the reaction mixture, PCR was performed for 30 cycles with the temperature cycle of 94°C for 30 seconds, 52°C for 1 minute, and 72°C for 1 minute to amplify the assembled DNA fragments.
- The PCR reaction mixture was separated by agarose gel electrophoresis using a 3% NuSieve GTG agarose (FMC BioProducts), and the agarose strips containing about 400 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, DNA fragments were recovered by ethanol precipitation. The recovered DNA fragments were digested with the restriction enzymes SplI (akara Shuzo) and BglII (Takara Shuzo) at 37°C for 4 hours. The digestion mixture was extracted with phenol and chloroform, and after the ethanol precipitation of the DNA fragments, they were dissolved in 10 µl of TE. The SplI-BglII DNA fragment prepared as above encoding the humanized L chain V region and the CVIDEC vector prepared by digesting with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 3'7°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions. The plasmid that contains the gene encoding the humanized antibody L chain V region and that has a BglII recognition sequence and the Kozak sequence at the 5'-end, and a SplI recognition sequence at the 3'-end was designated as hATR5Lva/CVIDEC. The nucleotide sequence (including the corresponding amino acid sequence) of the humanized L chain version "a" is shown in SEQ ID NO: 81. The amino acid sequence of version "a" is also shown in SEQ ID NO: 82.
- Versions "b" and "c" were generated by replacing (FR-shuffling) the FR3 of version "a". For version "b" the FR3 derived from human antibody S68699 (DDBJ, Hougs L. et al., Exp. Clin. Immunogen et., 10: 141-151, 1993) was used, and for version "c" the FR3 derived from human antibody P01607 (SWISS-PROT, Epp O et al., Biochemistry, 14: 4943-4952, 1975) was used, respectively.
- Primers F3SS (SEQ ID NO: 83) and F3SA (SEQ ID NO: 84) encoding the FR3 of version "b", or primers F3RS (SEQ ID NO: 85) and F3RA (SEQ ID NO: 86) encoding the FR3 of version "c" have a sequence complementary to each other, and have the recognition sequences of the restriction enzymes KpnI and PstI on both ends thereof. The synthesis and purification of F3SS, F3SA, F3RS, and F3RA were referred to Pharmacia Biotech. 100 pmole each of F3SS and F3SA, or F3RS and F3RA were annealed by treating at 96°C for 2 minutes and at 50°C for 2 minutes and the double stranded DNA fragments were generated.
- These double stranded DNA fragments were digested with the restriction enzyme KpnI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme PstI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was extracted with phenol and chloroform, and after it was precipitated with ethanol, it was dissolved in TE.
- The plasmid hATR5Lva/CVIDEC was digested with the restriction enzyme KpnI (Takara Shuzo) at 37°C for 1 hour, and then with the restriction enzyme PstI (Takara Shuzo) at 37°e for 1 hour. The digestion mixture was separated by agarose gel electrophoresis using a 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 3000 bp long DNA fragments were excised. The agarose strip was extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- The KpnI-PstI DNA fragment prepared as above encoding the FR3 of versions "b" or "c" and the hATR5Lva/CVIDEC vector in which the FR3 was removed by digesting with KpnI and PstI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight in 3 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmer). As the sequencing primer, M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- The plasmids that contain the gene encoding version "b" or version "c" in which the FR3 of humanized antibody L chain version "a" was replaced was designated as hATR5Lvb/CVIDEC or hATR5Lvc/CVIDEC, respectively. The nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b" contained in plasmid hATR5Lvb/CVIDEC and the amino acid sequence of version "b" are shown in SEQ ID NO: 87 and 88. The nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "c" contained in plasmid hATR5Lvc/CVIDEC and the amino acid sequence of version "c" are shown in SEQ ID NO: 89 and 90.
- Versions "b1" and "b2" were generated by replacing the FR2 of version "b". For version "b1" the FR2 derived from human antibody S65921 (DDBJ, Tonge DW et al., Year Immunol., 7: 56-62, 1993) was used, and for version "b2" the FR2 derived from human antibody X93625 (DDBJ, Cox JP et al., Eur. J. Immunol., 24: 827-836, 1994) was used, respectively.
- Primers F2SS (SEQ ID NO: 91) and F2SA (SEQ ID NO: 92) encoding the FR2 of version "b1", or primers F2XS (SEQ ID NO: 93) and F2XA (SEQ ID NO: 94) encoding the FR2 of version "b2" have a sequence complementary to each other, and have the recognition sequences of the restriction enzymes AflII and SpeI on both ends thereof. F2SS, F2SA, F2XS, and F2XA were synthesized by Pharmacia Biotech. 100 pmole each of F2SS and F2SA, or F2XS and F2XA were annealed by treating at 96°C for 2 minutes and at 50°C for 2 minutes, and the double stranded DNA fragments were generated.
- These double stranded DNA fragments were digested with the restriction enzymes AflII (Takara Shuzo) and Spel (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- The plasmid hATR5Lvb/CVIDEC was digested with the restriction enzymes AflII (Takara Shuzo) and SpeI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was separated by agarose gel electrophoresis using a 1.5% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 3000 bp long DNA fragments were excised. The agarose strip was extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- The AflII-SpeI DNA fragment prepared as above encoding the FR2 of version "b1" or "b2" and the hATR5Lvb/CVIDEC vector in which the FR2 was removed by digesting with AflII and SpeI were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant. The transformant was cultured overnight at 37°C in 4 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the QIAprep Spin Plasmid Kit (QIAGEN).
- The nucleotide sequence of the cDNA coding region in the plasmid was determined using the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin-Elmer) by the DNA Sequencer 373A (Perkin-Elmex). As the sequencing primer, M13 Primer M4 (Takara Shuzo) and M13 Primer RV (Takara Shuzo) were used, and the sequence was determined by confirming the nucleotide sequence in both directions.
- The plasmids that contain the gene encoding version "b1" or "b2" in which the FR2 of humanized antibody L chain version "b" was replaced was designated as hATR5Lvbl/CVIDEC and hATR5Lv2/CVIDEC, respectively. The nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b1" contained in plasmid hATR5Lvbl/CVIDEC and the amino acid sequence of version "b1" are shown in SEQ ID NO: 95 and 96. The nucleotide sequence and the corresponding amino acid sequence of the humanized L chain version "b2" contained in plasmid hATR5Lvb2/CVIDEC and the amino acid sequence of version "b2" are shown in SEQ ID NO: 97 and 98.
- The plasmid hATB5Hva/CVIDEC containing a H chain V region was digested with NheI and SalI, and a DNA fragment of the humanized H chain V region was recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATRS/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmid thus generated was designated as hFiva-chLv/N5KG4P.
- The plasmid hATR5Hvb/CVIDEC containing a H chain V region was digested with NheI and SalI, and a DNA fragment of the humanized H chain V region was recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmid thus generated was designated as hHvb-chLv/N5KG4P.
- The plasmids hATR5Hvc/CVIDEC, hATR5Hvd/CVIDEC, and hATR5Hve/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmids thus generated were designated as hHvc-chLv/N5KG4P, hHvd-chLv/N5KG4P, and hHve-chLv/N5KG4P.
- The plasmids hATR5Hvf/CVIDEC and hATR5Hvh/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmids thus generated were designated as hHvf-chLv/N5KG4P and hHvh-chLv/N5KG4P.
- The plasmids hATR5Hvi/CVIDEC and hATR5Hvj/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5XG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmids thus generated were designated as hHvi-chLv/N5KG4P and hHvj-chLv/N5KG4P.
- The plasmids hATR5Hbl/CVIDEC and hATR5Hvdl/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to chATR5/N5KG4P (SalI/NheI) prepared by digesting chATR5/N5KG4P, a chATR-5 antibody expression plasmid vector, with NheI and SalI. The plasmids thus generated were designated as hHvb1 chLv/N5KG4P and hHvdl-chLv/N5KG4P.
- Using an antibody expression vector N5KG4P, it was combined with a chimeric H chain and was expressed, and the humanized L chain was evaluated.
- The plasmids hATR5Lva/CVIDEC, hATR5Lvb/CVIDEC, hATR5Lvc/CVIDEC, hATR5Lvbl/CVIDEC, and hATR5Lvb2/CVIDEC were digested with the restriction enzymes BglII (Takara Shuzo) and SplI (Takara Shuzo) at 37°C for 2-3 hours. The digestion mixture was separated by agarose gel electrophoresis using a 1.5% or 2% NuSieve GTG agarose (FMC BioProducts), and the agarose strips having about 400 bp long DNA fragments were excised. The agarose strips were extracted with phenol and chloroform, and after the DNA fragments were precipitated with ethanol, they were dissolved in TE.
- The SplI-BglII DNA fragment containing the gene encoding the a humanized L chain V region of each of these versions and the hATR5Hv/N5KG4P digested with SplI and BglII were ligated using the DNA ligation kit ver.2 (Takara Shuzo) by reacting at 16°C for 1 hour according to the instructions attached to the kit.
- The ligation mixture was added to 100 µl of E. coli JM109 competent cells (Nippongene) and was incubated for 30 minutes on ice and for 1 minute at 42°C. Then, 300 µl of the Hi-Competence Broth (Nippongene) was added thereto, incubated at 37°C for 1 hour, and then the E. coli was plated on the LBA agar medium and incubated overnight at 37°C to obtain an E. coli transformant.
- The transformant was cultured overnight at 37°C in 250 ml or 500 ml of the LBA medium, and from the cell fractions, plasmid DNA was prepared using the Plasmid Maxi Kit (QIAGEN). The plasmid in which a gene encoding the chimeric H chain and humanized L chain was introduced were designated as chHv-hLva/N5KG4P, chHv-hLvb/N5KG4P, chHv-hLvc/N5KG4P, chHv-hLvbl/N5KG4P, and chHv-hLvb2/N5KG4P.
- The plasmid hATR5Hva/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLva/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv,-hLva/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "a" with NheI and SalI. The plasmid thus generated was designated as hHva-hLva/N5KG4P.
- The plasmids hATR5Hvb/CVTIDEC and hATR5Hvc/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLva/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLva/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "a" with NheI and SalI. The plasmids thus generated were designated as hRvb-hLva/N5KG4P and hHvc-hLva/N5KG4P.
- The plasmids hATR5Hvb/CVIDEC, hATR5Hvd/CVIDEC, and hATR5Hve/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI. The plasmids thus generated were designated as hHvb-hLvb/N5KG4P, hHvd-hLvb/N5KG4P, and hHve-hLvb/N5KG4P.
- The plasmids hATR5Hvf/CVIDEC, hATR5Hvg/CVIDEC, and hATR5Hvh/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/NSKG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI. The plasmids thus generated were designated as hHvf-hLvb/N5KG4P, hHvg-hLvb/N5KG4P, and hHvh-hLvb/N5KG4P.
- The plasmids hATR5Hvi/CVIDEC and hATR5Hvj/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI. The plasmids thus generated were designated as hHvi-hLvb/N5KG4P and hHvj-hLvb/N5KG4P.
- The plasmids hATR5Hvbl/CVIDEC and hATR5Hvdl/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI. The plasmids thus generated were designated as hHvb1-bLvb/N5KG4P and hHvdl-hLvb/N5KG4P.
- The plasmids hATR5Hvb3/CVIDEC and hATR5Hvd3/CVIDEC containing a H chain V region were digested with NheI and SalI, and cDNA fragments of the humanized H chain V region were recovered and introduced to hLvb/N5KG4P (SalI/NheI) prepared by digesting plasmid chHv-hLvb/N5KG4P containing the cDNA sequence of humanized ATR-5 antibody L chain version "b" with NheI and SalI. The plasmids thus generated were designated as hHvb3-hLvb/N5KG4P and hHvd3-hLvb/N5KG4P.
- The plasmid hATR5Hvb/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLvbl/N5KG4P (SalI/NheI) and hLvb2/N5KG4P (SalI/NheI) prepared by digesting plasmids chHv-hLvb1/N5KG4P and chHv-hLvb2/N5KG4P containing the DNA sequence of humanized ATR-5 antibody L chain versions "b1" and "b2" with NheI and SalI. The plasmids thus generated were designated as hHvb-hLvb1/N5KG4P and hHvb-hLvb2/N5KG4P.
- The plasmid hATR5Hvi/CVIDEC containing a H chain V region was digested with NheI and SalI, and a cDNA fragment of the humanized H chain V region was recovered and introduced to hLvb1/N5KG4P (SalI/NheI) and hLvb2/N5KG4P (SalI/NheI) prepared by digesting plasmids chHv-hLvb1/N5KG4P and chHv-hLvb2/N5KG4P containing the DNA sequence of humanized ATR-5 antibody L chain versions "b1" and "b2" with NheI and SalI. The plasmids thus generated were designated as hHvi-hLvb1/N5KG4P and hHvi-hLvb2/N5KG4P.
- In order to evaluate the activity of binding to the antigen and neutralizing activity of humanized antibody, the above antibody was transiently expressed in COS-7 cells.
- The constructed expression plasmid vector was transduced into COS-7 cells by electroporation using the Gene Pulser instrument (Bio Rad). Fifty µg or 20 µg of the plasmid was added to 0.78 ml of COS-7 cells suspended in PBS at a cell concentration of 1 × 107 cells/ml, which was subjected to pulses of 1,500 V and 25 µF capacity.
- After 10 minutes of the recovery period at room temperature, the electroporated cells were suspended in a DMEM medium (GIBCO) containing 5% Ultra low IgG fetal bovine serum (GIBCO), and cultured using a 10 cm culture dish or 15 cm culture dish in a 5% CO2 incubator. After culturing for 24 hours, the culture supernatant was aspirated off, and then a serum-free medium HBCHO (Irvine Scientific) was added. After further culturing for 72 hours or 96 hours, the culture supernatant was collected and centrifuged to remove cell debris.
- From the culture supernatant of the COS-7 cells, the antibody was purified using the AffiGel Protein A MAPSII kit (Bio Rad) or the rProtein A Sepharose Fast Flow (Pharmacia Biotech). Purification using the AffiGel Protein A MAPSII kit was carried out according to the instructions attached to the kit. Purification using the rProtein A Sepharose Fast Flow was carried out as follows:
- One ml of rProtein A Sepharose Fast Flow was filled into a column and the column was equilibrated by 10 volumes of TBS. The culture supernatant of COS-7 cells was applied to the equilibrated column, which was then washed with 10 volumes of TBS. The adsorbed antibody fraction was eluted by 13.5 ml of 2.5 mM HCl (pH 3.0). The eluate was neutralized by adding 1.5 ml of 1 M Tris-HCl (pH 8.0).
- By performing ultrafiltration two or three times for the purified antibody fraction using the Centriprep 30 or 100 (amicon), the solvent was replaced to TBS, and was finally concentrated to about 1.5 ml.
- ELISA plates for measurement of antibody concentration were prepared as follows: Each well of a 96-well ELISA plate (Maxisorp, NUNC) was immobilized by 100 µl of goat anti-human IgGγ antibody (BIO SOURCE) prepared to a concentration of 1 µg/ml in the immobilization buffer (0.1 M NaHCO3, 0.02% NaN3, pH 9.6) (hereinafter referred to as CB). After blocking with 200 µl of the dilution buffer (50 mM Tris-HCl, 1 mM MgCl2, 0.1 M NaCl, 0.05
% Tween 20, 0.02% NaN3, 1% bovine serum albumin BSA), pH 8.1) (hereinafter referred to as DB), the culture supernatant of the COS-7 cells in which antibody was expressed or purified antibody were serially diluted with DB, and then added to each well. - After incubating at room temperature for 1 hour followed by washing with the Dulbecco PBS containing 0.05% Tween 20 (hereinafter referred to as RB), 100 µl of alkaline phosphatase-conjugated goat anti-human IgGγ antibody (Biosource) which was diluted 1000-fold with DB was added. After incubating at room temperature for 1 hour followed by washing with the RB, Sigma104 (p-nitrophenyl phosphate, SIGMA) dissolved in the substrate buffer (50 mM NaHCO3, 10 mM MgCl2, pH 9.8) to 1 mg/ml was added, and then the absorbance at. 405/655 nm was measured using the Microplate Reader (Bio Rad). As the standard for the measurement of concentration, IgG4κ (Binding Site) was used.
- Cell ELISA plates for measurement of antigen binding were prepared as follows. Cells used were human bladder carcinoma cells J82 (ATCC HTB-1). To 60 wells of a 96-well cell culture plate, 1 × 105 J82 cells were inoculated. This was cultured (RPMI1640 medium containing 10% fetal bovine serum (GIBCO)) for one day in a CO2 incubator to allow the cells to be attached thereto. After discarding the culture liquid, each well was washed twice with 300 µl PBS. 100 µl of PBS containing 4% paraformaldehyde (hereinafter referred to as PFA/PBS) was added to each well, and placed on ice for 10 minutes to immobilize the cells.
- PFA/PBS was discarded, and each well was washed twice with 300 µl of PBS, and then blocked with 250 µl of DB. The culture supernatant or purified antibody was serially diluted with DB, 100 µl of which was added to each well. After incubating at room temperature for 2 hours followed by washing with RB, 100 µl of alkaline phosphatase-conjugated goat anti-human IgGγ antibody (BioSource) diluted 1000-fold with DB was added. After incubating for 1 hour followed by washing with RB, the substrate solution was added, and then absorbance at 405/655 nm was measured using the Microplate Reader (Bio-Rad).
- The neutralizing activity of mouse antibody, chimeric antibody, and humanized antibody was measured with the inhibiting activity against the Factor Xa-production activity by human placenta-derived thromboplastin, Thromborel S (Boehringer AG), as an index. Thus, 60 µl of the buffer (TBS containing 5 mM CaCl2 and 0.1% BSA) was added to 10 µl of 1.25 mg/ml Thromborel S and 10 µl of appropriately diluted antibody, which was then incubated in a 96-well plate at room temperature for 1 hour. Ten µl each of 3.245 µg/ml human Factor x (Celsus Laboratories) and 82.5 ng/ml human Factor VIIa (Enzyme Research) were added thereto, and then were incubated at room temperature for 1 hour.
- Ten µl of 0.5 M EDTA was added to stop the reaction, to which 50 µl of the chromogenic substrate solution was added and the absorbance at 405/655 nm was determined using the Microplate Reader (Bio Rad). After reacting at room temperature for 1 hour, the absorbance at 405/655 nm was determined again. The neutralizing activity may be determined by calculating the residual activity (%) from each change in absorbance with the hourly absorbance change at no antibody addition as a 100% activity.
- The chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, diluting 2-fold with purified water and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- An antibody (a-ch) which is the humanized H chain version "a" combined with a chimeric L chain was generated, and was tested for the binding activity to the antigen by the cell ELISA. The amount bound to the antigen was found to be decreased at the high concentration. The neutralizing activity against the antigen by FXa production-inhibition was weak as compared that of to the positive control chimeric antibody (ch-ch). Therefore, it was decided to perform the version-up of the humanized H chain by FR-shuffling. The chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- An antibody (ch-a) which is the humanized L chain version "a" combined with a chimeric H chain was generated, and was tested for the binding activity to the antigen by the cell ELISA. It was found to have the binding activity equal to or higher than that of the chimeric antibody. On the other hand, the neutralizing activity against the antigen was weak as compared to that of the positive control chimeric antibody. Therefore, it was decided to perform the version-up of the humanized L chain by FR-shuffling. The chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- An antibody (a-a) which is the humanized H chain version "a" combined with the humanized L chain version "a" was generated, and was tested for the binding activity to the antigen by the cell ELISA. The amount bound to the antigen was found to be decreased in the high concentration side. The neutralizing activity against the antigen by FXa production-inhibition was weak as compared to that of the positive control chimeric antibody. Therefore, it was decided to perform the version-up of the humanized H chain and L chain by FR-shuffling. The chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- Antibodies ("b-ch", "c-ch", and "d-ch", respectively) which are the humanized H chain subjected to version-up by FR-shuffling combined with a chimeric L chain were generated, and were tested for the binding activity to the antigen by the cell ELISA. "d-ch" exhibited a binding activity equal to that of the chimeric antibody, and "b-ch" and "c-ch" exhibited a slightly lower biding activity. On the other hand, the neutralizing activity against the antigen as compared to the that of positive control chimeric antibody was almost equal in "b-ch", and slightly weak in "d-ch". In version "c-ch", it was significantly weaker than that of the chimeric antibody. Therefore, the humanized H chain versions "b" and "d" were considered the ones of the humanized H chain to exhibit a high activity.
- An antibody (b-a) which is the humanized H chain version "b" subjected to version-up by FR-shuffling combined with the humanized L chain version "a" was generated, and was tested for the binding activity to the antigen by the cell ELISA. The amount bound to the antigen was found to be decreased at the high concentration. On the other hand, the neutralizing activity against the antigen was significantly weak as compared to that of the positive control chimeric antibody. Therefore, "b-a" and "a--a." were the ones that exhibit a high activity. The chimeric antibody used herein was the one that was expressed in COS-7 cells, purified, and evaluated.
- Antibodies ("ch-b" and "ch-c", respectively) which are the humanized L chain versions "b" and "c" combined with a chimeric H chain were generated, and both of them were found to have the binding activity to the antigen and the neutralizing activity against the antigen equal to the chimeric antibody. Therefore, versions "b" and "c" were chosen as a candidate for a humanized antibody L chain. Mouse antibody-derived version "b" which is one amino acid fewer in the amino acid residue number is considered to be superior to version "c" in terms of antigenicity. The chimeric antibody used herein was the one that was expressed in CHO cells DG44, purified, and evaluated. In the evaluation hereinafter the antibody was used as the positive control.
- Antibodies ("b-b" and "b-c", respectively) which are the humanized H chain version "b" combined with the humanized L chain versions "b" and "c" were generated, and tested for the binding activity to the antigen and the neutralizing activity against the antigen. Both of them had a slightly lower activity than that of the chimeric antibody in both the binding activity and the neutralizing activity.
- Antibodies ("b-b" and "d-b", respectively) which are the humanized H chain subjected to version-up by FR-shuffling combined with the humanized L chain version "b" were generated, and were tested for the binding activity to the antigen by the cell ELISA. "d-b" exhibited a binding activity equal to that of the chimeric antibody, and "b-b" exhibited a slightly lower binding activity at the high concentration. On the other hand, the neutralizing activity against the antigen as compared to that of the positive control chimeric antibody was slightly low in "b-b" , and significantly weak in "d-b". Therefore, it was shown that "b-b" is a high neutralizing activity version, whereas "d-b" is a high binding activity version.
- Antibodies ("e-ch" and "e-b", respectively) which are the humanized L chain version "e" combined with a chimeric L chain and the humanized version "b" were generated. "e-ch" exhibited a binding activity to the antigen equal to that of the chimeric antibody, but in "e-b" the amount of antibody expressed was very little and most of the binding activity was lost. The neutralizing activity against the antigen of "e-ch" was significantly low as compared to that of the chimeric antibody. Therefore, it was concluded that the H chain version "e" combined with L chain version "b" did not work well.
- Antibodies ("f-b", "g-b", and "h-b", respectively) which are the humanized H chain versions "f", "g", and "h" combined with the humanized L chain version "b" were generated. In "f-b" and "h-b" antibody, the amount of antibody expressed was very little. For versions "f" and "h", antibodies combined with the Chimeric L chain were generated, but were not expressed. "g-b" reached saturation at a low concentration, and exhibited a binding activity weaker than that of the chimeric antibody. The neutralizing activity against the antigen of "g-b" was significantly weak as compared to that of the chimeric antibody.
- Antibodies ("b1-b" and "d1-b", respectively) which are the humanized H chain versions "b1" and "d1" combined with the humanized L chain version "b" were generated. Almost no antibody was expressed in any of them. For these, antibodies combined with a chimeric L chain were generated, but were not expressed.
- Antibodies ("b3-b" and "d3-b", respectively) which are the humanized H chain versions "b3" and "d3" combined with the humanized L chain version "b" were generated. The binding activity to the antigen of "d3-b" was slightly lower than that of the chimeric antibody, and that of "b3-b" was much lower. The neutralizing activity against the antigen of "b3-b" was higher than that of "b-b", but was lower than that of the chimeric antibody, and "d3-b" and "b-b" remained equal in activity.
- Antibodies ("i-ch" and "j-ch", respectively) which are the humanized H chain versions "i" and "j" combined with a chimeric L chain, and antibodies ("i-b" and "j-b", respectively) combined with the humanized L chain version "b" were generated, and were tested for the binding activity to the antigen and the neutralizing activity against the antigen. The binding activity of any of the antibodies was almost equal to that of the chimeric antibody. "i-ch" exhibited the neutralizing activity higher than that of the chimeric antibody, and "j-ch" was significantly lower than that of the chimeric antibody. "i-b" exhibited the neutralizing activity equal to that of the chimeric antibody, and "j-b" exhibited a significantly weaker neutralizing activity than that of that of the chimeric antibody.
- When antibodies ("ch-b1" and "ch-b2", respectively) which are the humanized L chain versions "b1" and "b2" combined with a chimeric H chain were generated, both of them exhibited the binding activity to the antigen equal to that of the chimeric antibody. For the neutralizing activity against the antigen, "ch-b1" exhibited the binding activity equal to that of the chimeric antibody, while "ch-b2" exhibited an activity slightly higher than that of the chimeric antibody at the high concentration. Versions "b1" and "b2" can be candidates of a humanized antibody L chain, but "b2" is superior in that it has a stronger activity.
- An antibody ("b-b2") which is the humanized H chain version "b" combined with the humanized L chain version "b2" was generated, and was tested for the binding activity to the antigen and the neutralizing activity against the antigen. The binding activity was slightly lower than that of the chimeric antibody. The neutralizing activity, though slightly higher than that of "b-b", was lower than that of "i-b".
- Antibodies ("I-b1" and "i-b2", respectively) which are the humanized H chain version "i" combined with the humanized L chain version "b1" or "b2" were generated, and were tested for the binding activity to the antigen and the neutralizing activity against the antigen. The binding activity of "i-b2" was almost equal to that of the chimeric antibody, and that of "i-b1" was slightly lower than that of chimeric antibody. The neutralizing activity of "i-b1" and "i-b2" was higher than that of the chimeric antibody and "i-b" , which was in a decreasing order of "i-b2" > "i-b1".
- In order to establish cell lines that stably produce a humanized antibody (b-b, i-b, and i-b2), an antibody expression gene vector was introduced into CHO cells (DG44) acclaimed to a serum-free medium.
- Plasmid DNA, hHvb-hLvb/N5KG4P, hHvi-hLvb/N5KG4P, and hHvi--hLvb2/N5KG4P were digested with the restriction enzyme Sspl (Takara Shuzo) and linearized, which was extracted with phenol and chloroform, and purified by ethanol precipitation. The linearized expression gene vector was introduced into the DG44 cells using the electroporation instrument (Gene Pulser; Bio Rad). The DG44 cells were suspended in PBS at a cell concentration of 1 × 107 cells/ml, and to about 0.8 ml of this
suspension - After 10 minutes of the recovery period at room temperature, the treated cells were suspended in a CHO-S-SFMII medium (GIBCO) containing hypoxanthine/thymidine (GIBCO) (hereinafter referred to as HT), which was inoculated on two 96-well plates (Falcon) at 100 µl/well, and cultured in a CO2 incubator. Eight to nine hours after the start of culturing, 100 µI/well of the CHO-S-SFMII medium containing HT and 1 mg/ml GENETICIN (GIBCQ) was added to change to 500 µg/ml of the GENETICIN selection medium, and the cells into which the antibody gene had been introduced were selected. The medium was changed with a fresh one once every 3-4 days with 1/2 the volume. At a time point about 2 weeks after changing to the selection medium, an aliquot of the culture supernatant was recovered from the well in which a favorable cell growth was observed 4-5 days later. The concentration of antibody expressed in the culture supernatant was measured by the ELISA described above for measuring antibody concentration, and cells having a high production yield of antibody were selected.
- After the DG44 cell lines selected as above that produce the humanized antibody ("b-b", "i"b", and "i-b2") were cultured for a few days in a 500 ml/bottle of the CHO-S-SFMII medium using a 2 L roller bottle (CORNING), the culture medium was harvested and a fresh CHO-S-SFMII medium was added and cultured again. The culture medium was centrifuged to remove the cell debris, and filtered with a 0.22 µm or 0.45 µm filter. By repeating this, a total of about 2 L each of the culture supernatant was obtained. From the culture supernatant obtained, antibody was purified by the ConSep LC100 system (Millipore) connected to the Protein A affinity column (Poros),
- ELISA plates for measurement of antibody concentration were prepared as follows: Each well of a 96-well ELISA plate (Maxisorp, NUNC) was immobilized with 100 µl of goat anti-human IgGγ antibody (BioSource) prepared to a concentration of 1 µg/ml with CB. After blocking with 200 µl of DB, the culture supernatant of the CHO cells in which antibody had been expressed or the purified antibody was serially diluted with DB, and added to each well.
- After incubating at room temperature for 1 hour and washing with RB, 100 µl of alkaline phosphatase-conjugated goat anti-human IgGγ antibody (BioSource) diluted 1000-mold with DB was added. After incubating at room temperature for 1 hour and washing with RB, 100 µl of the substrate solution was added, and then the absorbance at 405/655 nm was measured using the Microplate Reader (Bio Rad). As the standard for the measurement of concentration, human IgG4κ (The Binding site) was used.
- Cell ELISA plates for measurement of antigen binding were prepared as follows. Cells used were human bladder carcinoma cells J82 (ATCC HTB-1), which were inoculated onto a 96-well cell culture plate at a cell count of 1 × 105 cells. This was cultured (RPMI1640 medium containing 10% fetal bovine serum (GIBCO)) for one day in a CO2 incubator to allow the cells to be attached thereto. After discarding the culture liquid, each well was washed twice with PBS. 100 µl of PFA/PBS was added to each well, and placed on ice for 10 minutes to immobilize the cells.
- PFA/PBS was discarded, and each well was washed twice with 300 µl of PBS and then blocked with 250 µl of DB. Based on the above result of measurement, the purified antibody was serially diluted with DB starting at 10 µg/ml by a factor of 2, 100 µl of which was added to each well. After incubating at room temperature for 2 hours and washing with RB, 100 µl of alkaline phosphatase-conjugated goat anti-human IgGγ antibody (BioSource) diluted 1000-fold with DB was added. After incubating at room temperature for 1 hour and washing with RB, 100 µl of the substrate solution was added, and then absorbance at 405/655 nm was measured using the Microplate Reader (Bio-Rad).
- The Factor Xa production-inhibiting activity of humanized antibody was measured with the inhibiting activity against the Factor Xa production activity by the human placenta-derived thromboplastin, Thromborel S (Boehringer AG), as an index. Thus, 60 µl of the buffer (TBS containing 5 mM CaCl2, and 0.1% BSA) was added to 10 µl of 5 mg/ml Thromborel S and 10 µl of the antibody, which was then incubated in a 96-well plate at room temperature for 1 hour. The antibody was serially diluted with the buffer starting at 200 µg/ml by a factor of 5.
- Ten µl each of 3.245 µg/ml human Factor X (Celsus Laboratories) and 82.5 ng/ml human Factor VIIa (Enzyme Research) were added thereto, and were further incubated at room temperature for 45 minutes. Ten µl of 0.5 M EDTA was added to stop the reaction. Fifty µl of the chromogenic substrate solution was added thereto and the absorbance at 405/655 nm was determined by the Microplate Reader (Bio Rad). After reacting at room temperature for 30 minutes, the absorbance at 405/655 nm was measured again. The residual activity (%) was determined from each change in absorbance with the absorbance change for 30 minutes at no antibody addition as a 100% activity.
- The chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- The inhibiting activity against the FX-binding of humanized antibody was measured using the human placenta-derived thromboplastin, Thrombore1 S (Boehringer AG), in which a complex of TF and Factor VIIa had previously been formed and the inhibiting activity against the FX-binding was measured with the Factor Xa production activity of the TF-FVIIa complex as an index. Thus, 60 µl of the buffer (TBS containing 5 mM CaCl2 and 0.1% BSA) was added to 10 µl of 5 mg/ml Thromborel S and 10 µl of 82.5 ng/ml human Factor VIIa (Enzyme Research), which was preincubated in a 96-well plate at room temperature for 1 hour.
- Ten µl of the antibody solution was added thereto, incubated at room temperature for 5 minutes, and 10 µl of 3.245 µg/ml human Factor X (Celsus Laboratories) was added and was further incubated at room temperature for 45 minutes. The antibody was serially diluted with the buffer starting at 200 µg/ml by a factor of 2. Ten µl of 0.5 M EDTA was added to stop the reaction. Fifty µl of the chromogenic substrate solution was added thereto and the absorbance at 405/655 nm was determined by the Microplate Reader (Bio Rad). After reacting at room temperature for 30 minutes, the absorbance at 405/655 nm was measured again. The residual activity (%) was determined from each change in absorbance with the absorbance change for 30 minutes at no antibody addition as a 100% activity.
- The chromogenic substrate solution was prepared by dissolving the Testzyme chromogenic substrate S-2222 (Chromogenix) according to the attached instructions, and mixing with a polybrene solution (0.6 mg/ml hexadimethylene bromide, SIGMA) at 1:1.
- The neutralizing activity against TF (inhibiting activity against the plasma coagulation) of humanized antibody was measured using, as an index, prothrombin time determined using the human placenta-derived thromboplastin, Thromborel S (Boehringer AG). Thus, 100 µl of human plasma (Cosmo Bio) was placed into a sample cup, to which 50 µl of antibody diluted at various concentrations was added, and heated at 37°C for 3 minutes. Fifty µl of 1.25 mg/ml Thromborel S that had previously been preheated at 37°C was added to start plasma coagulation. The coagulation time was measured using the Amelung KC-10A connected to the Amelung CR-A (both from M. C. Medical).
- The antibody was serially diluted with TBS containing 0.1% BSA (hereinafter referred to as BSA-TBS) starting at 80 µg/ml by a factor of 2. With the coagulation time of no antibody addition as 100% TF plasma coagulation activity, the residual TF activity was calculated from each coagulation time at antibody addition based on a standard curve obtained by plotting the concentration of Thromborel S and the coagulation time.
- The standard curve was created from the various concentration of Thromborel S and the coagulation time was measured. Fifty µl of BSA-TBS was added to 50 µl of appropriately diluted Thromborel S, which was heated at 37°C for 3 minutes, 100 µl of human plasma preheated at 37°C was added to start coagulation, and the coagulation time was determined. Thromborel S was serially diluted with the Hank's buffer (GIBCO) containing 25 mM caCl2 starting at 6.25 mg/ml by a factor of 2. The Thromborel S concentration was plotted on the abscissa, and the coagulation time on the ordinate on a log-log paper, which was rendered a standard curve.
- All humanized antibodies, "b-b", "i-b", and "i-b2" had an activity equal to or greater than that of the chimeric antibody (
Figure 1 ). For inhibiting activity against FXa production, inhibiting activity FX-binding, and inhibiting activity against plasma coagulation as well, the humanized antibodies, "b-b", "i-b", and "i-b2" had an activity equal to or greater than that of the chimeric antibody, and the activity was of a decreasing order "i-b2" > "i-b" > "b-b" (Figures 2 ,3 , and4 ). - The invention also relates to the following aspects as defined in the following numbered paragraphs:
- 1. An experimental animal having implanted therein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene, said animal being a non-human animal in which a hypercoagulable state persists for a long period of time,
- 2. The animal according to
paragraph 1 wherein said part of human tissue factor lacks the intracellular region. - 3. The animal according to
paragraph 1 or 2 wherein said animal cell is a mammalian cell. - 4. The animal according to paragraph 3 wherein said mammalian cell is a human myeloma cell.
- 5. The animal according to any one of
paragraphs 1 to 4 wherein said animal is a mouse. - 6. The animal according to any of
paragraphs 1 to 5 wherein said hypercoagulable state is indicated by at least one of the phenomena comprising an increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex, - 7. A method of generating the animal according to any one of
paragraphs 1 to 6, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected. - 8. A method of screening an anti-thrombotic agent which method comprises using the animal according to any one of
paragraphs 1 to 6. - 9. A preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody to human tissue factor (human TF).
- 9. A preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody to human tissue factor (human TF).
- 10. The preventive or therapeutic agent according to paragraph 9 wherein said antibody is a polyclonal antibody,
- 11. The preventive or therapeutic agent according to paragraph 9 wherein said antibody is a monoclonal antibody.
- 12. The preventive or therapeutic agent according to paragraph 9 or 11 wherein said antibody is a recombinant antibody.
- 13. The preventive or therapeutic agent according to paragraph 9 or 12 wherein said antibody is an altered antibody
- 14. The preventive or therapeutic agent according to paragraph 9, 12, or 13 wherein said altered antibody is a chimeric antibody or a humanized antibody
- 15. The preventive or therapeutic agent according to
paragraph 14 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. - 16. The preventive or therapeutic agent according to paragraph 9 or any one of paragraph 12-15 wherein said antibody is a modified antibody,
- 17. The preventive or therapeutic agent according to paragraph 18 wherein said modified antibody is an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scfv),
- 18. A preventive or therapeutic agent for a hypercoagulable state resulting from infections, said agent comprising an antibody against human tissue factor (human TF).
- 19. The preventive or therapeutic agent according to paragraph 18 wherein said antibody is a polyclonal antibody
- 20. The preventive or therapeutic agent according to paragraph 18 wherein said antibody is a monoclonal antibody
- 21. The preventive or therapeutic agent according to
paragraph 18 or 20 wherein said antibody is a recombinant antibody. - 22. The preventive or therapeutic agent according to
paragraph 18 or 21 wherein said antibody is an altered antibody., - 23. The preventive or therapeutic agent according to
paragraph 18, 21, or 22 wherein said altered antibody is a chimeric antibody or a humanized antibody. - 24. The preventive or therapeutic agent according to paragraph 23 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- 25. The preventive or therapeutic agent according to paragraph 18 or any one of paragraphs 21-24 wherein said antibody is a modified antibody.
- 26. The preventive or therapeutic agent according to
paragraph 25 wherein said modified antibody is an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scfv). - 27. A preventive or therapeutic agent for venous thrombosis, said agent comprising an antibody to human tissue factor (human TF).
- 28. The preventive or therapeutic agent according to paragraph 27 wherein said antibody is a polyclonal antibody.
- 29. The preventive or therapeutic agent according to paragraph 27 wherein said antibody is a monoclonal antibody.
- 30. The preventive or therapeutic agent according to paragraph 27 or 29 wherein said antibody is a recombinant antibody.
- 31. The preventive or therapeutic agent according to paragraph 27 or 30 wherein said antibody is an altered antibody.
- 32. The preventive or therapeutic agent according to paragraph 27, 30, or 31 wherein said altered antibody is a chimeric antibody or a humanized antibody.
- 33. The preventive or therapeutic agent according to paragraph 32 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- 34. The preventive or therapeutic agent according to paragraph 27 or any one of paragraphs 30-33 wherein said antibody is a modified antibody.
- 35. The preventive or therapeutic agent according to paragraph 34 wherein said modified antibody is an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scfv).
- 36. A preventive or therapeutic agent for arterial thrombosis, said agent comprising an antibody to human tissue factor (human TF).
- 37. The preventive or therapeutic agent according to paragraph 36 wherein said antibody is a polyclonal antibody.
- 38. The preventive or therapeutic agent according to paragraph 36 wherein said antibody is a monoclonal antibody.
- 39. The preventive or therapeutic agent according to paragraph 36 or 38 wherein said antibody is a recombinant antibody
- 40. The preventive or therapeutic agent according to paragraph 36 or 39 wherein said antibody is an altered antibody.
- 41. The preventive or therapeutic agent according to
paragraph 36, 39, or 40 wherein said altered antibody is a chimeric antibody or a humanized antibody. - 42. The preventive or therapeutic agent according to paragraph 41 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2,
- 43. The preventive or therapeutic agent according to paragraph 36 or any one of paragraphs 39-42 wherein said antibody is a modified antibody.
- 44. The preventive or therapeutic agent according to paragraph 43 wherein said modified antibody is an antibody fragment Fab. F(ab')2, or Fv, or a single chain Fv (scfv).
- 45. preventive or therapeutic agent for diseases resulting from the medial thickening of the vessels, said agent comprising an antibody to human tissue factor (human TF)
- 46. The preventive or therapeutic agent according to paragraph 45 wherein said antibody, is a polyclonal antibody.
- 47. The preventive or therapeutic agent according to paragraph 45 wherein said antibody is a monoclonal antibody.
- 48. The preventive or therapeutic agent according to paragraph 45 or 47 wherein said antibody is a recombinant antibody.
- 49. The preventive or therapeutic agent according to
paragraph 45 or 48 wherein said antibody is an altered antibody - 50. The preventive or therapeutic agent according to
paragraph - 51. The preventive or therapeutic agent according to
paragraph 50 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2. - 52. The preventive or therapeutic agent according to paragraph 43 or any one of paragraphs 48-51 wherein said antibody is a modified antibody.
- 53. The preventive or therapeutic agent according to
paragraph 52 wherein said modifiied antibody is an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scfv).
Claims (13)
- A preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody to human tissue factor (human TF).
- A preventive or therapeutic agent for a hypercoagulable state resulting from infections, said agent comprising an antibody to human tissue factor (human TF).
- A preventive or therapeutic agent for venous thrombosis, said agent comprising an antibody to human tissue factor (human TF).
- A preventive or therapeutic agent for arterial thrombosis, said agent comprising an anybody to human tissue factor (human TF).
- A preventive or therapeutic agent for diseases resulting from the medial thickening of the vessels, said agent comprising an antibody to human tissue factor (human TF).
- The preventive or therapeutic agent according to any one of claims 1 to 5 wherein said antibody is a polyclonal antibody.
- The preventive or therapeutic agent according to any one of claims 1 to 5 wherein said antibody is a monocional antibody.
- The preventive or therapeutic agent according to any one of claims 1, 2, 3,4, 5 or 7 wherein said antibody is a recombinant antibody,
- The preventive or therapeutic agent according to any one of claims 1, 2, 3, 4, 5 or 8 wherein said antibody is an altered antibody.
- The preventive or therapeutic agent according to any one of claims 1, 2, 3, 4, 5, 8 or 9 wherein said altered antibody is a chimeric antibody or a humanized antibody.
- The preventive or therapeutic agent according to claim 10 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.
- The preventive or therapeutic agent according to any one of claim 1 to 5 or any one of claims 8 to 11 wherein said antibody is a modified anybody.
- The preventive or therapeutic agent according to claim 12 wherein said modified antibody is an antibody fragment Fab, F(ab')2, or Fv, or a single chain Fv (scFv).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10180790A EP2351483A1 (en) | 1999-10-01 | 2000-09-29 | Prevention and treatment of blood coagulation-related diseases |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28219299 | 1999-10-01 | ||
JP28212099 | 1999-10-01 | ||
JP28213499 | 1999-10-01 | ||
JP28216799 | 1999-10-01 | ||
JP28218899 | 1999-10-01 | ||
JP28184399 | 1999-10-01 | ||
EP10180790A EP2351483A1 (en) | 1999-10-01 | 2000-09-29 | Prevention and treatment of blood coagulation-related diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00963006.2 Division | 2000-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2351483A1 true EP2351483A1 (en) | 2011-08-03 |
Family
ID=27554423
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00963006A Expired - Lifetime EP1222854B1 (en) | 1999-10-01 | 2000-09-29 | Prevention and treatment of diseases associated with blood coagulation |
EP10180790A Withdrawn EP2351483A1 (en) | 1999-10-01 | 2000-09-29 | Prevention and treatment of blood coagulation-related diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00963006A Expired - Lifetime EP1222854B1 (en) | 1999-10-01 | 2000-09-29 | Prevention and treatment of diseases associated with blood coagulation |
Country Status (18)
Country | Link |
---|---|
US (2) | US8062638B1 (en) |
EP (2) | EP1222854B1 (en) |
JP (1) | JP3859512B2 (en) |
KR (1) | KR20030008205A (en) |
AT (1) | ATE498305T1 (en) |
AU (1) | AU7450600A (en) |
BR (1) | BR0014667A (en) |
CA (1) | CA2388408A1 (en) |
CZ (1) | CZ20021035A3 (en) |
DE (1) | DE60045638D1 (en) |
DK (1) | DK1222854T3 (en) |
HU (1) | HUP0203486A2 (en) |
IL (1) | IL148980A0 (en) |
MX (1) | MXPA02003278A (en) |
NO (1) | NO20021410L (en) |
PL (1) | PL354961A1 (en) |
SK (1) | SK4442002A3 (en) |
WO (1) | WO2001024626A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703494B2 (en) | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
EP1374896A4 (en) * | 2001-03-26 | 2005-04-06 | Koji Suzuki | Blood rheology improving agents |
JP4683821B2 (en) | 2001-05-18 | 2011-05-18 | 中外製薬株式会社 | Knock-in non-human animals producing human tissue factor |
CZ2004454A3 (en) * | 2001-10-02 | 2004-09-15 | Novo Nordisk A/S | Human tissue factor antibodies |
US20060233786A1 (en) * | 2002-05-23 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
US8765124B2 (en) | 2003-02-28 | 2014-07-01 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparation containing protein |
US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
EP1939218A1 (en) * | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
JPH0159878B2 (en) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (en) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
WO1999051743A1 (en) * | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE81149B1 (en) * | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
WO1988009817A1 (en) * | 1987-06-12 | 1988-12-15 | Mount Sinai School Of Medicine Of The City Univers | Cloning and expression of human tissue factor |
US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
US5879677A (en) * | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
JP3865418B2 (en) | 1994-07-13 | 2007-01-10 | 中外製薬株式会社 | Reconstituted human antibody against human interleukin-8 |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-09-29 CA CA002388408A patent/CA2388408A1/en not_active Abandoned
- 2000-09-29 KR KR1020027004130A patent/KR20030008205A/en not_active Application Discontinuation
- 2000-09-29 EP EP00963006A patent/EP1222854B1/en not_active Expired - Lifetime
- 2000-09-29 CZ CZ20021035A patent/CZ20021035A3/en unknown
- 2000-09-29 US US10/089,501 patent/US8062638B1/en not_active Expired - Fee Related
- 2000-09-29 JP JP2001527640A patent/JP3859512B2/en not_active Expired - Fee Related
- 2000-09-29 HU HU0203486A patent/HUP0203486A2/en unknown
- 2000-09-29 AU AU74506/00A patent/AU7450600A/en not_active Abandoned
- 2000-09-29 AT AT00963006T patent/ATE498305T1/en not_active IP Right Cessation
- 2000-09-29 MX MXPA02003278A patent/MXPA02003278A/en unknown
- 2000-09-29 WO PCT/JP2000/006802 patent/WO2001024626A1/en not_active Application Discontinuation
- 2000-09-29 IL IL14898000A patent/IL148980A0/en unknown
- 2000-09-29 DK DK00963006.2T patent/DK1222854T3/en active
- 2000-09-29 DE DE60045638T patent/DE60045638D1/en not_active Expired - Lifetime
- 2000-09-29 BR BR0014667-6A patent/BR0014667A/en not_active IP Right Cessation
- 2000-09-29 SK SK444-2002A patent/SK4442002A3/en unknown
- 2000-09-29 EP EP10180790A patent/EP2351483A1/en not_active Withdrawn
- 2000-09-29 PL PL00354961A patent/PL354961A1/en unknown
-
2002
- 2002-03-21 NO NO20021410A patent/NO20021410L/en not_active Application Discontinuation
-
2011
- 2011-10-04 US US13/252,455 patent/US20120073002A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0159878B2 (en) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (en) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
WO1999051743A1 (en) * | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
EP1069185A1 (en) * | 1998-04-03 | 2001-01-17 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
Non-Patent Citations (59)
Title |
---|
BELYAVSKY, A. ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 2919 - 2932 |
BETTER, M.; HOROWITZ, A.H., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496 |
BIRD, R.E. ET AL., TIBTECH, vol. 9, 1991, pages 132 - 137 |
CARDIOVASCULAR RESEARCH, vol. 56, no. 3, December 2002 (2002-12-01), pages 454 - 463, ISSN: 0008-6363 * |
CARMELIET PETER ET AL: "Molecules in focus. Tissue factor", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 30, no. 6, June 1998 (1998-06-01), pages 661 - 667, XP002364501, ISSN: 1357-2725 * |
CHIRGWIN, J.M. ET AL., BIOCHEMISTRY, vol. 18, 1979, pages 5294 - 5299 |
CHOMCZYNSKI, P.; SACCHI, N., ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159 |
CO, M.S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976 |
COX JP ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - B36 |
CUNNINGHAM BA. ET AL., BIOCHEMISTRY, vol. 9, 1970, pages 3161 - 3170 |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2002 (2002-12-01), YIN XINHUA ET AL: "Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries.", Database accession no. PREV200300049390 * |
DDBJ, BEJCEK BE. ET AL., CANCER RES., vol. 55, 1995, pages 2346 - 2351 |
DDBJ, BORRETZEN M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 12917 - 12921 |
DDBJ, COLLECT TA. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10026 - 10030 |
DDBJ, GAO L. ET AL., UNPUBLISHED, 1995 |
DDBJ, HILLSON JL., J. EXP. MED., vol. 178, 1993, pages 331 - 336 |
DDBJ, HOUGS L. ET AL., EXP. CLIN. IMMUNOGEN ET., vol. 10, 1993, pages 141 - 151 |
DDBJ, PASCUAL V. ET AL., J. CLIN. INVEST., vol. 86, 1990, pages 1320 - 1328 |
DDBJ, VAN DER STOEP ET AL., J. EXP. MED., vol. 177, 1993, pages 99 - 107 |
DDBJ, WELSCHOF M. ET AL., J. IMMUNOL. METHODS, vol. 179, 1995, pages 203 - 214 |
DE ST. GROTH, S.F.; SCHEIDEGGER, D.J., J. IMMUNOL. METHODS, vol. 35, 1980, pages 1 - 21 |
EBERT, K.M. ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702 |
EPP 0 ET AL., BIOCHEMISTRY, vol. 14, 1975, pages 4943 - 4952 |
FAIR D. S. ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 11692 - 11698 |
FASEB J., vol. 6, 1992, pages 2422 - 2427 |
FROHMAN, M.A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 8998 - 9002 |
GALFRE G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
GALFRE, G. ET AL., NATURE, vol. 277, 1979, pages 131 - 133 |
H. MORRISSEY ET AL., CELL, vol. 50, 1987, pages 129 - 135 |
HARLOW AND DAVID LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
HUSTON, J.S. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 85, 1988, pages 5879 - 5883 |
ITO, T. ET AL., J. BIOL. CHEM., vol. 114, 1993, pages 691 - 696 |
J.H. MORISSEY ET AL., CELL, vol. 50, 1987, pages 129 - 135 |
JAMES H. MORRISSEY ET AL., CELL, vol. 50, 1987, pages 129 - 135 |
JANG I K ET AL: "Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis.", ARTERIOSCLEROSIS AND THROMBOSIS : A JOURNAL OF VASCULAR BIOLOGY / AMERICAN HEART ASSOCIATION. AUG 1992, vol. 12, no. 8, August 1992 (1992-08-01), pages 948 - 954, XP002364500, ISSN: 1049-8834 * |
KEARNEY, J.F. ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550 |
KOHLER, G.; MILSTEIN, C., EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 519 |
KOZAK, M. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 947 - 950 |
LAMOYI, E., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 652 - 663 |
LEI, S.P. ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379 - 4383 |
LEVI MARCEL ET AL: "Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees", JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 1, 1994, pages 114 - 120, XP009060557, ISSN: 0021-9738 * |
MARGULIES, D.H. ET AL., CELL, vol. 8, 1976, pages 405 - 415 |
MELIS E ET AL: "Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 333, no. 2, 29 July 2005 (2005-07-29), pages 488 - 495, XP004949510, ISSN: 0006-291X * |
MIZUSHIMA ET AL., NUCLEIC ACID RES., vol. 18, 1990, pages 5322 |
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 - 114 |
PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 497 - 515 |
RAGNI MASSIMO ET AL: "Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis", CIRCULATION, vol. 93, no. 10, 1996, pages 1913 - 1918, XP009060526, ISSN: 0009-7322 * |
ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 663 - 669 |
S. T. JONES ET AL., BIOTECHNOLOGY, vol. 9, 1991, pages 88 - 89 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856 |
SHULMAN, M. ET AL., NATURE, vol. 276, 1978, pages 269 - 270 |
SWISS-PROT, POLJAK RJ. ET AL., BIOCHEMISTRY, vol. 16, 1977, pages 3412 - 3420 |
TAYLOR F B JR ET AL: "LETHAL ESCHERICHIA-COLI SEPTIC SHOCK IS PREVENTED BY BLOCKING TISSUE FACTOR WITH MONOCLONAL ANTIBODY", CIRCULATORY SHOCK, vol. 33, no. 3, 1991, pages 127 - 134, XP009060554, ISSN: 0092-6213 * |
TONGE DW ET AL., YEAR IMMUNOL., vol. 7, 1993, pages 56 - 62 |
TROWBRIDGE, I.S., J. EXP. MED., vol. 148, 1978, pages 313 - 323 |
VANDAMME, A.M. ET AL., EUR. J. BIOCHEM., vol. 192, 1990, pages 767 - 775 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
YELTON, D.E. ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7 |
Also Published As
Publication number | Publication date |
---|---|
US8062638B1 (en) | 2011-11-22 |
NO20021410D0 (en) | 2002-03-21 |
AU7450600A (en) | 2001-05-10 |
ATE498305T1 (en) | 2011-03-15 |
NO20021410L (en) | 2002-05-24 |
CA2388408A1 (en) | 2001-04-12 |
US20120073002A1 (en) | 2012-03-22 |
WO2001024626A1 (en) | 2001-04-12 |
DE60045638D1 (en) | 2011-03-31 |
KR20030008205A (en) | 2003-01-24 |
EP1222854A4 (en) | 2006-07-05 |
JP3859512B2 (en) | 2006-12-20 |
EP1222854B1 (en) | 2011-02-16 |
EP1222854A1 (en) | 2002-07-17 |
PL354961A1 (en) | 2004-03-22 |
DK1222854T3 (en) | 2011-03-14 |
SK4442002A3 (en) | 2003-04-01 |
BR0014667A (en) | 2002-07-02 |
CZ20021035A3 (en) | 2002-08-14 |
IL148980A0 (en) | 2002-11-10 |
MXPA02003278A (en) | 2002-09-02 |
HUP0203486A2 (en) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120073002A1 (en) | Prevention and treatment of blood coagulation-related disases | |
EP1069185B1 (en) | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody | |
EP1108435B1 (en) | Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient | |
JP5254807B2 (en) | Chronic rejection inhibitor | |
JP4516711B2 (en) | Stable antibody composition and injection preparation | |
JP2009022275A (en) | Antibody for inhibiting blood coagulation and method of use thereof | |
KR20010083069A (en) | Remedies For Hypercalcemic Crisis | |
EP1374896A1 (en) | Blood rheology improving agents | |
JP4439488B2 (en) | Prevention and treatment of blood coagulation related diseases | |
EP1854481B1 (en) | Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient | |
US20030021783A1 (en) | Sepsis remedy comprising anti-IL-8 antibody as active ingredient | |
JP4404968B2 (en) | A preventive or therapeutic agent for stroke and cerebral edema containing an IL-8 binding inhibitor as an active ingredient | |
KR20200074160A (en) | Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody | |
JP2005330292A (en) | Humanized antibody against human tissue factor (tf) and process for producing humanized antibody | |
JP2007186522A (en) | Humanized antibody against human tissue factor(tf) and method for producing the humanized antibody | |
JP2004121253A (en) | Humanized antibody against human tissue factor (tf) and process for production of the same | |
MXPA00009667A (en) | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody | |
JPH1053536A (en) | Treating agent for myocardial infarction containing anti-il-8 antibody as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1222854 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20120131 |
|
17Q | First examination report despatched |
Effective date: 20120425 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140401 |